

CYTOCHROME P450-MEDIATED METABOLISM  
AND CYTOTOXICITY IN RAT CULTURED  
HEPATOCYTES

by

ALISON H. HAMMOND, B.Sc.

Thesis submitted to the University of Nottingham  
for the degree of Doctor of Philosophy, October 1990

<b>CONTENTS</b>	<b>PAGE</b>
Contents	i
Abstract	ii
<b>Acknowledgement</b>	<b>iv</b>
Abbreviations	v
Chapter 1	Introduction
	1
Chapter 2	<b>Materials</b> and Methods
	57
Chapter 3	<b>Supplementation</b> of culture medium with exogenous haem: Influence on the maintenance of P450-dependent enzyme activities
	80
Chapter 4	Influence of donor age and sex on the activity, and maintenance in culture of cytochrome P450-dependent enzyme activities
	90
Chapter 5	Induction of <b>alkoxycoumarin</b> <b>O-dealkylase</b> activities <u>in vivo</u> and <u>in vitro</u>
	105
Chapter 6	Induction of P450 and enzyme activities <u>in vivo</u> and maintenance in rat hepatocyte <b>cultures</b>
	118
Chapter 7	Toxicity studies in cultured hepatocytes
	132
Chapter 8	Discussion
	150
References	166
<b>Publications</b>	<b>195</b>

## ABSTRACT

The aim of this investigation was to define the in vitro conditions necessary to support cytochrome P450-mediated **metabolism** in rat cultured hepatocytes, such that this system could then be used as an in vitro model in the study of cytochrome P450-mediated cytotoxicity.

Maintenance of P450-dependent enzyme activities in culture was not affected by supplementation of **culture** medium with haem, but was markedly influenced by the age and sex of the hepatocyte donor **animal**.

Induction in primary culture by phenobarbitone and **beta-naphthoflavone** was investigated, and found to be quantitatively and **qualitatively** different to the induction observed in vivo, hepatocytes in culture being particularly refractive to induction by phenobarbitone. The maintenance in primary culture of a range of enzyme activities was determined following treatment of rats in vivo with isoniazid and dexamethasone, in addition to phenobarbitone and **beta-naphthoflavone**, and in general, there was good maintenance of the induced activities. The activities were chosen as possible selective substrates for the different induced isozymes, with a view to using the activity profiles to characterise different classes of inducer; however, although selective induction was observed with isoniazid, **beta-naphthoflavone** and dexamethasone, all the chosen activities were induced by phenobarbitone.

The final part of this work involved determining cytotoxicity in vitro, following induction of P450 in vivo with phenobarbitone and

beta-naphthoflavone. Seven known hepatotoxins were investigated, and the results obtained agreed well with available in vitro and in vivo literature data.

In summary, a range of constitutive and induced enzyme activities were maintained at high levels in hepatocytes cultured for **twenty-four** hours from adult male rats, and an induction in vivo/hepatocyte culture protocol shown to be a viable in vitro model for the study of **metabolism-mediated** toxicity, as an alternative to induction and detection of toxicity in vitro.

## ACKNOWLEDGEMENT

I **would like** to thank my supervisor, Dr Jeffrey Fry for **all** his **help** and advice, and also my other colleagues Michael **Garle** and Julia Fentem for many stimulating and amusing discussions and practical assistance. I would also like to acknowledge the help of the staff of the Animal Unit, my typists Janice Avery and Rose Jones, and Maureen Berresford for all the washing up. I would also **like** to thank The Fund for the Replacement of Animals in Medical Experiments (FRAME) for their financial support of this project. Finally, I am indebted to all my friends in the Department of Genetics, for "A Midsummer Nights Dream" and practically everything other than work, in particular Stuart Morton, Mark **Shelton** and Helen Smith and, last but never least, I must thank Kim Middleton, without whom my time in Nottingham would have been very **dull** and extremely sober.

**ABBREVIATIONS**

All abbreviations are defined the first time that they appear in the text, with the exception of the following, deemed acceptable by the Biochemical Journal (257: 1-21,1989) which are used without definition:

AMP	adenosine monophosphate
ATP	adenosine triphosphate
CoA	coenzyme A
DNA	<b>deoxyribonucleic acid</b>
EDTA	<b>ethylenediaminetetraacetic acid</b>
EGTA	<b>ethyleneglycol-bis (β-aminoethyl ether) N<sub>1</sub> N<sub>1</sub> N' N'-tetraacetic acid</b>
FAD	flavin adenine dinucleotide
FMN	flavin mononucleotide
HEPES	<b>N-(2-hydroxyethyl) piperazine-N'- (2-ethanesulphonic acid)</b>
NAD(H)	nicotinamide adenine dinucleotide
NADP(H)	nicotinamide adenine dinucleotide phosphate
mRNA	messenger ribonucleic acid
Tris	<b>tris(hydroxymethyl) aminomethane</b>
UDP	uridine diphosphate

## **CHAPTER 1**

### **INTRODUCTION**

## CHAPTER 1

CONTENTS		PAGE
General Introduction		4
1.1	CYTOCHROME P450	5
1.1.1	Background and history	5
1.1.2	Chemistry and enzymology of MFO reactions	7
1.1.3	Isozymic forms of P450	10
1.2	REGULATION OF P450 EXPRESSION	15
1.2.1	Constitutive P450 expression	15
1.2.2	Induction of P450	21
1.2.3	Molecular mechanisms of regulation	24
1.2.4	Inhibition of P450	25
1.3	P450 AND XENBIOTIC METABOLISM	26
1.3.1	Factors affecting drug metabolism	29
1.4	METHODS OF STUDYING HEPATIC DRUG METABOLISM AND TOXICITY	33
1.4.1	<u>In vivo</u> and perfused organ studies	33
1.4.2	<u>In vitro</u> techniques	34
1.4.3	Intact cell systems	37
1.4.4	Hepatocytes in primary culture	39
1.4.5	Maintenance of P450 in primary culture	42
1.4.6	Induction of P450 in culture	47
1.4.7	Metabolism/toxicity studies in cultured rat hepatocytes	50
1.4.8	Human hepatocytes in primary culture	51

1-4.9	Use of hepatoma cell lines	51
1-4.10	Species differences in metabolism	53
1.5	RATIONALE AND AIMS OF THIS STUDY	56

TABLES AND FIGURES

## CHAPTER 1

### GENERAL INTRODUCTION

The cytochrome P450 mixed-function oxygenases are involved in the metabolism of a variety of endogenous substrates. However, a considerable number of these enzymes also have the capacity to metabolise a wide range of structurally diverse xenobiotics including dietary constituents, environmental pollutants, insecticides and therapeutically administered drugs. Some of these xenobiotics are noxious to man per se, but many others are biotransformed to reactive highly toxic intermediates, predominantly by the action of cytochrome P450 enzymes. This can lead to cellular dysfunction, carcinogenesis and death. The function of these enzymes is probably to activate compounds such that they can be detoxified by the action of conjugative **enzymes**; however, the balance of these reactions can be disrupted by many factors. The potential for P450 to generate toxic metabolites has important ramifications in many areas of study e.g. occupational or accidental exposure to industrial chemicals or environmental pollutants, and drug development and therapy.

The cytochrome P450s have been found in most of the organisms in which they have been sought. They are **also** found in most **mammalian** tissues, hence the literature available on these enzymes is enormous, and this review cannot adequately cover every aspect of P450 **metabolism**. The work presented here is concerned with hepatic P450 metabolism and toxicity, and therefore most of this

introduction is confined to the role of cytochrome P450 in hepatic biotransformation, and the development of toxicity in this organ. Where possible, reference is made to drug metabolism in Man; however, much of our understanding of P450 metabolism has been obtained from rodent studies, particularly the rabbit, rat and mouse. This introduction is divided into four main sections; the latter parts deal with regulation of P450 expression and with methods of studying hepatic drug metabolism; the first part of this review deals with the integrated role of P450 in **metabolism**, particularly in the liver.

## **1.1 CYTOCHROME P450**

### **1.1.1 Background and history**

Cytochromes are electron carrier proteins that contain iron-porphyrin prosthetic groups. Electron transfer is effected by reversible valence changes of the iron during the catalytic cycle. The iron is complexed to the porphyrin ring by co-ordinate bonds (the number of which determine the spin-state of the cytochrome). Most cytochromes, including the mitochondrial respiratory cytochromes and cytochrome P450 contain a haem (iron protoporphyrin IX) prosthetic group (Lehninger, 1975).

In 1958 a membrane-bound cytochrome was described that had an unusual absorption maximum at 450nm on binding carbon monoxide in liver microsomes reduced with dithionite (**Garfinkle, 1958; Klingenberg, 1958**); this cytochrome was later characterized as a haemoprotein and designated cytochrome P450 (Omura and Sato, 1962).

P450 was later shown to be reduced by both NADH and NADPH, and was rapidly re-oxidised in the presence of oxygen (Omura and Sato, 1964). It is now known that there are multiple isozymic forms of P450; to date, over 50 mammalian gene products have been identified (Nebert et al., 1989). P450s have been found in bacteria, plants and most animal phyla; mammalian P450s are located in the endoplasmic reticulum (ER) of most tissues (Fevold, 1983; Nebert and Gonzalez, 1987), and are also present in the adrenal mitochondria (Nebert and Gonzalez, 1987). Recent work on the topology of P450s suggests that the **amino-terminal** amino acids, which are predominantly hydrophobic residues, anchor the cytochrome in the ER membrane, the bulk of the molecule sitting on the cytoplasmic side possibly with other regions of the molecule traversing the membrane, and the haem group parallel to, or at a slight angle to the membrane surface (Nelson and **Strobel**, 1988; Vergères et al., 1989).

P450 is the terminal oxidase component of the microsomal electron transport system (Cooper et al., 1965) which catalyses mixed function oxidation (MFO) of an extensive variety of structurally diverse endogenous and xenobiotic compounds (Table 1.1). These MFO reactions serve to make lipophilic compounds more **hydrophilic** by the addition of a polar functional group. This is essential in the detoxification process, since the resulting water-soluble derivatives can then be metabolised by conjugative enzymes to readily excretable compounds. Metabolism of xenobiotics falls into two main categories: Phase I, (oxidative or reductive) which adds a

functional group, and Phase II which are generally the true detoxification reactions.


### 1.1.2 Chemistry and enzymology of MFO reactions

There are three essential components of the MFO system: P450, NADPH-cytochrome P450 reductase and lipid (Lu and Coon, 1968; Lu et al., 1969). NADPH-cytochrome P450 reductase (P450 reductase) is a flavoprotein containing both FAD and FMN prosthetic groups. P450 reductase is also ER-membrane-bound and passes reducing equivalents from NADPH to P450. P450 reductase appears to be a 'transducer' protein, in that the reductase is a two electron acceptor whereas P450 is a one electron acceptor. Electrons are passed sequentially from NADPH +  $H^+$  to FAD to FMN to P450. A **heat-stable lipid** component is also required for MFO activity and appears to be **phosphatidylcholine**. Reconstitution studies indicate that the fatty acid composition is also vital for activity, suggesting that the composition of the **lipid** environment of P450 is a determining factor for MFO activity (Rietjens et al., 1989).

The role of P450 in MFO is to bind both molecular oxygen ( $O_2$ ) and the substrate, cyclic oxidation/reduction of P450 and P450 reductase resulting in the catalytic conversion of the substrate. Substrate binding to the ferric form of P450 changes the absorbance spectrum of the cytochrome. This is due to alterations in the spin **equilibrium**.

The spin state is determined by ligand co-ordination. In addition to the four equatorial iron-pyrrole nitrogen bonds there are 1 (penta-co-ordinate) or 2 (hexa-co-ordinate) axial bonds to amino acid side chains. Most P450s exist with the spin equilibrium predominantly in the low-spin state (hexa-co-ordinate), and substrate binding, usually to the protein part of the molecule, alters the conformation of the protein and therefore its ligand interactions with the haem group. This causes a spin-state shift to predominantly high-spin configurations (producing a Type I binding spectrum). Substrate binding to a high-spin form is thought to be via the haem iron itself producing a hexa-co-ordinated low-spin haemoprotein and a Type II binding spectrum (Gibson and Skett, 1986). Substrates were originally classified as to their ability to elicit Type I or II binding spectra (Schenkman et al., 1967), before the existence of multiple isozymes was fully realised.

The overall stoichiometry of MFO reactions is:



where SH is the substrate. A simplified version of the catalytic cycle is shown in Figure 1.1. Briefly;

(i) Substrate binds to P450 causing a shift in spin-state and a change in redox potential which facilitates electron acceptance.

(ii) Two electrons are transferred from  $\text{NADPH}+\text{H}^+$  to P450 reductase, and one electron transferred from P450 reductase to P450.

(iii) Binding of  $\text{O}_2$  to the reduced P450 to produce a highly unstable oxy-ferrous-substrate complex.


(iv) Second electron reduction by P450 reductase or cytochrome b5, oxygen insertion (via a **peroxy-intermediate?**) and product release.

These latter steps are not well characterized, along with the role of cytochrome b5 in the catalytic cycle. Cytochrome b5 can form a covalent complex with P450 that seems to enhance binding of selected substrates, and also the shift in spin-state equilibrium, for certain isozymes (Jansson et al., 1985).

**Also**, the second electron may be donated either by the reductase or by b5, which can **also** be reduced by cytochrome b5 reductase, with NADH as the electron donor. These electrons are transferred to stearyl CoA desaturase, but it now seems that they can also be passed from b5 to **P450**, explaining the observed NADH synergism on NADPH-supported **metabolism** (Schenkman et al., 1976).

It has also been suggested that b5 increases the 'coupling' of the cycle. During the catalytic cycle, there is an increase in hydrogen

peroxide ( $\text{H}_2\text{O}_2$ ) formation, since P450 also has an oxidase activity concomitant with **monooxygenation** of substrates:



This activity has been viewed as an 'uncoupling' of electron transfer from substrate oxidation. The binding of b5 to P450 may result in tighter coupling due to more efficient/faster electron transfer. It should be noted that P450 isozymes that exist as predominantly high-**spin** forms i.e. P450nE1, have high endogenous oxidase activity (Gorsky et al., 1984; Ingelman-Sundberg and Johansson, 1984).

### 1.1.3 Isozymic forms of P450

P450 exists as a superfamily of isozymic forms, which accounts for the observed broad and overlapping substrate specificity. The isozymes have been organised into thirteen **families** based on the divergent evolution of the P450 genes derived from protein primary sequence alignment data (Nebert et al., 1988; 1989). Families **I-IV** contain most of the mammalian hepatic catabolic P450s; families XVII, XIX, XXI and XXII comprise the mammalian extrahepatic P450s involved in steroid biosynthesis while family XI contains the mitochondrial P450s that use adrenodoxin for electron transfer. In addition there are the yeast (LI and **LII**) bacterial (CI and **CII**) and insect (VI) families (Gonzalez, 1989).

The isozymes have been classified into families and subfamilies based on the percentage similarity of their primary sequences. In general, there is less than **40%** similarity between isozymes of different families. Sequences within a family are taken to be greater than **40%** similar, and greater than 59% similar for **mammalian** subfamilies. Also, sequences that are more than 97% similar are assumed to be allelic variants, unless demonstrated to be different gene products. This classification has enabled a standard nomenclature for P450s to be devised. Table 1.2 gives the standard nomenclature for the main hepatic P450s from families I - III. This nomenclature for P450 proteins (e.g. P450IA1) and genes (CYP1A1) will be used here throughout, where possible.

Although the sequence similarity between isozymes from bacteria and mammals is less than 25%, there is sufficient localised sequence identity to classify these isozymes as members of one superfamily e.g. there is a highly conserved **21-residue** cysteinyl fragment associated with the haem-binding pocket that is present in all eukaryotic P450s and the prokaryotic P450 **C1** (Nebert and Gonzalez, 1987).

There is much speculation as to why there are so many P450 isozymes. Diversification of P450 forms probably occurred as species adapted to new environments. It has been suggested that changes in dietary flora necessitated the development of enzyme systems that could detoxify and/or utilise many of the plant products. In order to be

an evolutionary success, an organism must be able to protect itself from environmental poisons and survive on new energy sources (Gonzalez, 1989).

#### The P450I family

There are two proteins in this family: P450IA1 is found in most **phyla** from insects upwards to the mammals, whereas IA2 appears to be expressed only in the liver (Gonzalez, 1989). However, despite the ubiquitous nature of **IA1**, no endogenous substrate has been identified for this P450. **IA1** metabolises planar, aromatic compounds e.g. benzo-[a]-pyrene and **7-ethoxyresorufin**; IA2 **metabolises** predominantly **arylamines**. Both genes are inducible by polycyclic aromatic hydrocarbons e.g. tetrachlorodibenzo-(p)-dioxin (TCDD), **3-methylcholanthrene** (3-MC) and **beta-naphthoflavone** (BNF; Haugen et al., 1976; Thomas et al., 1983).

#### The P450II family

The P450II family has five main subfamilies A to E. There are at least three rat genes in the **IIA** subfamily: CYP2A1 and CYP2A2 are expressed in the liver, and although they exhibit 93% nucleotide sequence similarity, they are differentially and **developmentally** regulated. **IIA1** is a **testosterone-7 $\alpha$ -hydroxylase**, and **IIA2** a **15 $\alpha$ -hydroxylase**. A third gene is expressed in rat lung, although its orthologue in the mouse is expressed in the liver and kidney (Matsunaga et al., 1988; Gonzalez, 1989).

There are at least ten genes in the **IIB** subfamily, the rat phenobarbitone **(PB)-inducible** genes being CYP2B1 and 2, the proteins having similar substrate specificities e.g. for benzphetamine and testosterone (Ryan et al., 1979). These genes seem to have diverged from each other recently in the rat, as most rodents do not have orthologues for both these genes (Adesnik and Atchison, 1986).

The **IIC** subfamily contains mostly constitutive P450s, many of which are **developmentally/sex** regulated, although some are inducible by PB. The rat has at least five genes and one pseudogene. These include the male-specific **IIC11** and 13 and the female-specific **IIC7** and 12 isozymes involved in steroid **hydroxylations** (Waxman et al., 1983; Adesnik and Atchison, 1986). This subfamily also contains three genes (CYP2C8-10) responsible for mephenytoin metabolism (Nebert and Gonzalez, 1988; Gonzalez, 1989).

The **IID** subfamily is highly polymorphic in the rat and the human, being involved in debrisoquine **metabolism**. This subfamily appears to have a unique lineage, being less similar to the other subfamilies (Gonzalez et al., 1988; Gonzalez, 1989).

The **HE** subfamily contains two genes, although, to date only rabbits have been shown to possess both genes, however there is differential tissue expression (Porter et al., 1989). P450IIE1 is inducible by ethanol (Ryan et al., 1986), diabetes and fasting (Ma et al., 1989)

and acetone (Johansson et al., 1988), and substrates include acetone, acetoacetate, halothane and pyridine. This P450 may play a role in **gluconeogenesis** during fasting (Gonzalez, 1989).

#### The P450III family.

There are to date six genes in this family: 2 rat, 3 human and 1 rabbit. Of the rat genes, CYP3A1 is inducible by **pregnenolone-16 $\alpha$ -carbonitrile** and dexamethasone (Dex; Heuman et al., 1982), whereas CYP3A2 is constitutive in male rats. Macrolide antibiotics also induce P450IIIA proteins (Wrighton et al., 1978). However, it has been difficult to reconcile **interlaboratory** data with respect to the multiple isozymes in this family, and thus correspondence of different isozymes from different groups. It may be therefore, that there are several, very closely related isozymes in this family, all of which have not yet been resolved (Halpert, 1988). Both gene products appear to possess **testosterone-6 $\beta$ -hydroxylase** activity (Nebert and Gonzalez, 1988; Gonzalez, 1989).

#### The P450IV family.

These constitutive P450s catalyse the **- $\omega$ -hydroxylation** of lauric acid and arachidonic acid and are inducible by **hypolipidaemic** drugs that are also rodent peroxisome proliferators e.g. **clofibric acid** (Tamburini et al., 1984; Hardwick et al., 1987).

## 1.2 REGULATION OF P450 EXPRESSION

P450 expression is regulated at two levels. Physiological and environmental factors alter the isozyme complement of an organ by influencing the molecular mechanisms responsible for gene expression, while regulation at the molecular level can be via control of gene transcription, mRNA and/or apoprotein stability and haem biosynthesis/degradation. These will be discussed below (1.2.3). Many factors have been shown to affect P450 expression: there are compounds that induce their own biotransformation and/or the metabolism of other substances, in addition to physiological conditions that affect primarily constitutive P450s. In both cases, alterations in isozyme complement can have profound effects on metabolism/toxicity of P450 substrates, both endogenous and xenobiotic. Induction and control of constitutive expression are discussed in the following sections, and although dealt with separately, are not completely discrete processes.

### 1.2.1 Constitutive P450 expression

There are many factors that are known to influence constitutive expression of P450, including genotype, hormones and liver disease, as well as infection, starvation and stress (Vesell, 1988).

Genotype Species and strain differences in P450 metabolism in experimental animals have been recognised for a long time (Kato, 1979), but it is now known that there are several examples of genetic polymorphisms for drug metabolism in Man, some with racial

differences in distribution frequency. One of the best characterized is the polymorphic metabolism of the anti-hypertensive drug, debrisoquine (DB). The **4-hydroxylation** of DB shows a bimodal distribution between the extensive **metabolisers** and the poor **metabolisers** (who excrete no 4-hydroxydebrisoquine), with a low incidence of poor **metabolisers**. The deficient **hydroxylation** of DB is an autosomal recessive trait, and is associated with deficient metabolism of several other drugs e.g. sparteine, phenytoin and phenacetin, and is due to the absence of a single P450 isozyme: P450IID1 (Maghoub et al., 1977; Gonzalez et al., 1988). Mephenytoin metabolism is also polymorphic in humans, as well as the non-P450-mediated **N-acetylation** of many drugs e.g. isoniazid (Levi et al., 1968; Gonzalez, 1989).

Tissue-specific regulation Many P450s exhibit tissue-specific regulation, although the molecular mechanisms responsible are unknown. P450IIB1 is **constitutively** expressed in the lung and testis, but not in the liver of untreated rats, whereas IIB2 is only detectable in the liver of untreated animals. P450IA2 also appears to be **liver-specific** as are IIA1, IIA2 and IIC11 (Nebert and Gonzalez, 1988; Gonzalez, 1989). Recently, an olfactory-specific P450 was identified which appears to be a member of the II gene family (Nef et al., 1989); the P450IV family, in contrast, may be more ubiquitous, having been found in liver, lung, kidney, placenta, intestine and leukocytes (Gonzalez, 1989).

Hormonal regulation Hormonal influences on P450 expression cover a wide range of conditions including pregnancy and lactation, diabetes and fasting, and is also the basis of age and sex differences in drug metabolism, e.g. **7-propoxycoumarin O-dealkylation** (Kamatani et al., 1980), **hexachlorobenzene** metabolism (Rizzardini and Smith, 1982), phenytoin metabolism (Billings, 1983). Age and sex differences in drug **metabolism** are related to P450-mediated steroid metabolism which is regulated by growth hormone; the secretion and effects of growth hormone are discussed in detail in Chapter Four and will only be outlined here. Briefly, most P450s are not expressed prenatally: birth, weaning and puberty each influence the P450 profile (Waxman et al., 1985) in particular, neonatal, gonadal androgen production imprints the adult pattern of pituitary growth hormone secretion, which is different in males and females and which then influences hepatic P450 expression, primarily via suppression of P450 synthesis (extensively reviewed by Skett, 1987; 1988).

Thyroid hormones affect P450 expression, although their exact mode of action is unclear. Thyroxine appears to markedly affect the levels of P450 reductase (Kato, 1977; Waxman et al., 1989), and thyroidectomy has been shown to have substrate and sex-specific effects on P450 metabolism, which can be reversed or enhanced by subsequent administration of thyroxine (Skett, 1987). The confusing picture of thyroid effects on P450 metabolism may be a result of the failure in early studies to discriminate the actions of thyroxine and tri-iodothyronine and/or the compounding influence

of age, since thyroid suppression of P450 appears to be particularly marked for **neonatally** expressed P450s (Yamazoe et al., 1989).

There is a general decrease in drug **metabolism** in the pregnant rat, thought to be associated with increased progestagen levels (Gibson and Skett, 1986), Decreases in aniline **hydroxylation** and ethylmorphine **N-demethylation** were paralleled by changes in P450 content (Kato, 1977). These changes also correlate with the reported decreases in total microsomal phospholipid content and the **phosphatidylcholine: phosphotidylethanolamine** ratio in pregnancy, along with the decreased proportion of P450 in the high-spin state (Turcan et al., 1981; Symons et al., 1982). The lipid composition of reconstituted systems is known to markedly affect P450 activity (Yamazoe et al., 1988). It has been suggested that sex-differentiated activities as well as the pregnancy-associated inhibition of drug metabolism are due to specific lipid requirements of different isozymes (Skett, 1987).

Diabetes, although a disease state, is a **hormonally-based** disorder, and its effects on P450 will thus be discussed here. **Chemically-induced** or spontaneous diabetes mellitus dramatically alters drug metabolism in the male rat, effects in the female being less marked (Kato and Gillette, 1965a; Skett, 1987). In acute **chemically-induced** diabetes, there is suppression of male-specific and increases in female-specific activities in the male rat, which can be reversed by insulin replacement treatment (Kato and Gillette,

1965a). This is also seen in genetically diabetic rats, where it was also shown that diabetic males had lower serum testosterone levels than the control males (Warren et al., 1983). Castration and diabetes appear to have similar effects on male rats, in that androgens, like insulin, can partially reverse the effects of **diabetes**. However, the time-courses of changes in drug metabolism and serum testosterone levels do not correlate with each other (Skett, 1987). Despite this, it has been proposed that insulin and androgens may act through a common mediator i.e. growth hormone, this being a feminising factor, and insulin a **masculinising** factor with respect to P450 **metabolism** (Skett, 1987).

In addition to effects on sex-differentiated metabolism, diabetes induces a specific P450 isozyme, P450IIE1 (Bellward et al., 1988). This isozyme is also induced by ethanol and isoniazid and is associated with aniline hydroxylase activity (Ryan et al., 1986). Fasting and obesity also induce IIE1 (Hong et al., 1987; Salazar et al., 1988). Fasting appears to exaggerate sex differences in P450 metabolism, with **male-type metabolism** being depressed, as in diabetes (Kato and Gillette, 1965b; Ma et al., 1989). Fasting and diabetes, however, do not have identical effects on P450 isozyme expression; although IIC11 and IIA1 were decreased by both conditions, fasting decreased and diabetes increased the PCN-E isozyme (a male-specific steroid 6/3 **-hydroxylase**); fasting also increased total P450 whereas diabetes had no effect on the total microsomal P450 content (Ma et al., 1989), The induction of IIE1

in diabetes and fasting is associated with ketosis (Honn et al., 1977; Bellward et al., 1988); IIEI is also inducible by acetone and acetoacetate and it has been suggested that IIEI is involved in the gluconeogenic response to glucose deficiency (Gonzalez, 1989). However, there are molecular differences in IIEI induction by acetone and fasting - these **will** be discussed in section 1.2.3.

Disease Many liver disorders can adversely affect drug metabolism; cirrhosis and chronic viral hepatitis can reduce the number of functional hepatocytes and any disease that affects blood flow through the liver can affect extraction and clearance (Kato, 1977). In general, the impairment of drug **metabolism** in chronic liver disease correlates with the severity of dysfunction.

**Relatively little** is known about the effects of the porphyrias on drug **metabolism**, although clearly deficiencies in haem biosynthesis or increased degradation will reduce the amount of P450-holoenzyme. Regulation of haem biosynthesis and degradation in relation to P450 activity is discussed in Chapter Three. However, it is known that TCDD, oestrogens and **hexachlorobenzene** can induce hepatic porphyrias in Man and experimental animals (Rizzardini and Smith, 1982), and that acute intermittent porphyria selectively impairs drug metabolism (Anderson et al., 1976).

### 1.2.2 Induction of P450

Conney et al. (1956) first reported the induction of aminoazo dye metabolism by 3-methylcholanthrene (3-MC). The enzyme induced was benzpyrene hydroxylase or aryl hydrocarbon hydroxylase (AHH), now known to be associated with P450IA1. P450IA1, and to a lesser extent, IA2 have been shown to be inducible by the polycyclic aromatic hydrocarbons (PAH), e.g. 3-MC, BNF and TCDD, **isosafrole** being more selective for P450IA2 induction (Conney et al., 1967; Thomas et al., 1983). The early work on PAH-induction of P450 was facilitated by the discovery of a polymorphism in mice with respect to responsiveness to PAH-induction of AHH. PB and **PCN** were shown to induce different proteins to BNF and TCDD in responsive mice strains; in non-responsive strains there was no induction of AHH by BNF or TCDD (Haugen et al., 1976). TCDD was shown to be a potent **ligand** for a receptor whose binding affinity segregated with AHH-responsiveness in mice, and subsequently cytosolic receptor-bound TCDD was shown to be the factor responsible for AHH induction; this receptor is encoded by the **Ah** locus (Poland et al., 1976; Gonzalez, 1989). The TCDD-receptor complex appears to translocate into the nucleus where it acts as a positive transcriptional activation element, possibly binding to regulatory elements that have been identified upstream of the **CYP1A1** gene (Gonzalez, 1989).

**Autoregulation** of the **Ah** locus by an endogenous repressor has been postulated from work using cell lines with normal receptor levels but

no AHH induction. In these cell lines however there is high constitutive expression of **IA1** mRNA, i.e. in the absence of inducer. These mRNAs coded for defective proteins, and it was suggested that the **IA1** enzyme **metabolises** an endogenous compound to a repressor of the **Ah** locus (Hankinson et al., 1985).

Several other enzymes are associated with the **Ah** locus including a glutathione transferase, NAD(P)H:menadione oxidoreductase, a **UDP-glucuronyl** transferase and P450IA2 (Nebert and Gonzalez, 1988; Gonzalez, 1989), suggesting that there is co-ordinate regulation of certain components of Phase I and II **metabolism**.

In contrast to PAH-induction of P450, *very* little is known about the mechanism of PB induction, other than that PB stimulates de novo synthesis of P450, and there is no evidence for the involvement of a receptor (Adesnik et al., 1981). PB induces **proliferation** of the ER, and in addition to induction of total P450 and P450s **IIB1** and **IIB2**, levels of P450 reductase, epoxide hydrolase and a **UDP-glucuronyl** transferase are also increased (Hardwick et al., 1983a). The P450IIIA1/2 proteins and also some members of the **IIC** subfamily are also inducible by PB (Gonzalez, 1989). Induction of **IIB1** and 2 is co-ordinate, but the transcription rate is different to that of the reductase and epoxide hydrolase (Hardwick et al., 1983a). Other inducers of **IIB1/2** include SKF-525A, isoniazid, chlordane and Arochlor 1254 (Gonzalez, 1989).

Isoniazid, acetone and ethanol all induce P450IIE1, which is also inducible by fasting and diabetes (see section 1.2.1. above). The mechanism of induction appears to be primarily **post-transcriptional** and is discussed below.

P450s in the **IIIA** family are inducible by synthetic **glucocorticoids** (e.g. DEX) and synthetic steroids (e.g. PCN and betamethasone) as well as hydrocortisone and corticosterone, Progesterones, oestrogens, androgens and **mineralocorticoids** do not induce these P450s (Schuetz et al., 1984). DEX and PCN both induce the same P450, **IIIA1**, DEX being the better inducer (Heuman et al., 1982; Hardwick et al., 1983b). DEX/PCN induce the same protein in cultured hepatocytes as in vivo (Schuetz et al., 1984). Induction of P450 does not appear to be mediated by the **glucocorticoid** receptor: concentrations, time-courses and rank order of potency of the steroids are different for induction of P450 and tyrosine aminotransferase (Schuetz and Guzelian, 1984). PB and organochlorine pesticides also induce one of the IIIA proteins (Heuman et al., 1982; Schuetz et al., 1986).

Clofibrate and other **hypolipidaemic** agents induce peroxisomal and microsomal proteins involved in fatty acid  $\beta$ -oxidation, including P450IVA1; this P450 has no immunocrossreactivity with the PAH-, PCN- or **PB-inducible** P450s (Tamburini et al., 1984; Hardwick et al., 1987).

### 1.2.3 Molecular mechanisms of regulation

Transcriptional activation This is the major regulatory mechanism during developmental induction of P450 activities, and most xenobiotic inducers increase gene transcription to a greater or lesser extent. Induction of P450IA1 by PAHs and IIB1/2 by PB is almost exclusively transcriptional (Adesnik and Atchison, 1986; Gonzalez, 1989). PCN and DEX both transcriptionally activate the CYP3A genes (Hardwick et al., 1983b; Simmons et al., 1987).

Post-transcriptional regulation This can involve **stabilisation** of mRNA or of protein. Transcription of P450IA2 in vivo is activated two-fold by 3-MC but there is a 30-fold accumulation of protein; similar results were obtained in hepatocyte cultures, suggesting a considerable post-transcriptional component in IA2 regulation (Pasco et al., 1988; Silver and Krauter, 1988). DEX, in addition to transcriptional activation of the CYP3A genes, induces P450s IIB1/2 and P450 reductase via mRNA stabilisation (Simmons et al., 1987). Macrolide antibiotics e.g. **triacyl**oleandomycin (TAO) have been shown to induce a protein in vitro, indistinguishable from a **PCN-inducible** protein, in the absence of an increase in mRNA. It was proposed that TAO bound to the P450 inhibiting its degradation, thus stabilising (and inactivating) the P450 (Watkins et al., 1986).

IIE1 expression is also induced in the absence of any transcriptional activation. In untreated rats IIE1 degradation appears to be biphasic, whereas degradation is monophasic in

**pyrazole-treated** rats. Dimethyl sulphoxide and ethanol increased IIEI protein 2- to 7-fold, although there was no increase in mRNA levels (Eliasson et al., 1988); in contrast, fasting increased both protein and mRNA levels (Honn et al., 1987). It has been suggested that ligand binding by small organic molecules stabilises IIEI protein by inhibiting degradation whereas fasting and diabetes inhibit RNA catabolism (Eliasson et al., 1988; Gonzalez, 1989).

**1.2.4. Inhibition of P450** Induction and inactivation of **steroid-inducible** P450s by TAO was mentioned **above**. Other compounds, particularly inhibitors of P450 metabolism, interact with the protein to inactivate it. Inhibitors such as SKF-525A, safrole and piperonyl butoxide form stable, inactive complexes with P450: the inactivation is usually reversible, and these compounds do not destroy the haemoprotein. This type of inactivation requires **metabolism** of the inhibitor by P450 (Netter, 1980), Safrole and **alpha-naphthoflavone** selectively inhibit the **PAH-inducible** P450s (Delaforge et al., 1985), SKF-525A and metyrapone **preferentially** inactivate **PB-inducible** P450s (Netter, 1980; Parkinson et al., 1982). Metyrapone is a pyridine derivative, and binds at (or near) the haem iron centre, like carbon monoxide, so that the haemoprotein cannot bind oxygen (Netter, 1980). There are also suicide substrates of P450 that are **metabolised** to intermediates that irreversibly alkylate the P450 haem group, resulting in haem degradation and **accumulation** of porphyrins e.g. many olefins and acetylenes like **allylisopropylacetamide** and **ethinyloestradiol**.

Nitrosamines can also alkylate haem groups (Ortiz de Montellano and Correia, 1983). Metal ions also inhibit P450: **cobalt-protoporphyrins** decrease total P450 and total haem and also induce haem oxygenase (Galbraith and Jellinck, 1989); zinc, in the form of a **zinc-protoporphyrin**, inhibits P450 **metabolism** and decreases P450 content (Matsuura et al., 1988) and may decrease the ability of P450 to interact with substrate and/or reductase (Jeffery, 1982).

Recently it has been shown that P450 is a substrate for **cyclic-AMP-dependent** kinase (Pyerin et al., 1984) and that **phosphorylation** inhibits P450 activity: **IIB1/2** are markedly **phosphorylated**, leading to inactivation (Koch and Waxman, 1989). **Phosphorylation** is also associated with an increase in P420 (Taniguchi et al., 1985). **Phosphorylation** also inhibited the b5-induced spin-state transition and b5 interaction with P450 (Epstein et al., 1989).

### 1.3 P450 AND XENOBIOTIC METABOLISM

The P450/MF0 is the major contributory component to Phase I xenobiotic **metabolism**, however, there are other oxidative enzyme systems including the alcohol and aldehyde dehydrogenases, xanthine oxidase and monoamine oxidase. In addition, the reductases, P450 reductase and menadione:NAD(P)H oxidoreductase can contribute to Phase I metabolism (Gibson and Skett, 1986; Ziegler, 1988). There is also a flavin **monooxygenase**. This flavoprotein is an integral

microsomal membrane protein with a broad substrate specificity, active towards sulphur, phosphorus and nitrogen centres e.g. thioureas, hydrazines (Ziegler, 1988),

Phase I metabolism produces intermediates which are not necessarily less toxic than the parent compound, and have several possible fates. They can interact with cellular components which may cause toxicity, or they may be further **metabolised** by the Phase II conjugation enzymes. This usually results in a hydrophilic, readily excretable metabolite. These reactions involve conjugation of reactive intermediates with a variety of molecules e.g. sugars, sulphate and amino acids, these cofactors usually requiring activation prior to reaction (Gibson and Skett, 1986). As with Phase I activities, many endogenous compounds are substrates for Phase II metabolism (Table 1.3).

The major conjugation reaction for detoxification of a range of xenobiotic compounds is glucuronidation. **UDP-D-glucuronic** acid can be transferred to a variety of functional groups by the **UDP-glucuronyltransferases** (UDPGTs) to form a glucuronic acid conjugate. These molecules are very polar and easily excretable. The UDPGTs have recently been reviewed (Burchell and Coughtrie, 1989). The liver is the most important site of glucuronidation for many compounds e.g. clofibrate and valproic acid (Howell et al., 1986) and paracetamol (Prescott et al., 1981). The UDPGTs exist as a family of microsomal isozymes, **like** the P450s, and there is

differential induction of the isozymes, in Man and rats, by the common MFO inducers including PB, 3-MC and clofibrate (Thompson et al., 1982). Often there is simultaneous induction of MFO and conjugation enzymes (Hardwick et al., 1983a).

The **sulphotransferases** are soluble enzymes that also exist in multiple forms, but in general, sulphation is less important than glucuronidation in Man and rats, due to the limited availability of activated sulphate (phosphoadenosine-5'-phosphosulphate; Gibson and Skett, 1986). Paracetamol and 2 **-acetylaminofluorene** are two of the many drugs where sulphation is involved in the metabolism (Prescott et al., 1981; Meerman et al., 1987).

The glutathione transferases are another family of soluble isozymes, that are also inducible by MFO inducers. They catalyse glutathione-conjugation e.g. of paracetamol, but glutathione (GSH) can also spontaneously bind to drugs e.g, tetracycline (Gibson and Skett, 1988). GSH-conjugates can be further metabolised by the intestinal flora and the kidney **C-S-lyases**, to mercapturic acids (Jakoby, 1988). Glycine conjugation, **methylation** and hydrolysis are other Phase II reactions, but these are relatively minor pathways of metabolism (Jakoby, 1988).

Although Phase I metabolism is often referred to as the activation phase, and Phase II metabolism as detoxification, it is more a case

of Phase I and II metabolism together resulting in **detoxification**. The interactions between the two, especially under conditions of enzyme induction or limited cofactor availability, will determine the eventual fate and intracellular effects of a potential toxin,

### **1.3.1 Factors affecting drug metabolism**

The main biochemical factors that influence P450 activity are oxygen supply and substrate **availability**. Oxygen is essential for MFO activity, and under normal circumstances is readily available. However in the centre of an organ **like the liver**, and under certain pathological conditions oxygen supply may be limiting resulting in a predominance of reductive metabolism, which may markedly alter the **metabolic** profile of a drug, e.g. halothane can be **metabolised** by oxidative and reductive P450 pathways, which yield different metabolites with different toxic potentials (Timbrell, 1983). **Intra-tissue** gradients in oxygen tension may also influence hepatocyte heterogeneity with respect to isozyme activity (see below).

Substrate **availability** is also important in determining P450 activity: the **lipophilicity** of a compound will affect its access to the membrane-bound P450s and plasma binding will affect its availability to the hepatocytes. Biliary excretion and enterohepatic recirculation, e.g. of **glucuronides**, can also affect **bioavailability** (Gibson and Skett, 1986).

Cofactor supply can limit P450 reactions: NADPH is produced by the pentose phosphate pathway, but is also required for fatty acid biosynthesis and the reduction of oxidized glutathione (Thurman and Kauffman, 1980). Thus NADPH content is determined by prevailing metabolic conditions and may be limiting during oxidative stress. Cofactor supply also influences Phase II metabolism e.g. **UDP-glucuronic acid** formed from glucose-1-phosphate, which is derived from NAD<sup>+</sup>-dependent glycolytic pathways, may be depleted during glucuronidation of xenobiotics e.g. paracetamol (Howell et al., 1986; Hjelle et al., 1986). Maintenance of adequate GSH **levels** is **also** important in preventing oxidative stress. The factors that influence drug **metabolism** have all been extensively reviewed, especially with respect to the **liver** (Thurman and Kauffman, 1980; Gibson and Skett, 1986).

The major determinant of the metabolic profile of a compound is the P450 isozyme complement of the organ/cell (and to a lesser extent, the distribution of Phase II enzymes). Differential P450 isozyme expression is probably one of the main explanations for organ-specific toxicity although extra-hepatic toxicity may also be strongly **influenced** by other factors e.g. **solute** concentration in the kidney and oxygen tension in the lung; tissue-specific differences in isozyme expression were discussed in 1.2.1. Although the **liver** is the main site of MFO **metabolism** and a primary target for MFO-generated toxins, there are well documented examples of non-hepatic MFO-activated toxins e.g. the pulmonary **toxin**,

**4-ipomeanol** (Boyd and Burka, 1978); renal toxicity of chloroform and benzene toxicity to bone marrow (Gram et al., 1986),

With respect to the liver itself, it has been proposed that there is metabolic heterogeneity within the functional unit of the **liver**. The acinus as the functional unit of the liver was first described in 1954 (Rappaport et al.), and represents the cellular organisation around the hepatic blood vessels (Figure 1.2). Blood flow is unidirectional and sequential across the acinus from the hepatic portal venules to the hepatic venules, and the acinus is divided into three **zones**. Zone 1 is the periportal region and zone 3 the perivenous **region**. Functional differences between the two are thought to relate to composition of the perfusing blood; periportal hepatocytes are exposed to higher concentrations of solutes and oxygen (Gumucio, 1989). Many **metabolic** processes appear to be regulated by blood composition e.g. the zonal sites of maximal oxygen consumption and carbohydrate metabolism change as the direction of perfusion is changed. Although the oxygen tension of the sinusoidal blood might be expected to affect MFO activity, in fact activity seems to be unaffected by the direction of blood flow and instead appears to be associated with perivenous hepatocytes suggesting a heterogeneous distribution of P450 isozymes (Gumucio, 1989). Many hepatotoxins e.g. paracetamol, carbon tetrachloride, cause predominantly zone 3 necrosis i.e. perivenous, which also suggests that P450s may not be evenly distributed within the acinus. **Alternatively**, zone 3 hepatocytes may be more susceptible to damage

from P450-generated metabolites e.g. low levels of glutathione peroxidase in perivenous hepatocytes have been reported (Kera et al., 1987), From the work that has been done to date, P450IIE1, IIB1/2 and IA1 appear to be predominantly expressed in the centrilobular region or zone 3 (Gumucio and Chianale, 1988; Ingelman-Sundberg et al., 1988).

## 1.4 METHODS OF STUDYING HEPATIC DRUG METABOLISM AND TOXICITY

### 1.4.1 In vivo and perfused organ studies

There are many different techniques available for studying P450-mediated metabolism and toxicity including whole animal studies, intact cells, use of subcellular fractions and purified isozymes. In vivo metabolism studies involve sampling of urine, serum or expired air after administration of a drug, followed by analysis of metabolites or biochemical indicators of tissue damage. Thus, the different metabolites of a **radiolabelled** dose of antipyrine can be recovered from samples, providing information on the extent of **metabolism**, the relative proportions of the various metabolites and their rate of production and clearance (Poulsen and Loft, 1988), whilst the presence of **liver-specific** enzymes such as aspartate and alanine aminotransferases in serum samples are sensitive indicators of the extent and severity of hepatic damage (depending on whether the enzyme is cytoplasmic or organellar; Animal Clinical Association, 1988). However, whole animal studies are slow and costly and unsuitable for mechanistic studies or investigations into drug effects at the cellular level. For these reasons investigators have turned to in vitro methods of studying **metabolism**.

The perfused liver has been used as an alternative to in vivo studies of drug metabolism. The liver is perfused via the portal vein, but this must be initiated in situ to reduce the period of

potentially deleterious anoxia (Thurman and Kaufmann, 1980). The advantages of this system are that it is easy to sample the perfusate, the tissue can be **freeze-clamped** prior to future analysis and conditions can be carefully controlled, with high doses of drug being administered without the complication of toxicity in a whole animal. This approach has been used to investigate many aspects of drug metabolism including measurement of binding spectra and redox states of P450 (Sies and Brauser, 1970) and the biotransformation of drugs (e.g. valproic acid, Rettenmeier et al., 1985). However, the viability of these perfused organs is limited to a few hours, high flow rates must be used for **haemoglobin-free** perfusates (which is necessary since the presence of haemoglobin decreases MFO activity, interferes with fluorescence measurements and results in progressive haemolysis) and large volumes of perfusate are required in non-circulating systems (Thurman and Kauffman, 1980).

#### 1.4.2 In vitro techniques

Since the P450 system is located in the ER, microsomal fractions have been used to study drug metabolism and toxicity at the subcellular level. The studies include measurement of spectral changes on binding of substrate to P450 (Schenkman et al., 1967) determination of P450-dependent enzyme kinetics (Boobis et al., 1981); the metabolic activation of hepatotoxic compounds (Boyd et al., 1978; Ravindranath and Boyd, 1985); the detection of reactive metabolites (Garle and Fry, 1989). However, although microsomal fractions can generate active metabolites, no information is

obtained about possible cytotoxicity of these metabolites. There have been attempts to combine rodent S-9 fractions (9000g supernatant: microsomes and **cytosol**) with cultured cells to detect cytotoxic metabolites e.g. the activation of bromobenzene by S-9 fractions to metabolites cytotoxic to cultured Chinese hamster fibroblast cells (Horner et al., 1987); however, the use of this approach is not widespread in cytotoxicity studies, although microsomes/S-9 fractions are routinely used as the activation system in in vitro **mutagenesis** assays (Maron and Ames, 1983).

It is now possible to isolate and purify individual P450 enzymes, from **solubilised** microsomes and examine their catalytic properties in reconstituted systems (Lu and West, 1980). P450s, like other proteins, can be purified by gel electrophoresis, although resolution of individual isozymes by differential mobility due to molecular weight is difficult, since the molecular weight of most P450s is in the 45,000-60,000 **dalton** weight range. Purification and characterization of isozymic forms has been facilitated by the use of antibodies, although crossreactivity with closely related isozymes is always possible, even with monoclonal antibodies (Gonzalez, 1989).

However, the use of antibodies, in combination with microsomes and purified P450s in **reconstituted** systems has allowed both quantitation of different isozymes and estimations of isozymic

contributions to metabolism to be made e.g. an antibody to P450IIA1 that inhibited more than 98% of microsomal testosterone - ~~7α~~ -hydroxylase activity was used to probe the effects of age, sex and xenobiotics on P450IIA1 expression (Arlotto and Parkinson, 1989); antibodies have been used in conjunction with microsomes and reconstituted systems to identify P450IIC6, IIC11 and IIB1 as the isozymes that are primarily responsible for the activation of **cyclophosphamide** (Clarke and Waxman, 1989). There are disadvantages to the use of these systems: incorporation of different lipids in the reconstituted systems can affect the measured catalytic rate (Yamazoe et al., 1988); purified P450s may exhibit activities on reconstitution that cannot be inhibited by specific antibodies to the isozyme and vice versa (Waxman et al., 1985; Yamazoe et al., 1988); there is also the problem of crossreactivity of antibody preparations with more than one isozyme.

There are other difficulties associated with biochemical techniques for isolation and purification of P450 isozymes, in that intrinsic membrane proteins are difficult to purify, particularly the minor forms expressed at **very** low levels (e.g. extrahepatic P450s). There is also the problem of homogeneity, since **very** similar P450s can have identical **SDS-gel** mobilities, amino-terminal primary sequences and reactions with antibodies. These problems can be largely overcome by the use of molecular biological techniques. It is possible to generate cDNA (**complementary DNA**) libraries from mRNAs isolated from untreated or induced **animals**. Clones of these cDNAs

can then be screened with cDNA probes synthesized from the mRNAs, This method can also be used for low abundance mRNAs, by screening with antibodies. The development of cDNA expression vectors has further aided the isolation of minor P450 isozymes (Gonzalez, 1989).

Purified P450s are particularly useful for investigating substrate specificity and catalytic activity of individual isozymes (assuming that the preparation is homogeneous for a single isozyme). In addition, purified P450s and cDNAs can be used to analyse the primary amino acid and nucleotide sequences of the P450s. This has allowed the evolutionary and structural **relationships** between different isozymes to be explored (Nebert and Gonzalez, 1987).

The major limitation to the use of subcellular **fractions** and purified isozymes is in the effects of **P450-metabolism** on the intact cell, and the assessment of toxic potential. Intact cell systems possess the Phase II enzyme systems in addition to the MFO system, and since the balance between these two systems is crucial for determining the toxicity of many compounds the development of intact cell systems for metabolism studies has received much attention in the **last** twenty years.

#### **1.4.3 Intact cell systems**

The use of intact cells, i.e. isolated hepatocytes, cultured hepatocytes and cell lines, has several advantages over the sub-cellular preparations discussed above, including the presence of

intact intracellular **organisation**, Phase I and Phase II metabolism and physiological levels of co-factors (Fry, 1982). In addition, hepatocytes can be isolated from other liver cells and maintained in a defined environment free from nervous and hormonal influences. A preparation of **phenotypically** similar cells can be obtained, and many parameters of cellular **function/metabolism** can be examined concurrently. Isolated hepatocytes have been used to study many aspects of drug metabolism e.g. the metabolism of menadione (Thor et al., 1982); the effect of **tert-butyl** hydroperoxide metabolism on the pentose phosphate pathway (Rush and Alberts, 1985); the effect of ascorbic acid on conjugation of **4-hydroxybiphenyl** (Paterson and Fry, 1983); species differences in paracetamol toxicity (Tee et al., 1987); the effect of induction on the covalent binding of valproic acid (Porubek et al., 1989b). Although the cells are intact, there is disruption of the spatial heterogeneity of the liver (Thurman and Kauffman, 1980); however, the major drawback to the use of isolated hepatocytes is their limited life-span in suspension (several hours). In order to prolong the useful life span of hepatocytes for in vitro studies, methods of primary culture were devised, and these are discussed in the following section.

#### 1.4.4 Hepatocytes in primary culture

In the early seventies, it was reported that a high yield of viable hepatocytes could be isolated from adult rats by **collagenase-hyaluronidase** perfusion of the liver, and that these cells could be readily cultured (**Iype**, 1971; Williams and Gunn, 1974). After an initial burst of **proliferative** activity the cultures became static and many of the cells died. Since the reports of these early studies that established that hepatocytes could survive in primary culture, a large volume of research has ensued to enhance the longevity and improve the maintenance of the phenotype of hepatocytes in culture.

Some of the earliest work investigated the effects of media composition, especially the presence or absence of hormones, on cell survival and biochemistry. It was reported that inclusion of foetal calf serum (FCS) in the medium gave maximal attachment of rat hepatocytes at a concentration of 10%; the presence of **insulin** ( $2\text{mUml}^{-1}$ ) in addition to the FCS increased attachment further with the formation of confluent cultures, although there was no improvement in cell survival in the presence of **insulin**: 75% survival at 24 hours, around 30% survival at 48 hours (Laishes and Williams, 1976a). Inclusion of DEX ( $1\mu\text{M}$ ) maintained the morphology of the hepatocytes and increased longevity of the **cultures**: more than 80% of the cells survived for three days (Laishes and Williams, 1976b). It was later reported that DEX inhibited the production of a neutral protease, **and it** was suggested that this contributed to

the increased cell survival (Williams et al., 1978). Other workers reported that more than 80% of hepatocytes cultured in Williams' Medium E (WE) containing 10% FCS, insulin ( $10^{-6}\text{M}$ ) and DEX ( $10^{-5}\text{M}$ ) survived for six days in culture, and that, in contrast to freshly isolated cells, protein synthesis could be stimulated by hormones, the induction of tyrosine aminotransferase (TAT) and ornithine decarboxylase could be demonstrated and there was an increase in protein secretion into the medium. It was also shown that the **polysomes, which** disaggregated in freshly isolated cells, had reaggregated after five days in culture (Tanaka et al., 1978). In the presence of glucocorticoid, insulin and glucagon, the activities of glucokinase, pyruvate kinase and hexokinase were maintained for 2-3 weeks in rat hepatocyte cultures, in addition to albumin secretion and urea synthesis (Dich et al., 1988).

However, an increase in foetal hepatic protein expression, with a concomitant decrease in adult-specific proteins has been reported in primary cultures. As early as 1975, Guguen et al. observed that after seven days in primary culture the predominant form of pyruvate kinase in the **cells** isolated from adult rats was the K-type. This form is present in foetal liver, placenta and hepatoma cells, but is a minor form in adult parenchymal cells, where the L-type predominates. This form was detectable for five days in culture, but then decreased. **Gamma-glutamyl** transpeptidase (GGT) and  **$\alpha$ -foetoprotein** (which are not normally expressed in adults) also increase in rat hepatocytes **cultured** for more than three days

(Sirica et al., 1979). GGT levels are normally very low in adult **liver** and in early hepatocyte cultures, but levels are much higher in foetal and neonatal liver, and in rat hepatoma cells (Edwards, 1982). Although the presence of FCS in the medium suppressed the increase in GGT, DEX actually induced GGT in primary cultures, the effect being particularly marked at higher pH levels (i.e. 7.8; Edwards, 1982). It is not known why this reversion to the foetal phenotype occurs in culture, although the observed changes appear to be associated with less differentiated/ proliferative cellular states; however, these alterations in phenotype would seem to limit the use of hepatocyte primary culture to short-term studies.

In 1977 it was reported that the **drug-metabolizing** capacity of rat cultured hepatocytes was markedly reduced, compared to the **liver in vivo** (Guzelian et al., 1977), The P450 content of **non-proliferating** primary cultures was 20% of the initial fresh cell value at 24 hours, with 63% of the P450-reductase **remaining**. Although there was this rapid decrease in P450 levels, no increase in P420 was detected. The maintenance of P450-dependent enzyme activities after 24 hours in culture was variable: **aminopyrine-N-demethylase** and aniline hydroxylase activities both decreased by more than 70%, and aryl hydrocarbon hydroxylase (AHH) activity fell by more than 50%, whereas **nitroanisole** demethylase was maintained at 85% of the initial activity. Therefore, it appeared that there was selective loss of P450 activities (and therefore isozymes) in **culture**. The general **decline** in total P450 has been reported by

many workers and is not restricted to rat hepatocytes in culture: P450 declines in cultures from other rodent species (Maslansky and Williams, 1982), and in human cultured hepatocytes (Grant et al., 1985). This serious phenotypic alteration is a major obstacle in the use of hepatocytes for **metabolism/toxicity studies**. For this reason, many different ways of improving the maintenance of P450 in culture have been investigated.

#### **1.4.5 Maintenance of P450 in primary culture**

Media composition has received a lot of attention with respect to maintenance of P450 in cultured hepatocytes, Decad et al. (1977) reported that medium supplemented with fatty acids, **delta-amino-laevulinate (ALA)**, **alpha-tocopherol** and various hormones (including insulin, hydrocortisone and thyroxine) maintained P450 content of rat cultured hepatocytes at 100% of the initial level for 24 hours. A similar medium was shown to significantly improve the maintenance of 7-ethoxycoumarin and 7-ethoxyresorufin **O-dealkylases** (ECOD, EROD) and **biphenyl-4-hydroxylase** activities (Dickins and Peterson, 1980). A more recent report suggests that hormone-supplementation alone cannot attenuate the loss of P450 in culture, although the presence of DEX (**1 $\mu$ M**) stabilised the total P450 content at 65% of initial levels for three weeks (Dich et al., 1988).

Ascorbate ( $4 \times 10^{-4}$  M) supplementation partially attenuated the early decline in P450 content, as well as improving the maintenance of cytochrome **b5** and P450 reductase (**Bissell and Guzelian**, 1979). Paine

et al. (1979) demonstrated that the NAD content (NAD<sup>+</sup> and NADH together) of rat hepatocytes after 24 hours in culture was 40% of the fresh cell value, and that nicotinamide supplementation could prevent the loss of NAD. In addition, unphysiological levels of nicotinamide i.e. 25mM could prevent the loss of P450 in culture. Isonicotinamide was more effective in maintaining P450 levels, but had no effect on NAD content. A substituted pyridine, metyrapone (0.5mM) was also effective in preventing the loss of total P450 in rat hepatocyte **cultures**: more than 95% of the total P450 remained after seven days in culture, compared to only 48% at 24 hours in medium lacking metyrapone (Paine et al., 1982). This medium also maintained **ethylmorphine-N-demethylase** activity for four days, together with a gradual increase in benzphetamine-N- **demethylase** to 84% of the initial value over the same time-period. There was also induction of both ECOD and EROD activities over the four days in culture (Lake and Paine, 1982). Therefore, the maintenance of activities observed in culture was not always at the same level as in vivo. A cystine/cysteine-free medium containing ALA maintained total P450 at 96% for 24 hours, however, all enzyme activities were **very low** (Lake and Paine, 1982).

Nicotinamide, at a lower concentration (5mM) than that reported by Paine et al. (1979) was shown to **stabilise** ECOD and 7-propoxycoumarin **O-dealkylase** (PCOD) activities in rat cultured hepatocytes (around **50-60%** of fresh cell values) similar to DEX alone, whereas nicotinamide and DEX (**1µM**) together resulted in large

increases in these activities. However, this effect was still selective for certain P450 forms in that there was no effect on the decline of **7-methoxycoumarin** O-dealkylase (MCO) activity in culture (Warren and Fry, 1988).

Steward et al. (1985) reported the differential decline of immunoreactive P450 isozymes in primary culture. It was also observed that whereas the total immunoreactive P450 fell to 76% after 72 hours, the total spectrally active haemoprotein was 68% of initial levels, and it was suggested that loss of haem was responsible for a loss of **holocytochrome** in culture. The same report showed that metyrapone attenuated the loss of immunoreactive P450 over 72 hours, and that nicotinamide had a selective effect with respect to maintenance of immunospecific P450s in culture.

Inclusion of exogenous haem, ALA and selenium has also been reported to maintain total P450 for 72 hours in culture (Engelmann et al., 1985) and 3mM PB has been shown to markedly enhance the long-term survival of hepatocytes in culture, with attenuation of the decline in total P450 (Miyazaki et al., 1985).

Vind et al. (1988) reported that **hormonal-supplementation** of culture media diminished the loss of P450 over 72 hours only in hepatocytes from adult female rats; there was no effect on hepatocytes from adult males. Croci and Williams (1985) observed little difference in the % maintenance of P450, AHH and benzphetamine-N -demethylase

activities in hepatocytes cultured for 24 hours in hepatocytes from male and female rats, with sex differences in basal activities being maintained in culture. However, glutathione conjugation of 1,2-dichloro-4-nitrobenzene declined rapidly in hepatocytes from male rats to around 20% of the fresh cell value; hepatocytes from female rats only lost 66% of this **activity**.

Thus, media **supplementation** can profoundly affect the maintenance of P450 and its associated activities. Many supplements appear to exert selective effects on particular isozymes, which are not reflected in measurements of total P450, but are unmasked on immunochemical detection or determination of enzyme activities. Different effects are also observed depending on the concentration (and possible interactions with other supplements) **used**. This is particularly true for hormonal supplementation. Many different media are employed, depending greatly on personal preference and the aim of the study. However, no medium has yet been formulated that maintains in vivo P450 levels in culture, **qualitatively** or quantitatively.

Early work involved plating of isolated hepatocytes directly onto plastic culture vessels (e.g. Laishes and Williams, 1976a and b), or onto plastic coated with a thin layer of rat tail collagen (e.g. Bissell and Guzelian, 1980; Dickins and Peterson, 1980) to improve attachment and spreading of the hepatocytes. Other workers have investigated the effects of **extracellular** matrix components on

hepatocyte function and maintenance of phenotype. Hepatocytes cultured on floating **collagen gels** have been reported to have a superior induction response of TAT to hydrocortisone ( $10^{-5}$  M) after eight days in culture relative to cultures on the usual **collagen-coated** plates (Michalopoulos and Pitot, 1975); P450 and cytochrome b5 were maintained at detectable **levels** after ten days of culture on floating collagen gels (Michalopoulos et al., 1976). In a comparison of different extracellular matrix components (Sawada et al., 1987) there were no differences in attachment, longevity or induction of TAT; however, after two weeks in culture GGT activity was highest in cells cultured on collagen and lowest in cells cultured on fibronectin. Matrigel is a mouse tumour cell extract, which has been shown to be superior to collagen as a substratum for hepatocyte culture (Schuetz et al., 1988). More cells survived for eight days on Matrigel than on collagen and there was increased secretion of albumin, transferrin, haemopexin and glutathione peroxidase on Matrigel. Haem oxygenase and P450 reductase gradually declined over the eight day culture period. However, it is still not clear whether the observed changes in gene expression (many of the studies on substrate effects on hepatic function have not involved P450 activities) are sufficiently advantageous to routinely supplant the use of **collagen-coated** plates, or **electrostatically-treated** plates ('Primaria' plates, obtainable from Falcon Plastics) which appear to be equivalent with respect to maintenance of hepatocyte cultures.

Another method for maintenance of P450 in culture, which has received a lot of attention in recent years is co-culture of hepatocytes with other hepatic cells. Begue et al. (1984) demonstrated that in hepatocytes co-cultured with rat liver **epithelial cells** P450 was maintained at initial **levels** for nine days, together with aminopyrine **N-demethylase activity**. The P450 content and demethylase activity of conventional cultures declined to negligible levels after four days in culture.

Overall, manipulation of culture media composition appears to be the most successful (and also the simplest) method of maintaining P450 and its associated activities in short-term primary cultures (less than 72 hours) of hepatocytes, although the effects of supplementation are selective for particular isozymic forms. Although different substrata and the presence of other cell types can affect hepatic gene expression and biochemistry, relatively **little** is known about the effects of these culture components on the **drug-metabolizing** system of cultured hepatocytes.

#### 1.4.6 Induction of P450 in culture

It was mentioned above that 3mM PB attenuated the loss of P450 in primary cultures of rat hepatocytes; however, P450IIB1, the major PB-inducible isozyme was not **immunochemically** detectable in these cells (Miyazaki et al., 1985). Other workers have also reported a reduced or **negligible** response of P450 to inducers in culture, especially the response to barbiturates. Forster et al. (1986)

reported that the **aldrin** epoxidase activity of rat hepatocytes declined to 55% and 8% of initial levels at 1 and 5 days in culture respectively, and that PB and PCN treatment resulted in statistically insignificant increases in this activity, in contrast to the situation in vivo. Benzanthracene and PB both induced EROD activity in culture (12- and 8-fold respectively), this induction being markedly reduced in the absence of DEX (present in the medium). It was also shown that the time-course of induction depended on the media used, and that P450IA1 increased over five days in control cultures. This anomalous increase in **3-MC-inducible, alpha-naphthoflavone-inhibitible P450s** in untreated cultures has also been observed by others (Fry et al., 1980; Turner and Pitot, 1989), although the reason is unknown. PB and BNF induction of ECOD activity is much reduced in culture compared to in vivo, even in the presence of DEX (Warren and Fry, 1988), as is the induction of **pentoxyresorufin** O-dealkylase by PB in chemically-defined media (Turner and Pitot, 1989). Cultured hepatocytes have also **been** used to study the **metabolism** of 2-AAF(McManus et al., 1987), In control cultures, **3-hydroxylation** remained constant for 24 hours in culture, whereas the 1-, 5-, 7-, 9- and **N-hydroxylations** declined rapidly. DEX (0.1µM) did not prevent the initial decline in activity, but after 72 hours in culture the 5- and **3-hydroxylations** activities had increased over initial levels and the **7-hydroxylation** activity had increased to initial levels (after a decline at 24 hours). There was also some recovery of **N-hydroxylation**. PCN only induced **7-hydroxylation** in

vitro. It was noted that the induction response in vitro was much smaller than that seen in vivo, and also **qualitatively** different, 3- and **5-hydroxylation** being induced by DEX in vitro but not in vivo. Therefore, media composition also affects induction responses in vitro, although in general, P450 induction in vitro is poor, and **qualitatively** as well as quantitatively different to that seen in vivo. This will be discussed further in Chapter Five.

#### 1.4.7 Metabolism/toxicity studies in cultured rat hepatocytes

In 1977, Decad et al. demonstrated that aflatoxin B<sub>1</sub> could be metabolised by cultured hepatocytes to aflatoxin M<sub>1</sub> and various conjugates. It was also shown that a significant amount of radioactivity (after exposure to radioactive aflatoxin) was non-extractable i.e. remained bound to the hepatocytes.

Rat hepatocyte cultures have also been used to demonstrate that substantial acetaminophen covalent binding in the cells occurs before any observable toxicity, and that the covalent binding is mostly in the microsomal fraction (37%) and in the cytosol (25%; Acosta et al., 1987). It has also been shown that cyclophosphamide can be activated to a metabolite stable enough to kill fibroblasts co-cultured with the hepatocytes, and that the toxicity can be inhibited by SKF-525A (Fry and Bridges, 1977).

Cultured hepatocytes have also been used to discriminate between hepatotoxic and non-toxic substances, especially of a related group of compounds e.g. non-steroidal anti-inflammatory drugs (Sorensen and Acosta, 1985). It was demonstrated that indomethacin was the most toxic of the five compounds tested, followed by benoxaprofen and ibuprofen, and aspirin and orpanoxin were non-toxic at the concentrations tested, as judged by viability, lactate dehydrogenase leakage and urea synthesis of the cultures, A more detailed discussion of the parameters used to assess toxicity is given in Chapter Seven.

#### 1.4.8 Human hepatocytes in primary culture

Less work has been done on drug metabolism in human cultured hepatocytes since adult samples are difficult to obtain and it is much harder to get high yields of cells suitable for culture, mainly due to the nature of the samples. However, from the work that has been done, it appears that human hepatocytes in culture de-differentiate slower than their rodent counterparts, and also, that the P450 content declines more slowly: 60% of the spectrally determined P450 remains after four days in culture (Strom et al., 1987). Grant et al. (1987) demonstrated that P450-dependent activities and glucuronidation were well maintained for 72 hours in human cultured hepatocytes; sulphation however decreased within the first 24 hours, and the P450 reductase had declined to 32% after 72 hours in culture. Begue et al. (1983) investigated the metabolism of an anti-anaphylactic, ketotifen, in human cultured hepatocytes: the main metabolites produced in vitro correlated with the known metabolic pathways in vivo. Also, the rate of metabolism did not alter significantly over the first four days of conventional culture, or seven days for human hepatocytes co-cultured with rat epithelial cells. Thus, human hepatocytes would appear to have several advantages over rodent hepatocytes with respect to maintenance of drug metabolism in vitro.

#### 1.4.9 Use of hepatoma cell lines

It is still not possible to obtain substantial (and reproducible) levels of mitotic activity in adult cultured hepatocytes. Some

work has been done on drug metabolism in hepatoma cell lines, both human and rodent in origin, since a dividing cell line would provide a continuous supply of hepatocytes, obviating the need to isolate and culture cells for every study. Wiebel et al. (1984) examined the P450 activity of six differentiated rat hepatoma cell lines and found that the constitutive activities were very low, and some were undetectable. The expression of MFO sensitive to antibodies to PB-inducible P450s was present in widely differing amounts in the differentiated lines, Benzanthrancene, PB and DEX induction of P450 IA1 and AHH activity and PB and DEX induction of P450IIB1/2 and aldrin epoxidase have also been observed in differentiated cell lines (Wiebel et al., 1984; Corcos and Weiss, 1988). The human hepatoma, HepG2 has been shown to have levels of glucuronidation and cytochrome reductase similar to those of freshly isolated human hepatocytes although levels of O-dealkylation were reduced (Grant et al., 1988). Although HepG2 cells remain differentiated in culture, their P450 content was 10-20% that of fresh human hepatocytes, and their P450 activities were 10-fold lower. However, medium composition altered drug metabolism activities (Doodstdar et al., 1988). HepG2 cells also synthesize and secrete the major plasma proteins, and morphologically resemble hepatocytes, although they do possess an abnormal chromosome number (50-56) with a distinctive rearrangement of chromosome 1 (Knowles et al., 1980).

#### 1.4.10 Species differences in metabolism

The preceding sections referred primarily to the use of rodent in vitro systems, principally rat hepatocytes, in the study of drug metabolism and mechanisms of toxicity. Increasingly these cells are being used in the development of predictive toxicity tests. In addition to the limitations imposed by the decline of P450 and metabolic capacity in vitro discussed above, there are also problems, particularly with toxicity testing, associated with **extrapolation** both from in vitro to in vivo and from rodents to Man.

Correlations between drug metabolism studied in vivo and in vitro have been discussed in the previous sections (1,3.1-5) and the same advantages of in vitro techniques with respect to the study of drug metabolism also extend to toxicity studies. Many compounds e.g. heavy metals, mineral fibres and arsenic usually test negative in short-term mammalian cell culture assays, despite the fact that they are known human carcinogens (Lave and Omenn, 1988). In addition, volatile and particulate compounds present special problems. There is also the problem of detection of pro-toxins i.e. the test system must be able to activate known non-toxic precursors to their reactive intermediates. The most successful in vitro toxicity assays to date have been those that detect genotoxins by assessing DNA damage e.g. unscheduled DNA synthesis (UDS) and sister chromatid exchange (Grisham and Smith, 1984). The sensitivity of the UDS assay has been improved by use of rat hepatocytes cultured from animals **pre-treated** with MFO inducers i.e. Arochlor 1254 and PB

(Shaddock et al., 1989). Hepatocytes from inducer-treated animals have also been used as an activation system for the mouse lymphoma cell mutagenicity assay (Oglesby et al., 1989).

Even when in vitro toxicity information has been obtained, there is still the problem of correlation with the in vivo data, as to which measure of acute toxicity is the most suitable comparison (Fry et al., 1988). The in vivo data exists in many forms with variations in routes of administration, species tested and assessment of toxicity. It is also difficult to make sensible **extrapolations** of toxic concentrations from static culture systems to organisms with dynamic **elimination** systems.

There are also many known species differences in P450 metabolism, reviewed by Kato (1979), which have important implications for (but do not necessarily preclude) the use of experimental animals in the assessment of human metabolism and toxicity. There are species differences with respect to rate of **metabolism e.g. hexobarbitone** sleep time (Quinn et al., 1958) and the pattern of metabolites produced from a given substrate e.g. **7-hydroxycoumarin** is the major metabolite of coumarin in Man, whereas in the rat **3-hydroxylation** predominates, with **very** little 7-hydroxycoumarin being produced (Cohen, 1979). Species differences in P450 composition can result in differences in toxicity due to differing metabolite profiles e.g. the guinea pig, unlike the rat, mouse and rabbit, is resistant to 2-AAF-induced hepatomas. The guinea pig forms very

little N-hydroxylated-AAF, with ring hydroxylations predominating. In contrast, N-hydroxylase activity in the other species correlated well with susceptibility to 2-AAF-induced carcinoma, with hamsters being the least resistant, with the highest N- and lowest ring-hydroxylase activities (Miller et al., 1960; Kato, 1979). Thus, differences in metabolite profiles could be used to predict toxicity in susceptible species. It has also been shown that species differences in susceptibility to paracetamol-induced necrosis correlate with the extent of tissue covalent binding and GSH depletion (Davies et al., 1974). There are also differences in induction and inhibition (Kato, 1979). Another problem is that experimental animals are highly inbred and kept under uniform conditions e.g. diet, and therefore, unlike humans, are very homogeneous with respect to response on exposure to xenobiotics (Gregory, 1988). However, the rat is still the most popular model for studying P450 metabolism and toxicity, not least because of the large accessible data base, and the ready availability of animals. Despite the differences in metabolism, vast improvements in predictive toxicology could be made by increased understanding of mechanisms of toxicity, and routes of metabolism in susceptible and resistant species (Grisham and Smith, 1984).

### 1.5 RATIONALE AND AIMS OF THIS STUDY

The aims of this study were to develop an in vitro system for the investigation of hepatic cytochrome P450-mediated **toxicity**. Cultured rat hepatocytes have the potential for use as a prime in vitro model of hepatic drug metabolism and toxicity as has been discussed above (1.4.3 - 1.4.4). However, in order to investigate hepatic **metabolism-mediated** toxicity, the full range of biotransformation and detoxification enzymes must be present and active in the cultured cells. In this respect, the inability to maintain the P450 isozymes in cultured hepatocytes has proved to be a major drawback to their use in **activation/toxicity** studies. The large body of work concerned with the maintenance of P450 in culture was reviewed in section 1.4.5, Included in this was the effects of media supplementation of P450 activity in vitro. It has been shown that DEX in particular could maintain P450 activities in primary culture, and that DEX (**1 $\mu$ M**) and nicotinamide (5mM) together improved the maintenance of P450-dependent **alkoxycoumarin** O-dealkylase activities in vitro (Warren et al., 1985; Warren and Fry, 1988). However, this maintenance was selective in that the ECOD and PCOD activities were well maintained for 72 hours, whilst MCOD activity was rapidly lost in culture (Warren and Fry, 1988). In the same study, reduced induction by PB and BNF in vitro compared to in vivo was reported.

Most of the work presented here was concerned with developing the culture conditions described above to support both the stable maintenance of a wider range of P450 activities and also induction of P450s in vitro. The effects of induction in vivo on P450 activity and P450-mediated toxicity in vitro were also investigated.

## **TABLES AND FIGURES**

**TABLE 1.1. ENDOGENOUS AND XENOBIOTIC SUBSTRATES OF CYTOCHROME P<sub>450</sub><sup>1</sup>.**

<b>SUBSTRATE</b>	<b>REACTION</b>
<i>steroids</i> <i>prostaglandins</i> <i>leukotrienes</i> <i>arachidonic acid</i> <i>vitamin D</i> <i>lauric acid</i> phenobarbitone	HYDROXYLATION (aryl or aliphatic)
<i>arachidonic acid</i> benzo-pyrene bromobenzene	EPOXIDATION
<i>thyroid hormones</i> halothane	DEHALOGENATION
<i>uroporphyrinogen</i> <sup>2</sup> valproic acid <sup>3</sup>	DESATURATION
benzphetamine codeine 6-methypurine	N-,O- and S- DEALKYLATION
amphetamine	OXIDATIVE DEAMINATION
2-acetylaminofluorene	N-OXIDATION
ethanol	ALCOHOL OXIDATION
azo, nitro compounds halogenated hydrocarbons	REDUCTION

---

<sup>1</sup> information from Gibson and Skett (1986), except where indicated.

Endogenous substrates are in italics, and xenobiotic substrates in plain print.

<sup>2</sup> Jacobs *et al.*, 1988

<sup>3</sup> Rettie *et al.*, 1988

**TABLE 1.2. P<sub>450</sub> NOMENCLATURE.** P<sub>450</sub> nomenclature has now been standardized by Nebert *et al.*(1987,1989), and this is shown in the first column below. Isozyme designations from different laboratories are shown in subsequent columns, and are based on the summaries by Waxman (1988) and Ryan and Levin (1990).

	LEVIN	GUENGERICH	SCHENKMAN	WAXMAN	KAMATAKI
<b>IA1</b>	c	BNF-B			
<b>IA2</b>	d	ISF-G			
<b>IIA1</b>	a	UT-F	RLM2b	3	
<b>IIA2</b>	m*				
<b>IIB1</b>	b	PB-B	PB RLM5	PB-4	
<b>IIB2</b>	e	PB-D	PB RLM6	PB-5	
<b>IIC6</b>	k	PB-C	RLM5a/PBRLM4	PB-1	
<b>IIC7</b>	f		RLM5b		
<b>iiC11</b>	h	UT-A	RLM5	2c	male
<b>IIC12</b>	i	UT-I	fRLM4	2d	female
<b>IIC13</b>	g		RLM3(g)		
<b>IIE1</b>	j		RLM6		
<b>IIIA1</b>	p				
<b>IIIA2</b>			PCN-E"	2a**	

\* Arlotto and Parkinson, 1989.


\*\* It is not entirely clear which of the isozymes isolated in the different laboratories are equivalent to P<sub>450</sub>IIIA1, and which to P<sub>450</sub>IIIA2; also, there have been changes in nomenclature of these isozymes within laboratories; the multiplicity of this particular gene family has been discussed by Halpert (1988).

**TABLE 1.3. ENDOGENOUS AND XENOBIOTIC SUBSTRATES OF PHASE II METABOLISM<sup>1</sup>**


<b>SUBSTRATE</b>	<b>REACTION</b>
<i>steroid hormones</i> <i>bilirubin</i> <i>thyroxine</i> <i>catecholamines</i> acetaminophen salicylic acid morphine	GLUCURONIDATION
<i>steroids</i> <i>heparin</i> acetaminophen 2-acetylaminofluorene salicylamide	SULPHATION
<i>histamine</i> <i>catecholamines</i> thiouracil	N-METHYLATION
<i>serotonin</i> Isoniazid	ACETYLATION
<i>bile acids</i> benzoic acids	AMINO ACID CONJUGATION
<i>bilirubin</i> <i>steroids</i> <i>leukotrienes</i> <i>vitamin K</i> bromobenzene acetaminophen urethane	GLUTATHIONE CONJUGATION

---

<sup>1</sup> information from Gibson and Skett (1986) and Ziegler(1988).  
Endogenous substrates in italics, xenobiotics In plain print.



**FIGURE 1.1. THE CYTOCHROME P<sub>450</sub> CATALYTIC CYCLE,**  
 Based on information from several sources, including Jansson *et al.*,  
 (1985) and Gibson and Skett (1986).



**FIGURE 1.2.** DIAGRAMMATIC REPRESENTATION OF THE LIVER ACINUS. Adapted from Gumucio and Chianale (1988).

The concept of the acinus as the functional unit of the liver was first proposed by Rappaport *et al.* (1954).

A terminal hepatic venule

B bile ductule

C hepatic arteriole

D terminal portal venule

E zone 1, periportal region

F zone 2, midzonal region

G zone 3, pericentral or perivenous region

Arrows show the direction of blood flow.

CHAPTER 2

MATERIALS AND METHODS

**CHAPTER 2**

<b>CONTENTS</b>		<b>PAGE</b>
<b>MATERIALS</b>		<b>60</b>
2.1	ANIMALS	60
2.2	CHEMICALS	60
<b>METHODS</b>		
2.3	STERILIZATION PROCEDURES	62
2.4	ISOLATION OF HEPATOCYTES	63
2.5	ASSESSMENT OF CELL VIABILITY	67
2.5.1	Trypan blue exclusion	67
2.5.2	Reduction of MTT	67
2,6	USE OF FRESH CELLS	68
2,7	PRIMARY CULTURE OF HEPATOCYTES	68
2,7.1	<b>Culture</b> medium	68
2,7.2	Culture procedure	69
2,8	PREPARATION OF CELL HOMOGENATES	69
2.9	DETERMINATION OF PROTEIN	70
2.10	ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES	70
2.10.1	Kinetics	70
2.10.2	Determination of activity	72
2.11	DETERMINATION OF P450 CONTENT	73
2.12	ANALYSIS OF ENZYME ACTIVITIES IN CELL HOMOGENATES	73
2,13	DETERMINATION OF 7-ETHOXYRESORUFIN O-DEALKYLASE ACTIVITY	74

2.14	DETERMINATION OF NITROPHENOL HYDROXYLASE ACTIVITY	75
2.15	DETERMINATION OF N-DEMETHYLASE ACTIVITY	75
2.16	DETERMINATION OF CELLULAR GLUTATHIONE	76
APPENDIX		77
A2,1	Kinetic analysis of enzyme activity	77
A2,2	Statistical analyses	79

TABLES AND FIGURES

## CHAPTER 2

### MATERIALS AND METHODS

#### MATERIALS

##### 2.1 ANIMALS

The Wistar albino rats used in these studies were obtained from the University of Nottingham Animal Breeding Unit. Male and female rats (70 - 180g) were allowed free access to food and water and were housed at 22°C, with a 12 hour light/dark cycle (light: 08.00 - 20.00). The animals were bedded from birth on the synthetic bedding, Lablit (W.P. Usher, London, U.K.), to minimise enzyme induction from wood shavings (Vesell, 1982; Törrb'nen et al., 1989).

##### 2.2 CHEMICALS AND EQUIPMENT

The suppliers of the chemicals used in these studies were as follows: **delta-aminolaevulinate** hydrochloride, 7-methoxycoumarin, **2-methylfuran**, resorufin and selenious acid were obtained from Aldrich Chemical Co. (Dorset, U.K.); foetal calf serum, glutamine, trypan **blue** and **Williams'** medium E, **cellulose acetate filters** (pore size 0.2µm) and plate sealers were obtained from Flow Laboratories (Irvine, Scotland); collagen type I was obtained from B.C.L. (Sussex, U.K.); phenobarbitone and acetyl acetone were obtained from **B.D.H.** (Dorset, U.K.); fungizone was obtained from Squibb Surgicare Ltd. (Hounslow, U.K.), dexamethasone (Decadron) from Merck, Sharp and Dohme Ltd. (Hoddesdon, U.K.), insulin

(Actrapid MC) from Novo Industri A/S (Denmark); and gentamicin from **Roussel** Laboratories Ltd. (Uxbridge, U.K.). Ammonium acetate, benzalkonium chloride, benzphetamine, **beta-glucuronidase H-I** (E.C. 3.2.1.31), **beta-naphthoflavone**, beta-NADP, bovine serum albumin, butylated **hydroxytoluene**, **collagenase** type IV (E,C, 3,4,24,3) Coomassie Brilliant Blue G, dicoumarol, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), EDTA, EGTA, erythromycin, **glucose-6-phosphate**, **glucose-6-phosphate** dehydrogenase type XI (E,C. 1.1.1.49), glutathione, hemin type 1, HEPES, hyaluronidase type II (E.C. 3.2.1,35), 7-hydroxycoumarin, **isoamylalcohol**, isoniazid (isonicotinic acid hydrazide), nicotinamide (niacinamide), **4-nitrocatechol**, **4-nitrophenol**, N,N-dimethylformamide, **o-phthalaldehyde**, Percoll, precocenes I and II, Rhodamine B, semicarbazide, 6-thiopurine (6-mercaptapurine) and valproic acid were all obtained from Sigma Chemical Co. (Dorset, U.K.). **4-Ipomeanol** was a gift from Dr. M.R. Boyd, National Cancer Institute, Bethesda, MD, U.S.A. **7-Ethoxycoumarin**, 7-propoxycoumarin and 7-ethoxyresorufin had been synthesized by the method of Prough et al. (1978). "Primaria" culture dishes were obtained from Falcon (Becton Dickinson Ltd., Oxford, U.K.) and **24-well** plastic culture dishes from Nunc (Denmark). All other reagents and organic solvents were of analytical reagent grade and obtained from local **suppliers.**

Low-speed centrifugation was carried out using an MSE Centaur bench centrifuge or an MSE Mistral 6000 refrigerated centrifuge.

A Stuart Tube Rotator TR-2 was used for extraction procedures. Cell suspensions were homogenised using an MSE Soniprep. Spectrophotometric analysis was carried out using a **Perkin-Elmer** 550S UV-Vis spectrophotometer or a Dynatech plate reader and fluorometric analysis was performed using a Baird RC200 Ratiometric fluorimeter.

## **METHODS**

### **2.3 STERILIZATION PROCEDURES**

Standard **sterilization** procedures and aseptic techniques were practised throughout these studies, as outlined by Paul (1970) in addition to **supplementation** of culture media with antibiotics to reduce the risk of microbiological contamination of cell cultures. Water baths and the water tray inside the incubator all contained benzalkonium chloride (0.1%), and the water was changed **frequently**.

#### **Dry heat**

All glassware (openings covered with aluminium foil) and glass pipettes (bunged with cotton wool and placed in metal canisters) were sterilized in a Gallenkamp oven, set at 160-180°C for 2 **hours**.

#### **Moist heat**

Plastic and rubber items, wrapped in aluminium foil, and heat stable solutions were autoclaved in a Cabburn autoclave set at 121°C for a 25 minute cycle.

## **Filtration**

Non-heat stable solutions and small volumes of liquid were sterilized by filtration through cellulose acetate filters with a 0.2 $\mu$ m pore size.

## **Aseptic technique**

All sterile procedures were performed in a laminar flow hood (Intermed, Microflow, Hants., U.K.) regularly swabbed with 70% alcohol. Bottle and glassware openings and pipettes were all regularly flamed during use.

## **2.4 ISOLATION OF HEPATOCYTES**

Hepatocytes were isolated either by the **slice** method of Paterson and Fry (1983) or by the lobe perfusion method of Reese and Byard (1981).

### **Slice method**

The wash solution was a calcium-, magnesium-free Hanks buffer pH 7.4 (140mM NaCl, 5mM KCl, 0.4mM KH<sub>2</sub>PO<sub>4</sub>, 0.3mM Na<sub>2</sub>HPO<sub>4</sub>, 20mM HEPES, 50 $\mu$ M phenol red, 20 ml l<sup>-1</sup> 0.5N NaOH), to which NaHCO<sub>3</sub>, glucose, methionine and gentamicin, at 14.8, 5.5, 2mM and 50 $\mu$ gm<sup>-1</sup> (final concentrations), were added on the day of **isolation**. The wash solution was pre-gassed with air/CO<sub>2</sub> (95%/5%), by placing in a LEEC incubator throughout the isolation.

The rat was killed by cervical dislocation, the liver lobes removed and placed in 10ml wash solution. The liver was blotted dry and

weighed; 3.0g was used. Subsequent manipulations were carried out in a flow cabinet. Individual lobes were placed on a filter paper on a Perspex sheet and thinly sliced using a degreased razor blade (Wilkinson Sword). Slices in 10ml wash solution were placed in a sterile 250ml conical flask sealed with a sterile rubber bung in a shaking water bath at 37°C, for 10 minutes at 90 **oscillations/minute**. The solution was then removed and the slices washed twice more. The cells were then washed twice with **10ml** wash solution containing 0.5mM EGTA. This chelating solution was removed and replaced with enzyme solution (10ml wash solution containing 1000 units (U) of collagenase Type IV, 4250 U of hyaluronidase and 5mM  $\text{CaCl}_2$ ). The flask was then shaken for 45-70 minutes until the slices had **disintegrated**. The resulting suspension was filtered through a piece of sterile surgical gauze into 20ml wash solution in a sterile beaker. The suspension was centrifuged for 90 seconds at 50g, and the pellet washed twice with fresh wash solution. The final pellet was resuspended in incubation or culture medium (see sections 2.6 and 2.7).

#### **Lobe perfusion method**

The apparatus was set up as in Figure 2.1, perfusates being circulated using a Watson-Marlow peristaltic pump. The water bath was kept at **40°C** to allow for the **3°C** drop in temperature between water bath and lobe (Chenery et al., 1987). Alcohol (70% v/v, 50ml), **followed** by 100ml sterile water was run through the apparatus prior to perfusion of the lobes. The calcium-, magnesium-free

Hanks buffer containing  $\text{NaHCO}_3$ , glucose, methionine and gentamicin as described above was used to make up the perfusates, which were gassed continuously with  $\text{O}_2/\text{CO}_2$  (95%/5%). On changing solutions, perfusate was run through the system for 30 seconds before being re-circulated, to flush the previous solution from the system. During perfusion the lobes **were covered** with a piece of sterile gauze, soaked in Hanks buffer.

The rat was killed by cervical dislocation, and the liver lobes removed and rinsed with Hanks buffer. Care was taken not to damage the lobes, which were cannulated with a 21G x  $1\frac{1}{2}$ " needle through a vein on an exposed cut surface. The same lobes were routinely used. The lobes were perfused for several minutes with non-circulating Hanks buffer containing 0.5mM EGTA, to flush out the blood. When the lobes were evenly blanched, fresh buffer with EGTA was recirculated for 15-20 minutes. The flow rate was set at 10-15 ml perfusate minute  $^{-1}$  cannula $^{-1}$ . The lobes were then perfused with **re-circulating** buffer containing 100  $\text{Uml}^{-1}$  of collagenase Type IV and 5mM  $\text{CaCl}_2$ , for 30 minutes. The lobes were carefully transferred to a beaker containing a small volume of Hanks buffer and minced gently with a pair of scissors. After filtration through a piece of sterile gauze the cell suspension was centrifuged at 50g for 90 seconds and the pellet washed with Hanks buffer. The cells were then resuspended in 5ml culture medium (see 2.6) which was added to 5ml Percoll solution (Percoll diluted 1:10 with concentrated Hanks salt solution: 1.4M NaCl, 50mM KCl, 4mM  $\text{KH}_2\text{PO}_4$ ,

3mM  $\text{Na}_2\text{HPO}_4$ , 55mM glucose). Centrifugation at 50g for 10 minutes resulted in a separation of the viable and non-viable cells (Kreamer et al., 1986). The pellet of viable cells was washed with culture medium, followed by centrifugation at 50g for 90 seconds, and finally resuspended in culture **medium**.

The viability of the final cell suspension obtained from both isolation methods was assessed using trypan blue exclusion (2,5,1). Suspensions of viability less than 85% were rejected. The concentration of the cell suspension was then adjusted (usually to  $2,0 \times 10^6$  cells  $\text{ml}^{-1}$ ) and the cells either used fresh, placed into culture or sonicated to give an homogenate (2,6-2.8).

For the initial kinetic studies (2.10) hepatocytes were isolated by the slice method. In all subsequent experiments lobe perfusion was preferred, since, in combination with the use of larger rats, the yield of hepatocytes per animal was consistently increased whilst the isolation time was decreased. Table 2.1 shows the cytochrome P450-dependent **alkoxycoumarin** O-dealkylase activities measured in fresh hepatocytes isolated by slicing or lobe perfusion, and the maintenance in culture for 24 hours of these activities. The fresh cell activities are similar, as are the maintenance values, indicating that the method of isolation does not influence the P450 activities measured in fresh or cultured hepatocytes.

## 2.5 ASSESSMENT OF CELL VIABILITY

### 2.5.1 Trypan blue exclusion

Viability of hepatocyte suspensions was determined using the trypan blue dye exclusion test, which has been shown to be as sensitive a parameter of viability as lactate dehydrogenase leakage (Jauregui et al., 1981). It is also quicker and simpler to perform, and it enables a quick estimate of the number of viable cells to be made. Cells with an intact plasma membrane will exclude the dye: these cells are judged to be viable. Where membrane integrity is compromised the cells take up the dye and appear blue when viewed under a light microscope. The number of viable and non-viable cells were counted by mixing 0.25ml cell suspension with 0.1ml trypan blue (0.5% dye solution in 85% saline) and placing the mixture onto an improved Neubauer haemocytometer (depth 0.1mm). The percentage viability was then calculated.

### 2.5.2 Reduction of MTT

In experiments where compounds were screened for toxicity to cultured hepatocytes the number of viable cells remaining after treatment was determined by assessment of mitochondrial function. The mitochondrial enzyme, succinate dehydrogenase, can reduce the yellow tetrazolium salt, MTT, to a blue formazan product which absorbs at 560-570nm. Only cells with viable mitochondria can reduce the MTT and the amount of formazan produced is proportional to the number of viable cells (Figure 2.2). The method was modified from that of Denizot and Lang (1986), for use with hepatocyte

cultures. WEC containing  $0.2\text{mgml}^{-1}$  MTT was placed on the cells. After a 3 hour incubation at  $37^{\circ}\text{C}$ , the medium was removed and the formazan that precipitated in the cells solubilised in isopropanol. Absorbance was determined **spectrophotometrically** at 560nm or at 570nm using a Dynatech plate reader.

## 2.6 USE OF FRESH CELLS

For all enzyme assays in freshly isolated hepatocytes, cells were resuspended at  $2.0 \times 10^6$  cells  $\text{ml}^{-1}$  in culture medium or Hanks buffer (2.4) containing 20mM HEPES. Incubations were performed in 25ml conical glass flasks shaken continuously in a  $37^{\circ}\text{C}$  water bath. Incubation times of 20-30 minutes were routinely used, the cells being used immediately after isolation. There was no loss of **viability** of the cells over these time periods.

## 2.7 PRIMARY CULTURE OF HEPATOCYTES

### 2.7.1 Culture medium

Hepatocytes were cultured in Williams' medium E, the composition of which is shown in Table 2.2. To 445ml single strength Williams' E was added: glutamine 2mM, fungizone  $2.5\mu\text{gml}^{-1}$ , gentamicin  $50\mu\text{gml}^{-1}$ , foetal calf serum 10% v/v, insulin  $10\text{mU ml}^{-1}$ , nicotinamide 5mM and dexamethasone  $1\mu\text{M}$ . All concentrations are final concentrations. This medium is referred to as WEC, and has been shown to maintain certain P450-dependent activities (Warren and Fry, 1988).

### 2.7.2 Procedure

Hepatocytes were cultured either on 60mm diameter "Primaria" petri dishes at  $2.5 \times 10^6$  cells dish<sup>-1</sup>, or on collagen-coated plastic 24-well plates at  $2.5 \times 10^5$  cells well<sup>-1</sup>. Collagen was diluted down to  $250\mu\text{gml}^{-1}$  with sterile 0.1M acetic acid and spread over each well to give a coating of  $5\mu\text{gcm}^{-2}$ . "Primaria" dishes are electrostatically treated to promote attachment and survival of cells. Both the "Primaria" dishes and the multiwell plates were pre-incubated with WEC, before hepatocytes were plated onto them. After allowing 1-2 hours for attachment, monolayers were rinsed with Hanks buffer and fresh WEC was added. Medium was replaced every 24 hours.

### 2.8 PREPARATION OF CELL HOMOGENATES

Fresh cell suspensions were centrifuged at 50g for 90 seconds, and the pellet resuspended in ice-cold Tris-sucrose-EDTA buffer, pH 7.4 (20mM - 0.25mM - 5.4mM final concentrations respectively) at approximately  $10 \times 10^8$  cells ml<sup>-1</sup>. Cultured hepatocytes were scraped from the culture dishes, the contents of 5 "Primaria" plates being pooled into a final volume of 1.5ml ice-cold buffer. The resulting suspensions were sonicated using a Soniprep probe at an amplitude of 15 for two 15 second pulses. This achieved maximum disruption with minimum enzyme damage. Homogenates were either used fresh, or frozen in liquid nitrogen and stored until required (always less than 1 week from preparation).

## 2.9 DETERMINATION OF PROTEIN

The protein content of fresh cell samples, cultures and homogenates was determined using the Bradford assay (Bradford, 1976). Samples were dissolved in 0,5N NaOH and diluted to approximately  $100\mu\text{gml}^{-1}$ . NaOH extract (100 $\mu$ l) was mixed with 1.0ml dye reagent (100mg Brilliant Blue G in 50ml absolute ethanol added to 100ml 85% orthophosphoric acid, made up to 1 litre with water) and left to stand for 5 minutes. Absorbance at 595nm was determined and the protein content derived by interpolation from a standard curve, constructed with bovine serum albumin. Protein content of hepatocytes was shown to be linear with respect to cell number (Figure 2.3).

## 2.10 ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES

### 2.10.1 Kinetics

The O-dealkylation of alkoxycoumarins are P450-dependent activities that have been shown to have biphasic kinetics in rat liver microsomes (Boobis et al., 1981; Paterson et al., 1984), preliminary experiments in isolated hepatocytes confirming these observations. The kinetics of 7-methoxy- and 7-ethoxycoumarin O-dealkylation (MCOD, ECOD), determined in freshly isolated hepatocytes are shown in Figures 2.4 and 2.5 respectively. The kinetics were analysed using Hanes plots (see Appendix:A2.1). The two activities are clearly biphasic in the freshly isolated cells. Similar kinetic studies in hepatocytes cultured for 24 hours showed that whereas ECOD remained biphasic in culture (Figure 2.7), MCOD became

monophasic (Figure 2.6).

Estimations of the kinetic **parameters**,  $K_m$  and  $V_{max}$ , are presented in Table 2.3. The  $K_m$  of MCOd activity measured in the cultured hepatocytes is similar to that of the total activity in the fresh **cells**. This suggests that it is the low affinity form of the activity that is retained, albeit at a reduced level (reduced  $V_{max}$ ), whereas the high affinity form is lost completely. Both components of ECOD activity were present in cultured hepatocytes (**similar**  $K_m$  values), although the activity was reduced (lower  $V_{max}$  values).

This information suggests that different populations of P450 are involved in the high and low affinity components of these activities, a suggestion which is reinforced by the differential response of the substrates to P450 inducers (Matsubara et al., 1983; Okuno et al., 1989). Therefore, the **alkoxycoumarins** provide a series of substrates for the investigation of a range of P450s, since multiple isozymes appear to be involved in the O-dealkylase activities. In the studies reported here, O-dealkylase activities have been used in this way as markers for different populations of P450 isozymes, those responsible for **the high** and low affinity components of each activity. For this reason, activities are measured at two substrate concentrations: 10 or **20 $\mu$ M** for the high affinity form (MCOd activity could not be accurately and reproducibly determined at substrate concentrations lower than **20 $\mu$ M**) and **500 $\mu$ M** for the total activity. This two substrate concentration

approach has been suggested previously by Boobis et al. (1986).

### 2.10.2 Determination of activity

**Alkoxycoumarin** O-dealkylase activities were determined by the well characterised method of Fry and Bridges (1980) in which the 7-hydroxycoumarin (7-HC) produced by **O-dealkylation** is assayed **fluorometrically**. Substrate (the **alkyl** ether) in N,N-dimethylformamide (DMF) at  $2\mu\text{lml}^{-1}$  medium was added to freshly **isolated** or cultured hepatocytes. Fresh hepatocytes were incubated with substrate for 20 minutes at 37°C in a shaking water bath; cultured hepatocytes were incubated with substrate for 4 hours at 37°C. No toxicity of the substrates to the cells was observable after these incubations. The reaction was stopped by adding the incubate (medium + fresh cells or medium alone from the cultures) to **4ml** ice-cold water/0.2M acetate buffer (3:1 v/v). **320 U** of **beta-glucuronidase H-1** (in 1ml acetate buffer) was added to each sample to deconjugate the glucuronide and sulphate derivatives of 7-HC prior to extraction and assay; incubation with enzyme was for 2 hours or overnight at 37°C. Under these conditions more than 97% of the conjugates were released with no hydrolysis of the sulphate (Paterson et al., 1984). The 7-HC was then extracted into **4ml diethylether** (containing **isoamylalcohol** 1.5% v/v). Organic phase (1ml) was then extracted into 4ml 0.05M **glycine-NaOH** buffer, pH 10.4, and the fluorescence determined at an excitation wavelength of 370nm (ex 370nm) and an emission wavelength of 450nm (em 450nm). The 7-HC content was then derived by **interpolation** from a standard

curve. The production of 7-HC under these conditions was shown to be **linear** with respect to time and cell number.

### **2.11 DETERMINATION OF CYTOCHROME P450 CONTENT**

The P450 content of hepatocyte homogenates was determined using the method of Estabrook et al. (1972). Homogenates were **diluted** in **0.1M** Tris buffer (pH 7.4), containing 20% v/v glycerol, to the equivalent of  $1-2 \times 10^6$  cells ml<sup>-1</sup>. Carbon monoxide was bubbled through the suspension for 1 minute, at 1-2 bubbles second<sup>-1</sup>. The sample was split equally between 2 cuvettes and scanned between 390 and 510nm. Sodium dithionite was added to one cuvette, which was mixed well, and re-scanned. The P450 content was calculated, using the absorbance difference between 450 and 490nm, and the extinction coefficient of  $9 \text{ lM}^{-1} \text{ cm}^{-1}$ .

### **2.12 ANALYSIS OF ENZYME ACTIVITIES IN CELL HOMOGENATES**

Enzyme activities in cell homogenates were determined using an Incubation mix similar to that described by Paterson and Fry (1983) for microsomal Incubations. Determination of enzyme activities in homogenates has also been described previously (Grant et al., 1985). The 1ml incubation mix contained 5mM magnesium sulphate,  $10 \text{ ml}^{-1}$  **glucose-6-phosphate** dehydrogenase, and cofactors (0.5mM NADP and 5mM **glucose-6-phosphate**, final concentrations) in 0.2M phosphate buffer, pH 7.4. Cell homogenates were routinely used at concentrations of  $0.5-1.0 \text{ mg}$  protein ml<sup>-1</sup> incubation mix.

Activities were determined from standard curves of the amount of product. Substrate was also included in blank and standard samples. Reactions were determined to be **linear** at the chosen substrate concentrations over the incubation period at the required homogenate protein concentration, in homogenates from control and Inducer-treated animals.

### 2.13 DETERMINATION OF 7-ETHOXYRESORUFIN O-DEALKYLASE ACTIVITY

7-Ethoxyresorufin is **dealkylated** in microsomes to a **fluorescent** product, resorufin (Pohl and Fouts, 1980). The incubation mix used was a slight modification of that described in 2.12, in that homogenate was used at  $0.1 \text{ mg protein ml}^{-1}$  and bovine serum albumin ( $1 \text{ mg ml}^{-1}$ ) was included in the phosphate buffer, to prevent product inhibition, and maintain linearity of the reaction **respectively**. Prior to assay with substrate, dicoumarol (final concentration  $10 \mu\text{M}$ ) was added to the incubation mix, which was then incubated at  $37^\circ\text{C}$  for 10 **minutes**. The dicoumarol inhibits microsomal reductases that can reduce the unstable resorufin (Lubet et al., 1985). 7-Ethoxyresorufin (final concentration  $1.7 \mu\text{M}$  in DMSO) was then incubated with the samples for 30 minutes. When homogenates from BNF-treated rats were assayed, the incubation period was reduced to 10 minutes. The reaction was terminated by the addition of 2ml methanol. The fluorescence of the resorufin in the cleared supernatant was then determined. The product, resorufin, is relatively unstable, therefore Rhodamine B was used as a standard. The fluorescence of Rhodamine 8 at  $\text{ex } 550 \text{ nm}$  and  $\text{em } 585 \text{ nm}$  was

determined to be twice that of resorufin.

#### **2.14 DETERMINATION OF NITROPHENOL HYDROXYLASE ACTIVITY**

**4-Nitrophenol** hydroxylase activity was assayed by determination of the amount of 4-nitrocatechol produced. The method used was essentially that of Reinke and Moyer (1985). Nitrophenol (**100 $\mu$ M** final concentration) was incubated in 1ml standard incubation mix (2.12) for 30 minutes at 37°C. TCA (15%, 0.1ml) was used to stop the reaction. After centrifugation to remove the precipitated protein, 0.1ml **10N** NaOH was added to the supernatant. The absorbance of the nitrocatechol was determined at 546nm.

#### **2.15 DETERMINATION OF N-DEMETHYLASE ACTIVITY**

**N-Demethylase** activity was measured by determining the amount of formaldehyde produced from **benzphetamine** or erythromycin (final concentration **50 $\mu$ M**). The formaldehyde was trapped with semicarbazide (**10mM** final concentration in incubation mix). Samples were incubated for 30 minutes at **37°C**, and then stopped with 15% TCA. Fresh Nash reagent (30g ammonium acetate + 0.4ml acetyl acetone in 100ml water, 1ml) was added to 1ml protein-free supernatant, and incubated at 37°C for 45-50 minutes. Samples were centrifuged if necessary to clear the supernatant. The formaldehyde was then measured **spectrophotometrically** at 412nm or **fluorometrically** at ex 410nm em 510nm (Nash, 1953; Belman, 1963).

Structures of P450-dependent enzyme substrates and products are shown in Figure 2.8.

## 2.16 DETERMINATION OF CELLULAR GLUTATHIONE

Cellular glutathione was determined by a modification of the method of Hissin and Hilf (1976), in which **o-phthalaldehyde** forms a fluorescent derivative with reduced glutathione. Hepatocyte suspensions were treated with 15% TCA, and 0.1ml supernatant added to 3ml 0.4M  $K_3PO_4$  buffer, pH 8.2. **o-Phthalaldehyde** solution (0,1ml;  $1mg\ ml^{-1}$  in methanol) was added to each sample, with thorough mixing. The fluorescence was then measured exactly 15 minutes later at ex 350nm, em 420nm. The glutathione content was determined from a standard curve.

## APPENDIX

### A2.1 Kinetic analysis of enzyme activity

The kinetics of enzyme-catalysed reactions can be described by the Michaelis-Menten equation:

$$V = \frac{V_{\max}[S]}{K_m + [S]} \quad [1]$$

where  $v$  is the rate of reaction at substrate concentration  $[S]$ ,  $V_{\max}$  is the maximum rate at saturating substrate concentrations and  $K_m$  is the Michaelis constant, commonly defined as the substrate concentration at which  $v = \frac{V_{\max}}{2}$ . The  $K_m$  is thus a measure of the

enzyme's affinity for the substrate, and the  $V_{\max}$  gives an indication of the amount of active enzyme present. Equation [1] describes a rectangular hyperbola which can be linearly transformed in several ways to enable graphical estimations of  $K_m$  and  $V_{\max}$  to be made (Roberts, 1977),

The kinetics of MCOD and ECOD activities were described in 2.10 by use of a Hanes plot, in preference to the double-reciprocal Lineweaver-Burk plot. For a Hanes plot (Hanes, 1932)  $[S]/v$  is plotted against  $[S]$ , re-arrangement of equation [1] giving:

$$\frac{[S]}{v} = \frac{1}{V_{\max}} [S] + \frac{K_m}{V_{\max}} \quad \dots [2]$$

A plot of  $[S]/v$  against  $[S]$  of a biphasic activity will give two components, each described by equation [2], from which the  $K_m$  and  $V_{\max}$  can be calculated. The component with the lower  $K_m$  is the

high affinity form and the component with the higher  $K_m$  represents the total activity. Subtraction of the high affinity form from the total will give the contribution of the low affinity component.

With regard to estimations of the kinetic parameters  $V_{max}$  and  $K_m$ , statistical considerations indicate that of the graphical determinations of  $V_{max}$  and  $K_m$  more accurate subjective estimates can be obtained from Hanes plots than from the Lineweaver-Burk, assuming a homogeneous variance of  $v$  (Wilkinson, 1961).

The **Lineweaver-Burk** plot becomes vastly inferior to the Hanes when applied to unweighted linear regression lines, since the smaller (and less accurate) determinations of  $v$  become inordinately important in determining the position of the line. If the error in  $V$  is assumed to be small, the Hanes plot gives reasonably reliable estimates of  $K_m$  and  $V_{max}$  for unweighted lines. This means that  $K_m$  and  $V_{max}$  values can be graphically estimated, especially **if** the aim is to compare values from two **similar** experiments where the bias of the unweighted data will be similar, rather than to obtain values for the true  $V_{max}$  and  $K_m$  (Dowd and Riggs, 1965). Thus, in the kinetic experiments presented in 2.10,  $K_m$  and  $V_{max}$  values were estimated from the unweighted linear regression lines **obtained** from Hanes plots of the data. The  $K_m$  and  $V_{max}$  values obtained from the graphs were used to compare the isozymic **populations** present in fresh and cultured hepatocytes, and should not be taken as accurate measures of the true values of the kinetic parameters.

## A2.2 Statistical analyses

Standard statistical tests were applied to the data presented in this thesis, which are described in detail in general statistics texts (Bailey, 1959). Briefly, linear regression analysis was applied to linear, graphical data, to obtain the line of best fit. Student's t-test was used to compare two group means where only one variable was being studied; for multiple comparisons analysis of variance (ANOVA) was employed. If the ANOVA detected differences between groups Dunnett's test (Winer, 1971) was used to compare the treated groups to the control group. The important point regarding this test is that the significance level applies to the collective data - **the** test is not Independent for each group v control test (i.e. groups x and y but not group z **are** significantly different to the control group at a level of  $p < 0,05$ ). The Mann-Whitney U-test (Campbell, 1967) is a distribution-free test which can be used on transformed data, e.g. culture maintenance data which is expressed as a percentage of, or relative to, a fresh cell **value**. It assesses the overlap of two population distributions, differing in the location of their median value by ranking the data.

## **TABLES AND FIGURES**

**TABLE 2.1a. ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES IN HEPATOCYTES ISOLATED BY THE SLICE AND LOBE PERFUSION METHODS,**

SUBSTRATE CONCENTRATION ( $\mu\text{M}$ )	ACTIVITY ( $\text{pmol min}^{-1}\text{mg}^{-1}$ )	
	SLICE	PERFUSION
7-MC 20	18 $\pm$ 2	17 $\pm$ 4
7-MC 500	106 $\pm$ 10	91 $\pm$ 9
7-EC 10	15 $\pm$ 2	19 $\pm$ 4
7-EC 500	293 $\pm$ 44	309 $\pm$ 9
VIABILITY	89 $\pm$ 1%	91 $\pm$ 1%

Values are the mean  $\pm$  SEM activity where n = 6 (slice) and n = 4 (perfusion).

**TABLE 2.1b.MAINTENANCE OF ACTIVITIES AFTER 24 HOURS IN CULTURE.**

SUBSTRATE CONCENTRATION ( $\mu\text{M}$ )	MAINTENANCE	
	SLICE	PERFUSION
7-MC 20	0.17	0.21
7-MC 500	0.27	0.54
7-EC 10	0.35	0.49
7-EC 500	0.22	0.40

Activities in the fresh and cultured cells were determined in separate experiments, therefore each value is the mean activity at 24 hours relative to the mean fresh cell activity, which = 1.0. Slice: n = 4; perfusion: n = 4.

**TABLE 2.2. COMPOSITION OF WILLIAMS' MEDIUM E<sup>1</sup>**

<b>Component</b>	<b>mg L<sup>-1</sup></b>
INORGANIC SALTS	
CaCl <sub>2</sub> (anhydrous)	200.0000
CuSO <sub>4</sub> .5H <sub>2</sub> O	0.0001
Fe(NO <sub>3</sub> ) <sub>3</sub> .9H <sub>2</sub> O	0.0001
KCl	400.0000
MgSO <sub>4</sub>	400.0000
MgSO <sub>4</sub> .7H <sub>2</sub> O	200.0000
MnCl <sub>2</sub> .4H <sub>2</sub> O	0.0001
NaCl	6800.0000
NaHCO <sub>3</sub>	2200.0000
NaH <sub>2</sub> PO <sub>4</sub> .H <sub>2</sub> O	140.0000
ZnSO <sub>4</sub> .7H <sub>2</sub> O	0.0002
AMINO ACIDS	
L-Alanine	90.0000
L-Arginine	50.0000
L-Asparagine.H <sub>2</sub> O	20.0000
L-Aspartic acid	30.0000
L-Cysteine	40.0000
L-Cystine	20.0000
L-Glutamic acid	50.0000
Glycine	50.0000
L-Histidine	15.0000
L-Isoleucine	50.0000
L-Leucine	75.0000
L-Lysine HCl <sup>2</sup>	87.5000
L-Methionine	15.0000
L-Phenylalanine	25.0000
L-Proline	30.0000
L-Serine	10.0000
L-Threonine	40.0000
L-Tryptophan	10.0000
L-Tyrosine	35.0000
L-Valine	50.0000

(continued over)

---

<sup>1</sup> From Williams and Gunn (1974)

<sup>2</sup> The original formula lists lysine at 70.00 mg L<sup>-1</sup>

**TABLE 2.2.(continued)**

VITAMINS	
Ascorbic acid	2.00
Biotin	0.50
D-Ca <sup>2+</sup> pantothenate	1.00
Choline chloride	1.50
Ergocalciferol	0.10
Folic acid	1.00
<b>i-Inositol</b>	2.00
Menadione sodium bisulphate	<b>0.01</b>
Nicotinamide	1.00
Pyridoxal HCl	1.00
Riboflavin	0.10
<b>α-Tocopherol</b> phosphate, disodium	0.01
<b>Thiamine</b> HCl	1.00
Vitamin A acetate	0.10
Vitamin <b>B<sub>12</sub></b>	0.20
OTHER COMPONENTS	
<b>D-Glucose</b>	2000.00
Glutathione	0.05
Methyl linoleate	0.03
Phenol red	10.00
Sodium pyruvate	25.00


**TABLE 2.3. ESTIMATED KINETIC PARAMETERS OF MCOD AND ECOD ACTIVITIES,**

ENZYME ACTIVITY		HIGH AFFINITY		TOTAL	
		$K_m1$	$V_{max1}$	$K_m2$	$V_{max2}$
MCOD	fresh	33	53	270	167
	24 h	-	-	210	42
ECOD	fresh	35	77	160	200
	24h	36	33	135	77

Kinetic parameters were graphically determined (see Appendix 2.1).

1 Units of  $K_m$  are  $\mu\text{M}$

2 Units of  $V_{max}$  are  $\text{pmol min}^{-1} \text{mg}^{-1}$ .



**FIGURE 2.1. APPARATUS FOR THE PERFUSION OF INDIVIDUAL HEPATIC LOBES.** Method modified from Reese and Byard, (1981); for details, see section 2.4.

A peristaltic pump

B 21G×1.5" needle inserted into an exposed vein


C lobe of liver

D wire mesh, to support lobe


E 95% O<sub>2</sub> : 5% CO<sub>2</sub>

F water bath maintained at 40°C

G re-circulated perfusate




**FIGURE 2.2, RELATIONSHIP OF FORMAZAN ABSORBANCE TO HEPATOCYTE NUMBER,** The absorbance of the reduced MTT at 560nm was determined in hepatocyte suspensions ( $n=4$ ;  $SE<0.01$ ), as described in section 2.5.2.




**FIGURE 2.3. RELATIONSHIP OF CELL PROTEIN TO CELL NUMBER.** Protein content of hepatocyte suspensions was determined as described in section 2.9. ( $\bar{x} \pm SEM, n=5$ ).

**FIGURES 2,4-2,7.** These figures show the data obtained for ECOD and MCOD activities measured in freshly isolated and cultured hepatocytes as Hanes plots. The details of this kinetic analysis are given in Appendix A2.1. For all figures,  $[S]/v$  was determined using the mean activity at each substrate concentration of 7 separate preparations, each from a different animal.



**FIGURE 2.4.** HANES PLOT OF MCOD ACTIVITY MEASURED IN FRESHLY ISOLATED HEPATOCYTES.

See Appendix 2.1 for details of kinetic analysis.



**FIGURE 2.5.** HANES PLOT OF ECOD ACTIVITY MEASURED IN FRESHLY ISOLATED HEPATOCYTES, See Appendix 2.1 for details of kinetic analysis.






FIGURE 2.6. HANES PLOT OF MCOD ACTIVITY MEASURED IN HEPATOCYTES CULTURED FOR 24 HOURS, See Appendix 2.1 for details of kinetic analysis.




**FIGURE 2.7.** HANES PLOT OF ECOD ACTIVITY MEASURED IN HEPATOCYTES CULTURED FOR 24 HOURS. See Appendix 2.1 for details of kinetic analysis.

**A. O-DEALKYLATION OF ALKOXYCOUMARINS.** Method: 2.10.




R= methyl, ethyl or propyl group

**B, O-DEETHYLATION OF 7-ETHOXYRESORUFIN.** Method: 2.13




**CHDROXYLATION OF P-NITROPHENOL,** Method: 2.14



**FIGURE 2.8.** SUBSTRATES AND METABOLIC PRODUCTS OF THE P450-DEPENDENT ASSAYS USED IN THIS INVESTIGATION, For details of the relevant methods see pages 70-75.

**D, N-DEMETHYLATION OF BENZPHETAMINE AND ERYTHROMYCIN,  
Method: 2,15.**



**FIGURE 2.8. CONTINUED. SUBSTRATES AND METABOLIC PRODUCTS OF P450-DEPENDENT ACTIVITIES.**

CHAPTER 3

SUPPLEMENTATION OF CULTURE MEDIUM WITH  
EXOGENOUS HAEM: INFLUENCE ON THE MAINTENANCE  
OF P450-DEPENDENT ENZYME ACTIVITIES

**CHAPTER 3**

<b>CONTENTS</b>		<b>PAGE</b>
3.1	INTRODUCTION	82
3.2	METHODS	84
3.3	RESULTS	85
3.3.1	Maintenance of activities in culture	85
3.3.2	Comparison of <b>dealkylase</b> activities and <b>viabilities</b>	86
3.4	DISCUSSION	87

TABLES AND FIGURES

## CHAPTER 3

### 3.1 INTRODUCTION

A variety of methods have been employed in attempts to attenuate the loss of cytochrome P450 that occurs in hepatocyte cultures, including manipulation of culture medium composition (reviewed in Chapter One). In 1985 Engelmann et al. reported that addition of exogenous haem to culture medium maintained the P450 content of rat cultured hepatocytes at more than 80% of the level in freshly isolated cells for 72 hours; there was no effect on the haem content of the hepatocytes. The rationale of this supplementation centres on haem as the prosthetic group of mammalian **haemoproteins**.

Haem (or iron (II)-protoporphyrin IX) is synthesized in the hepatocyte for incorporation into mitochondrial cytochromes, **catalase** and tryptophan **pyrrolase** as well as the microsomal cytochromes; however, on induction up to 70% of newly synthesized haem can be incorporated into cytochrome P450s (Muller-Eberhard and Vincent, 1985). It is known that deficiencies in haem biosynthesis can result in selective deficiencies in drug metabolism (Anderson et al., 1976). Also, Steward et al. (1985) showed that although total P450 declined in culture over 72 hours, there was a selective maintenance of certain apoproteins. They **concluded** that loss of the haem moiety was responsible for the overall loss of holoenzyme in culture. This, coupled with the shorter turnover of haem relative to apoprotein (Sadano and Omura, 1983), suggests that some deficiency, block or inhibition of haem biosynthesis is responsible

for the loss of P450 in culture.

It is thought that haem is extracted from an Intracellular haem pool (or pools), fed both exogenously and endogenously, for synthesis of microsomal haemoproteins (Muller-Eberhard and Vincent, 1985), although the mechanism of regulation of this pool is uncertain. Haem itself exerts feedback repression on the mitochondrial enzyme **delta-aminolaevulinate** synthase (ALAS), which is the rate limiting enzyme in haem biosynthesis (Granick, 1966), outlined in Figure 3.1. Haem also induces haem oxygenase which degrades free haem from P450s to **biliverdin** (Kutty et al., 1988). The administration of **delta-aminolaevulinate** (ALA) in vivo can also induce haem oxygenase in the rat, presumably by stimulating haem synthesis, resulting in an expansion of the haem pool (Anderson et al., 1981). However, Paine and Legg (1978) could find no correlation between induction of haem oxygenase activity and loss of P450 in hepatocyte cultures, making increased degradation of haem unlikely as a cause of P450 loss. Evarts et al. (1984) reported that although the P450 content fell rapidly within the first 24 hours, hepatic ALAS remained elevated throughout four days of culture; therefore the biosynthetic pathway does not appear to be repressed although the sustained increase in ALAS suggests a demand for haem in the cultured hepatocyte.

Addition of exogenous haem, both in vivo and in vitro, has been shown to have a sparing effect on **allylisopropylacetamide-induced**

destruction of P450, presumably by promoting incorporation of haem into newly synthesized apoproteins (Liem et al., 1983). This protection against degradation following allylisopropylacetamide administration appears to be specific for certain isozymes, favouring those predominating at the time of treatment (De Matteis et al., 1983; Bornheim et al., 1984), Exogenous haem also seems to act directly, as a positive modulator of P450 gene transcription, via the nuclear haem pool (Bhat and Padmanaban, 1988).

Selenium is an essential trace element that is an inducer of both ALAS and haem oxygenase (Maines and Kappas, 1976). It is not porphyrinogenic, thus the Induction of both enzymes appears to maintain a steady state. At concentrations greater than  $0.5\mu\text{M}$  the element is an Inhibitor of ALAS,

In this experiment, the effect of culture medium supplemented with haem, ALA and selenium on the maintenance of P450-dependent dealkylase activities was investigated, these conditions being similar to those described by Engelmann et al. (1985).

### 3.2 METHODS

Hepatocytes were isolated from 150g male rats by lobe perfusion. MCOD and ECOD (both total and high affinity components) were measured in hepatocytes cultured for 24 hours and in freshly Isolated cells from the same **animals**; hepatocytes were cultured on "Primaria" dishes in either WEC or in WEC supplemented further with

haem ( $1\mu\text{M}$ ), ALA ( $200\mu\text{M}$ ) and selenious acid (Se;  $0.1\mu\text{M}$ ). Haem was dissolved in a bovine serum albumin solution ( $1\text{mgml}^{-1}$   $0.1\text{N}$  NaOH) to enable dilution into culture medium as described by Engelmann et al. (1985). This medium is designated WEC+H. Protein content of fresh cells and cultures was determined and all activities expressed as  $\text{pmol } 7\text{-HC produced min}^{-1} \text{mg protein}^{-1}$ . Maintenance of activities in culture is expressed as a percentage of the fresh cell activity, and calculated for each animal.

### 3.3 RESULTS

#### 3.3.1 Maintenance of activities in culture

Figure 3.2 shows the activities measured in fresh cells, and in hepatocytes cultured for 24 hours in WEC or WEC+H. It is clear that the activities in the cultured hepatocytes are similar regardless of the medium. The WEC+H conferred no advantage over the unsupplemented WEC. However, the WEC (and also WEC+H) appeared to be adequate for maintenance of three of the activities measured. However, total MCOD was not maintained, falling to 46% of the fresh cell activity.

Table 3.1 presents the maintenance data for all four activities as percentages of the fresh cell data, for both media. The mean values and ranges were *very* similar for the two media, and although only three animals were used, the maintenance of total and high affinity ECOD and high affinity MCOD is Indisputable. This maintenance of activity, however, is in contrast to that of the

kinetics experiments (Chapter 2.10, Table 2.4) where none of the four activities were maintained, using the same WEC medium. The maintenance data from the two experiments are presented together in Table 3.2 for comparison, and it **is** necessary to consider the possible reasons for the inconsistency of these results. The most obvious causes of discrepancies in maintenance data are differences in the viabilities and/or fresh cell activities of the initial fresh cell suspensions.

### **3.3.2 Comparison of dealkylase activities and viabilities**

The activities and initial viabilities of the cell preparations used in this and the former experiments (taken from Table 2.1a) are presented in Table 3.3. The **viabilities** were identical ( $91 \pm 1\%$ ), and the ECOD activities were *very* similar. However, the MCOD activities were very different. Total MCOD activity in this experiment was twice that measured previously whereas the high affinity form had around half the activity of the former determination. These differences in MCOD activity, whilst requiring an explanation, do not account for the observed differences in maintenance between the two experiments.

Thus supplementation of WEC with haem, ALA and Se did not improve maintenance of dealkylase activities over those obtained with WEC alone, but **this** maintenance in WEC of three of the four activities *over* the 24 hour culture period was completely unexpected given the previous maintenance data for the same activities in similar culture conditions.

### 3.4 DISCUSSION

The use of WEC supplemented with haem did not improve maintenance of P450-dependent enzyme activities in hepatocyte cultures, but then again there was good maintenance over twenty four hours in the **unsupplemented** medium. There was a selective loss of MCOB activity in this experiment, and supplementation of WEC with haem, ALA and Se did not prevent this loss. Engelmann et al. (1985) reported an overall maintenance of P450 content in contrast to a **25%** loss at 24 hours in medium minus haem. They used adult female rats, for which haem supplementation of media may have been more effective, since hepatocytes from female rats appear to be more susceptible to haem loss (Evarts et al., 1984).

Total MCOB activity of hepatocytes fell by 50% during 24 hours **in** culture and whereas this is consistent with data from the preliminary kinetic experiments, the maintenance of the other three activities, at more than 90% of the fresh cell value in WEC, is not. Also, the MCOB activities in the fresh cells were different to those measured previously. Those experiments had ascertained that cell preparations isolated by slice or perfusion were equivalent with respect to dealkylase activity and maintenance. A major difference between the experiments, however, is the size, and therefore age, of the hepatocyte donor animal. For the initial kinetics and perfusion experiments 70g male rats were used, but in this study larger **150g** rats were used. This made **cannulation** of the lobes easier, as well as increasing the yield of hepatocytes per rat.

The male Wistar rats used as donors are sexually mature at 150g (6 - 8 weeks old) unlike the 70g rats (4 weeks old).

It is known that changes in some P450-dependent activities occur during post-natal development in the rat, especially at the onset of puberty (Gram et al., 1969). It is possible that MCOD activity is dependent on a **developmentally** regulated P450(s) which accounts for the observed differences in MCOD activity. It is also possible that the age of the animal influences the maintenance of P450 activities in culture.

It has been reported that the haem moiety of P450 undergoes biphasic turnover (Levin et al., 1975), with both a fast and a slow component. The ratio of fast : slow turnover forms decreased with increasing age in the male rat (ratio of 4.4 in immature males and 1.9 in adult males). Parkinson et al. (1983) investigated turnover of both the haem and apoprotein moieties for specific P450 Isozymes and reported biphasic turnover for the total apoprotein. However, only one purified isozyme showed biphasic turnover of haem (and of apoprotein). This was P450IIA, now known to exist as at least two very similar isozymes IIA1 and **IIA2** which are differentially regulated. P450IIA2 is adult male-specific; P450IIA1 **is** expressed only in females and **pre-pubertal** males (Matsunaga et al., 1988). It is possible that the rats of Parkinson et al., used at 4-6 weeks of age, contained both forms of P450IIA, and that one is a fast and one a slow turnover form.

Other workers have only found monophasic turnover kinetics for a number of purified P450s (Shiraki and **Guengerich**, 1984) but it is possible that changes in rate of turnover are associated with the **developmentally** regulated P450s like P450IIA1, which is a steroid hydroxylase, under hormonal control (Arlotto and Parkinson, 1989). Also, adult females, like immature males, appear to have predominantly fast turnover P450s (Levin et al., 1975). Thus, an increase in slow turnover forms of P450 at puberty in the male rat could explain the improved maintenance of P450-dependent activities in this experiment relative to the kinetics experiment, due to the differences in age of the **animals** used for the hepatocyte isolations. It could also **explain** why haem **supplementation** of medium had no effect on maintenance, in contrast to the results of Engelmann et al. (1985), who used hepatocytes from female rats, in which fast turnover P450 forms predominate (Levin et al., 1975).

In summary, these results are not consistent with hepatocyte haem deficiency being responsible for the loss of P450 activities in culture. They do indicate that hepatocytes isolated from adult males may show better maintenance of selected activities in our chosen medium than those from immature males. The effects of age and sex of donor animal on P450-dependent activities is examined in more detail in the **following** chapter.

## **TABLES AND FIGURES**

**TABLE 3.1. MAINTENANCE OF ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES IN CULTURE FOR 24 HOURS: EFFECT OF MEDIUM SUPPLEMENTED WITH HAEM.**

SUBSTRATE CONCENTRATION ( $\mu\text{M}$ )	MAINTENANCE (% fresh cell value)	
	WEC	WEC+H
7-MC 10	96 (57-150)	93 (91-113)
7-MC 500	46 (36-50)	51 (48-53)
7-EC 10	101 (63-126)	84 (66-111)
7-EC 500	91 (85-104)	69 (59-79)

Values are means with ranges in brackets, for 3 animals.

**TABLE 3.2. MAINTENANCE OF ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES IN CULTURE FOR 24 HOURS: COMPARISON OF DATA FROM TWO DIFFERENT EXPERIMENTS.**

SUBSTRATE CONCENTRATION ( $\mu\text{M}$ )	MAINTENANCE IN WEC (% fresh cell value)	
	I	II
7-MC 20	96	21
7-MC 500	46	54
7-EC 10	101	49
7-EC 500	91	<b>40</b>

I data from Table 3.1.

II data from Table 2.1b.

**TABLE 3.3. ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES IN FRESHLY ISOLATED HEPATOCYTES FROM TWO DIFFERENT EXPERIMENTS.**


SUBSTRATE CONCENTRATION ( $\mu\text{M}$ )	ACTIVITY ( $\text{pmol min}^{-1} \text{m g protein}^{-1}$ )	
	I	II
7-MC 20	10 $\pm$ 1	17 $\pm$ 4
7-MC 500	195 $\pm$ 43	91 $\pm$ 9
7-EC 10	19 $\pm$ 1	19 $\pm$ 9
7-EC 500	277 $\pm$ 45	309 $\pm$ 92
Viability of preparation	91 $\pm$ 1%	91 $\pm$ 1%

Values are means  $\pm$  SEM for 3(I) or 4(II) animals.

I data from Figure 3.1.



II data from Table 2.1a.

**FIGURE 3.1. HAEM BIOSYNTHESIS**  
 (adapted from Maines and Kappas, 1977)



1 δ-Aminolaevulinate synthase

2 Iron (II)-ferrochelatase



**FIGURE 3.2.** MCOD AND ECOD ACTIVITIES IN FRESHLY ISOLATED HEPATOCYTES AND IN CELLS CULTURED FOR 24 HOURS IN THE PRESENCE OR ABSENCE OF EXOGENOUS HAEM. Hepatocytes were cultured for 24 hours in either WEC medium (see 2.7.1.) or in WEC+H (see 3.2.).

CHAPTER 4

INFLUENCE OF DONOR AGE AND SEX ON  
THE ACTIVITY, AND MAINTENANCE IN CULTURE  
OF CYTOCHROME P450-DEPENDENT ENZYME ACTIVITIES

CHAPTER 4

CONTENTS		PAGE
4.1	INTRODUCTION	92
4.2	METHODS	95
4.3	RESULTS	96
4.3.1	Dealkylase activities in hepatocytes from male rats	96
4.3.2	Dealkylase activities in hepatocytes from male and female rats	97
4.3.3	Maintenance of activities in culture	98
4.4	DISCUSSION	100

TABLES AND FIGURES

## CHAPTER 4

### INFLUENCE OF DONOR AGE AND SEX ON THE ACTIVITY, AND MAINTENANCE IN CULTURE OF CYTOCHROME P450-DEPENDENT ENZYME ACTIVITIES

#### 4.1 INTRODUCTION

To date, at least fourteen different Isozymes of cytochrome P450 are known to exist in rat liver (Nebert and Gonzalez, 1987). The isozyme profile changes with age in both male and female rats, although the total P450 content remains relatively constant. These changes in Isozyme profile are reflected in changes in enzyme activity (Gram et al., 1969; Waxman et al., 1985). Major alterations occur during post-natal development and sexual maturation, and again at the onset of old age, the changes being particularly marked in male rats. This is due to the development of a distinct sex difference in P450 activities at puberty (Waxman et al., 1985), which disappears in older rats (Kamataki et al., 1985). This is probably caused by changes in the levels of the sex-specific P450 forms (Kamataki et al., 1982; Maeda et al., 1984). These age and sex differences in P450 forms are related to changes in constitutive steroid hydroxylase activities (Waxman et al., 1985).

A summary of the various sex-specific P450 forms and their associated activities is presented in Table 4.1.

It is now known that these hepatic sex differences are initiated and maintained by androgens and pituitary growth hormone (extensively reviewed by Skett, 1987; 1988). The pattern of secretion of growth

hormone is different in male and female rats, although the mean level is similar. In males there is a pulsatile secretion with high peak values every 3-4 hours and a very low basal secretion during the intervening periods, whilst in females there is a more continuous secretion, but at a higher baseline level (Edén, 1979). Hypophysectomy or continuous growth hormone (GH) infusion in male rats essentially feminises hepatic P450 metabolism, whereas intermittent infusion of GH in hypophysectomised animals restores the male pattern of metabolism (Waxman, 1988), Neonatal exposure to androgens imprints or programmes the pattern of adult male P450 steroid **metabolism** by imprinting the **pulsatile** pattern of growth hormone secretion (Jansson et al., 1985; Waxman et al., 1985; Waxman, 1988). This imprinting appears to function via the oestrogen receptor (Reyes and Virgo, 1988). Androgens are also required in adult life to maintain a male pattern of activity (Skett, 1988; Waxman, 1988); interruption of the **hypothalamic-pituitary** axis by **cisplatin** in adult male rats reduces the amount of circulating androgen, resulting in a **feminisation** of P450 metabolism (LeBlanc and Waxman, 1988).

The male-specific IIC11 (Nebert et al., 1989; named as P450-2c by Waxman et al., 1985) is dependent on pulsatile secretion of GH **for** its expression, whilst the female-specific IIC12 form (named as 2d by Waxman et al., 1985) requires a more constant secretory pattern (Waxman, 1988). The male-specific 2a form does not depend on pulsatile GH secretion, as it is constitutively expressed **in** male

rats, and in immature females (Waxman et al., 1985). However, P450-2a appears to be repressed by high levels of GH (Waxman et al., 1988), and this accounts for the suppression of this form in adult females, when GH is secreted at a higher, although still continuous, **baseline** level than in the immature male and female animals. It is possible that synthesis of P450-2a in the adult male is continually suppressed and de-repressed as the GH concentration fluctuates (Waxman et al., 1988).

In addition to sex differences in metabolism due to direct hormonal influences on P450 levels, it has been reported that hypophysectomy and/or continuous GH supplementation lower the amount of hepatic P450 reductase, (which is lower in female than male rats), but that this (and steroid hydroxylase activities) can be raised again by addition of thyroxine (Waxman et al., 1989).

Results presented in the previous chapter suggested that hepatocytes cultured from adult male rats may maintain P450-dependent enzyme activities better than hepatocytes from younger immature males, and that differences in P450 turnover may be the reason. **Adult females** also have a greater proportion of rapid turnover P450s, like Immature males (Levin et al., 1975), and therefore if turnover is affecting maintenance, hepatocytes from female rats should maintain activities at a similar level to the younger male rats. However, Vind et al. (1988) reported that P450 and demethylase activities were maintained better in hepatocyte cultures from female rats. It

is likely that the in vivo hormonal regulation of P450 expression, which changes with age and sex in the rat, is disrupted or lost in vitro, and it is this that affects the differential maintenance of P450 in hepatocytes from male and female rats of different ages. The maintenance of **alkoxycoumarin** O-dealkylase activities was therefore investigated in hepatocytes from immature and adult males, and adult females to assess the relative stabilities of P450-dependent activities in hepatocyte cultures.

#### 4.2 METHODS

The rats used in this study were immature males (**IM**) and young adult male (AM) and female rats (AF). The adult animals were 8 weeks old and the immature males were 4 weeks old. Puberty occurs 4-6 weeks after birth in the male rat (Gram et al., 1969; Levin et al., 1975). Dealkylase activities were determined in fresh cells and hepatocytes cultured for 24 and 72 hours from each animal. Hepatocytes were cultured on "Primaria" dishes in WEC. In addition to MCOD and ECOD, 7-propoxycoumarin **O-depropylase** (PCOD), which **is** known to be a male-specific activity (Kamataki et al., 1983; 1985), was also measured at two substrate concentrations in the same manner as ECOD and MCOD (Chapter 2.10). Protein content of fresh cells and cultures was also determined and all activities expressed as pmol 7-HC produced min<sup>-1</sup> mg protein<sup>-1</sup>. Statistical analysis on mean fresh cell activities was by unpaired t-tests. Maintenance at 24 and 72 hours was calculated as a percentage of the fresh cell value for

each animal and expressed as mean  $\pm$  range; statistical analysis was by the Mann-Whitney U-test.

### 4.3 RESULTS

Viabilities of initial cell preparations were very similar: AM  $93 \pm 1\%$ , AF  $93 \pm 1\%$ , IM  $96 \pm 1\%$ .

#### 4.3.1 Dealkylase activities in hepatocytes from male rats

Dealkylase activities measured in freshly isolated cells from AM and IM rats are presented in Table 4.2. Previous studies confirmed the biphasic nature of MCO<sub>D</sub> and ECO<sub>D</sub> in IM cells (2.10), the high affinity component representing less than 25% of the total activity. The data in Table 4.2 is consistent with these activities, as well as PCOD, being biphasic in cells from AM rats.

ECO<sub>D</sub> activities of IM and AM cells were very similar. Total PCOD activity was significantly less in AM cells together with a numerical but non-significant decrease in the activity of the high affinity component relative to IM cells. Total MCO<sub>D</sub> was significantly greater and the high affinity activity significantly less in AM cells compared to IM cells (as observed in the previous chapter). Therefore, total PCOD and both components of MCO<sub>D</sub> activity appear to change with age in the male rat, implying some developmental regulation.

#### 4.3.2 Dealkylase activities in hepatocytes from male and female rats

The dealkylase activities in fresh cells from **female** rats, together with those from AM rats are presented in Table 4.3. The high affinity components of both MCOD and ECOD represented less than 25% of the total activity, indicating that these activities are probably also biphasic in hepatocytes from AF rats. However, PCOD activity measured at  $10\mu\text{M}$  accounted for 60% of the total activity in AF cells; from this, and the known involvement of a male-specific form of P450 in PCOD activity (Kamatani et al., 1985), it is suggested that PCOD is a monophasic activity in AF cells, existing only as a high affinity form. Consequently, data on the maintenance of PCOD in cultures from AF rats are reported only for the high affinity form.

Total MCOD activity was significantly less in AF cells relative to AM cells and was very similar to that measured in IM cells (AF  $71 \pm 5$  pmol min<sup>-1</sup> mg<sup>-1</sup>; IM  $88 \pm 17$  pmol min<sup>-1</sup> mg<sup>-1</sup>). High affinity MCOD in AF cells was not significantly different to that in AM cells. Total ECOD was markedly and significantly less in AF cells, whereas high affinity ECOD was slightly **increased**. The high affinity PCOD activity in AF cells was not significantly different to that of AM cells and, like total MCOD, was **very** similar to the activity in IM cells (AF  $24 \pm 5$  pmol min<sup>-1</sup> mg<sup>-1</sup>; IM  $25 \pm 6$  pmol min<sup>-1</sup> mg<sup>-1</sup>). Therefore, there appear to be sex differences as well as age differences in several of these activities.

### 4.3.3 Maintenance of activities in culture

#### (a) MCOD

Maintenance of MCOD activities in **culture** is shown in Figure 4.1. Both components of MCOD activity in IM cells **declined** to 50 - 60% of the fresh cell value at 24 hours. Kinetic studies (2.10) demonstrated that MCOD becomes monophasic in IM cultures with loss of the high affinity component; this explains the similarity in the magnitudes of the loss of activity at the two substrate concentrations. There was a similar **decline** in cultures from AF rats, suggesting the loss of the high affinity form. The MCOD activity declined further by 72 hours in IM and AF cells. In contrast, MCOD remained biphasic in AM cultures, the high affinity form being maintained (83% fresh activity) alongside a decline in the total activity (44% of fresh activity). These results for the AM rats are similar to those reported in the previous chapter. Both components fell to less than 20% of the fresh activity after 72 hours in culture.

#### (b) ECOD

Figure 4.2 shows the maintenance of ECOD activity in hepatocyte cultures. ECOD appeared to remain biphasic over the 72 hour culture period in all three donor cell types. High affinity ECOD activity was maintained for 72 hours in hepatocytes from IM and AM rats, whilst the activity fell to around 50% of fresh in cultures from AF rats.

Total ECOD was significantly reduced at 24 hours in cultures from IM rats but was retained in AM cells. By 72 hours the activity had declined to the same level as in cells from IM rats. In cultures from AF rats the activity fell to around 80% at 24 hours and fell **slightly** further by 72 hours.

**(c) PCOD**

Maintenance of PCOD activity in culture is shown in Figure 4,3, High affinity PCOD was maintained at high levels over 72 hours in cultures from IM and AM rats; the equivalent activity fell to around 50% in AF cells, PCOD also remained biphasic in cultures from male rats, although, in contrast to the high affinity form, total PCOD **fell** rapidly within 24 hours in **culture**, and **declined** further by 72 hours.

Overall, these dealkylase activities were maintained at higher **levels** in **cells** from AM rats than in **cells** from either IM or AF animals. This maintenance was significantly greater for four out of the six activities, with a further activity being maintained in both AM and IM cells. All three enzymes remained biphasic in cultures from AM rats. Although total MCOD and total PCOD fell to less than 70% of the fresh activity after 24 hours in culture the other four activities were maintained at high levels, with the high affinity forms of ECOD and PCOD being maintained for 72 hours.

#### 4.4 DISCUSSION

The results of this study have demonstrated that the maintenance in culture of rat hepatic P450-dependent **alkoxycoumarin** O-dealkylase activities is dependent upon the choice of coumarin used as substrate, its concentration and the age and sex of the hepatocyte donor animal. It is highly likely that selective maintenance of particular P450 enzymes accounts for these **variabilities**, but the exact nature of these forms remains to be established. The general conclusion is one of better maintenance of activity over 24 hours in culture in hepatocytes isolated from AM rats, but that such selectivity for AM cells is lost by 72 hours in culture. This is consistent with the idea that maintenance is linked to differential turnover of P450, as discussed in the previous chapter. To recapitulate briefly: AM rats have a lower fast:slow turnover ratio for haemoproteins than IM or AF rats, which implies a more stable population of P450 forms in the AM rat, and also improved maintenance in culture. The lack of selectivity for AM cells after 72 hours in culture is also consistent with this, given the reported half-life of 41-44 hours for the slow turnover component (Levin et al., 1975). If changes **in** turnover do influence P450 maintenance **in** culture, this would suggest that total MCO and total PCOD activities are fast turnover forms, since they are the least well maintained (at 40-60% of fresh activity at 24 hours), even in AM cells.

Total M<sub>1</sub> activity is 50% greater in AM cells than in IM or AF cells, indicating a possible adult male-specific component in this activity. P<sub>1</sub> activity has already been described as male-specific (Kamataki et al., 1983; 1985), and the results from this study imply that it is the low affinity form(s) that is male-specific, and that this is absent in AF cells. This agrees with the work of Kamataki et al., who also measured P<sub>1</sub> activity at a 500 $\mu$ M substrate concentration. However, the P450-male isozyme reported to be responsible for P<sub>1</sub> activity (Kamataki et al., 1983), and equivalent to Waxman's P450-2c (1985), is sharply induced (20-fold) at puberty in the male rat, and the P<sub>1</sub> activities presented here do not fit with this pattern of expression. The total P<sub>1</sub> activity measured in this study does agree with the expression of P450-PB-2a (also known as 2a, Waxman et al., 1985; 1988), which is similar in both AM and IM rats but suppressed in AF rats. This isozyme has also been shown to catalyse more than 85% of microsomal testosterone 6 $\beta$ -hydroxylase activity in the male (Waxman et al., 1985), and recently Yamazoe et al. (1988) demonstrated that male-specific P<sub>1</sub> activity correlated with 6 $\beta$ -hydroxylase activity in microsomes. They also showed that whereas antibodies to P450-male (P450-2c) inhibited P<sub>1</sub> activity in a reconstituted system, they did not inhibit P<sub>1</sub> activity at all in microsomal preparations. With regard to the maintenance of this P450, the content of P450-2a (measured immunochemically) was not reduced during culture of AM rat hepatocytes for 72 hours in medium containing glucocorticoid and nicotinamide (Steward et al., 1985), whereas the low affinity

(total) PCOD activity measured here, is markedly reduced by this time in culture. These workers also proposed that loss of haem rather than apoprotein accounted for much of the loss of active P450 in **culture**. Supplementation of media with haem, reported in the previous chapter, had no effect on maintenance of activities; nevertheless, it seems that the apparent anomaly in maintenance of PCOD activity and the putative isozymes involved can be rationalized in terms of selective maintenance of apoprotein, but not holoenzyme.

It appears then that the male-specific PCOD activity is mediated by the P450 involved in constitutive **6 $\beta$ -steroid hydroxylation**. This **isozyme/activity** is regulated by growth hormone (GH, Waxman et al., 1988; Yamazoe et al., 1988), continuous high level secretion of GH suppressing its synthesis. It was also suggested (Waxman et al., 1988) that the Isozyme may be suppressed in pre-pubertal males, as well as in adult females, the same or a **very** similar Isozyme being subsequently re-introduced at puberty. This situation would be analogous to that reported for P450IIA1 and IIA2, where P450IIA1 is expressed in IM rats and IIA2 (a **very** closely related Isozyme) in adult males (Matsunaga et al., 1988). This would also explain the significantly lower total PCOD activity in the AM cells in this study.

It could also be argued from this Investigation that the **developmentally regulated** P450s are the most susceptible to **decline** in culture, being dependent for expression on GH and androgen levels

(Skett, 1988). The addition of GH to hormone-free culture medium causes a feminisation of the P450 phenotype, similar to that seen in hypophysectomised male rats (Guzelian et al., 1988), and recent reports have implicated the thyroid hormones, thyroxine and tri-iodothyronine, in addition to the effects of GH, in suppression of liver-specific P450IIA2, the male-specific  $6\beta$ -hydroxylase and the female-specific  $7\alpha$ -hydroxylase (Arlotto and Parkinson, 1989; Yamazoe et al., 1989). Both GH and thyroxine are present at significant levels in calf serum (Honn et al., 1975), and it is possible that these serum constituents suppress liver-specific functions in vitro (Enat et al., 1984; Silver and Krauter, 1988). The WEC used also contains insulin, which can mimic the effects of GH on the hepatocyte, but is also essential for culture of hepatocytes under most conditions (Guzelian et al., 1988).

Pulsatile secretion of GH, with peaks every 3-4 hours that suppress selective P450 synthesis, could be envisaged to maintain relatively constant levels of rapid turnover P450s (t<sub>1/2</sub> 6-7h, Levin et al., 1975), whereas slow turnover P450s (regulated by GH) would tend to accumulate. It is plausible (if speculative) that GH/thyroid hormones regulate rapid turnover P450s to maintain constant levels of constitutive P450s, in the adult at least.

It has been demonstrated in this study that donor age and sex influence both the activity and maintenance in culture of hepatic P450-dependent alkoxy coumarin O-dealkylase activities. The best

maintenance of a range of activities was achieved in hepatocytes from AM rats, cultured for 24 hours in WEC,

## **TABLES AND FIGURES**

**TABLE 4.1. SEX-SPECIFIC CYTOCHROME P450 ISOZYMES AND THEIR ASSOCIATED STEROID HYDROXYLASE ACTIVITIES.**

<b>P450 FORM</b> <sup>1</sup>	<b>ACTIVITY</b>	<b>SPECIFICITY</b>
P450IIA1	testosterone 7 $\alpha$ -hydroxylase <sup>2</sup>	female, immature male
P450IIA2	testosterone 15 $\alpha$ -hydroxylase <sup>3</sup>	adult male
P450IC11	testosterone 16 $\alpha$ -hydroxylase <sup>4</sup>	adult male
P450IIC12	steroid 15 $\beta$ -hydroxylase <sup>5</sup>	female, immature male
P450IIC13	progesterone 16 $\alpha$ ,6 $\beta$ - hydroxylase <sup>6</sup>	adult male
P450IIIA2	testosterone 6 $\beta$ -hydroxylase <sup>7</sup>	adult male, immature male, female

---

<sup>1</sup> Nebert et al.,(1989)

<sup>2</sup> Arlotto and Parkinson, (1989)

<sup>3</sup> Matsunaga et al., (1988)

<sup>4</sup> Waxman et al., (1985)

<sup>5</sup> Waxman et al., (1985)

<sup>6</sup> Swinney et al.,(1988)

<sup>7</sup> Waxman et al., (1985); Yamazoe et al.,(1988).

**TABLE 4.2. ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES IN HEPATOCYTES ISOLATED FROM IMMATURE (IM) AND ADULT (AM) MALE RATS.**

SUBSTRATE CONCENTRATION ( $\mu\text{M}$ )	ACTIVITY ( $\text{pmol min}^{-1} \text{mg}^{-1}$ )	
	IM	AM
7-MC 500	88 $\pm$ 17	157 $\pm$ 16* *
7-MC 20	19 $\pm$ 2 (21.6)	11 $\pm$ 2* (7.0)
7-EC 500	247 $\pm$ 34	228 $\pm$ 17
7-EC 10	19 $\pm$ 4 (7.7)	13 $\pm$ 1 (5.7)
7-PC 500	297 $\pm$ 32	215 $\pm$ 8** *
7-PC 10	25 $\pm$ 6 (8.4)	15 $\pm$ 1 (7.0)

Values are mean $\pm$  SEM (n=4).

Figures in brackets are the mean activities at 10 or 20 $\mu\text{M}$  (the high affinity form) expressed as a percentage of the mean activity at 500 $\mu\text{M}$  (the total activity).

AM values significantly different to IM values at \*p < 0.05 or \*\*p < 0.01.



**TABLE 4.3. ALKOXYCOUMARIN O-DELAHYLASE ACTIVITIES IN HEPATOCYTES ISOLATED FROM ADULT MALE (AM) AND ADULT FEMALE (AF) RATS.**

SUBSTRATE CONCENTRATION ( $\mu\text{M}$ )	ACTIVITY ( $\text{pmol min}^{-1} \text{mg}^{-1}$ )	
	AM	AF
7-MC 500	157 $\pm$ 16	71 $\pm$ 5 **
7-MC 20	11 $\pm$ 2 (7.0)	16 $\pm$ 2 (22.5)
7-EC 500	228 $\pm$ 17	67 $\pm$ 12* * *
7-EC 10	13 $\pm$ 1 (5.7)	16 $\pm$ 1 * (23.9)
7-PC 500	215 $\pm$ 8	40 $\pm$ 6 ***
7-PC 10	15 $\pm$ 1 (7.0)	24 $\pm$ 6 (60.0)

Values are mean  $\pm$  SEM (n+4).

Figures in brackets are the mean activities at 10 or 20  $\mu\text{M}$  (the high affinity form) expressed as a percentage of the mean activity at 500  $\mu\text{M}$  (the total activity).

AF values significantly different to AM values at \*p < 0.05; \* \*p < 0.01; \* \*\* p < 0.001.



**FIGURE 4.1. MAINTENANCE OF MCOD ACTIVITY IN HEPATOCYTES CULTURED FOR 24 AND 72 HOURS FROM IM, AM AND AF RATS.** Values shown are the mean maintenance values (n=4) with the ranges.

\* AM significantly different to IM, and AF significantly different to AM values,  $p < 0.05$  (Mann-Whitney U-test).







FIGURE 4.2. MAINTENANCE OF ECOD ACTIVITY IN HEPATOCYTES CULTURED FOR 24 AND 72 HOURS FROM IM, AM AND AF RATS, Values shown are the mean maintenance values (n=4) with the ranges.

\* AM significantly different to IM, and AF significantly different to AM values,  $p < 0.05$  (Mann-Whitney U-test).



**FIGURE 4.3.** MAINTENANCE OF PCOD ACTIVITY IN HEPATOCYTES CULTURED FOR 24 AND 72 HOURS FROM IM, AM AND AF RATS, Values shown are the mean maintenance values ( $n=4$ ) with the ranges.

\* AM significantly different to IM, and AF significantly different to AM values,  $p<0.05$  (Mann-Whitney U-test).

CHAPTER 5

INDUCTION OF ALKOXYCOUMARIN  
O-DEALKYLASE ACTIVITIES  
IN VIVO AND IN VITRO

**CHAPTER 5**

<b>CONTENTS</b>		<b>PAGE</b>
5.1	INTRODUCTION	107
5.2	METHODS	109
5.2.1	Induction <u>in vivo</u>	109
5.2.2	Induction <u>in vitro</u>	110
5.2.3	Expression of results	110
5.3	RESULTS	111
5.3.1	Induction <u>in vivo</u>	111
5.3,2	Induction <u>in vitro</u>	112
5.3.3	Comparison of induction <u>in vivo</u> and <u>in vitro</u>	113
5.3,4	Effect of selenium on PB induction <u>in vitro</u>	113
5,4	DISCUSSION	114

TABLES AND FIGURES

CHAPTER 5

INDUCTION OF ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES IN VIVO AND IN VITRO

5.1 INTRODUCTION

Many xenobiotics that are **metabolised** by cytochrome P450 induce their own biotransformation and/or the metabolism of other compounds, endogenous and exogenous. This induction of P450 activity can have a profound effect on the **metabolism** and toxicity of xenobiotics, since increased activation as well as increased detoxification can occur. The different classes of inducer have already been discussed in Chapter One.

Induction of hepatic P450s can be studied in microsomes and hepatocytes isolated from animals that have been treated with inducers. The changes in P450 and its associated activities can be easily measured in these systems. The **alkoxycoumarin O-dealkylases** have been used to Investigate Induction in vivo since the enzymes have different induction profiles. Microsomal MCOA activity (measured at **500 $\mu$ M**) is Induced by PB, and ECOD (at **500 $\mu$ M**) by PB and BNF (Matsubara et al., 1983; Paterson et al., 1984). This pattern of induction has also been reported for total MCOA and ECOD activities measured in hepatocytes Isolated from animals Induced in vivo with PB and BNF (Warren and Fry, 1988). Boobis et al. (1986) showed that the total and **high** affinity components of microsomal ECOD activity were **differentially** Induced by 3-MC, total ECOD activity being induced 9-fold more than the high affinity form. PB

induced the total and high affinity forms 5- and 2-fold respectively. The differential Induction of the components of this biphasic activity is further evidence for the Involvement of multiple P450 forms, making the **alkoxycoumarins** good substrate markers for a range of hepatic P450 isozymes.

More recently, researchers have tried to Induce P450 activities in cultured hepatocytes, with little success in reproducing the observed in vivo induction in the in vitro situation. The induction in vitro of total ECOD activity by 3-MC (and **3-MC-like** compounds) has been demonstrated to be similar to that seen in vivo (Fry et al., 1980; Edwards et al., 1984), and the Induction and expression of P450IA1 and IA2 mRNAs in response to 3-MC in cultured hepatocytes has also been reported (Silver and Krauter, 1988). However, the anomalous expression of P450IA1 in untreated and in PB-treated cultures has been noted by several workers (Fry et al., 1980; Steward et al., 1985; Turner and Pitot, 1989). In contrast to the situation in vivo, total MCOD activity is not induced by PB in hepatocyte cultures (Warren and Fry, 1988), and the poor (and altered) response of P450 in culture to PB is now a well recognised phenomenon (Edwards et al., 1984; Forster et al., 1986). Interestingly, **it** is known that selenium deficiency leads to a reduced induction response to barbiturates (Burk and Masters, 1975), although the reason for this is not known; it has also been reported that selenium **is** necessary for PB induction of P450 in cultured hepatocytes (Engelmann et al., 1985).

Although the two components of microsomal ECOD activity were shown to be **differentially** induced by 3-MC and PB (Boobis et al., 1986), only the induction of total MCOD activity has been reported, (Matsubara et al., 1983; Warren and Fry, 1988). Also, the previous Induction in vitro study on MCOD and ECOD was performed with substrate concentrations of **500 $\mu$ M**, representative only of the total activity (Warren and Fry, 1988). Therefore, in this study, the in vitro induction of both components of MCOD and ECOD activities by PB and BNF was determined, and compared to that measured in fresh hepatocytes isolated from animals Induced in vivo. The effect of Se on PB induction of MCOD activity in vitro was also investigated.

## 5.2 METHODS

### 5.2.1 Induction in vivo

Adult male Wistar rats (150g) were injected i.p. with PB (80  $\text{mgkg}^{-1}$ , **saline**), BNF (80  $\text{mgkg}^{-1}$ , oil of arachis), **saline** or oil of arachis, once a day for 3 days. Hepatocytes were then isolated by lobe perfusion, and **alkoxycoumarin** O-dealkylase activities determined in the freshly Isolated cells, as described in 2.10, except that incubation with substrate was for 5 minutes only (over which period the production of 7-HC was linear in cells from inducer-treated animals).

### 5.2.2 Induction in vitro

Hepatocytes from untreated **adult** male rats (150g) were cultured for 72 hours, in WEC, in the presence or absence of inducer, which was added after the 2 hour attachment **period**. Fresh medium containing inducer was placed on the cells after 24 and 48 hours in culture. After 72 hours, O-dealkylase activities were determined as described in 2.10 except that incubation of Inducer-treated cultures with **500 $\mu$ M** 7-EC was for 1 hour only. MCO activity (at **500 $\mu$ M** substrate concentration) was also determined in PB-treated hepatocytes **cultured** in WEC and WEC containing haem (**1 $\mu$ M**), ALA (200mM) and Se (**0.1 $\mu$ M**) as described in 3.2. PB was used at 3.0mM (dissolved in saline) and BNF at **50 $\mu$ M** (dissolved in DMF). These concentrations were ascertained, from initial experiments, to give maximal Induction in the absence of any observable toxicity (before and after incubation of the induced cells with substrate). Cultured hepatocytes were exposed to inducer for 3 days to compare directly the induction in vitro with that in vivo.

### 5.2.3 Expression of Results

O-Dealkylase activities are expressed as  $\text{pmol 7-HC min}^{-1} \text{mg protein}^{-1}$ , and induction of activity is expressed relative to the control activity (which is given the value 1.0). Statistical analysis was by use of t-tests and ANOVA, as appropriate.

### 5.3 RESULTS

#### 5.3.1 Induction in vivo

The **viabilities** and yields of the cell preparations from the groups of treated rats were compared. These values from a group of untreated rats were also included in the comparison. The results are presented in Table 5.1. There were no significant differences in yield (as judged by ANOVA), although the yield from BNF-treated rats was lower than in the other groups. There were also no differences in viability. The O-dealkylase activities of the two control groups, saline and oil of arachis treated, were compared with those obtained from untreated animals (data from Table 4.3). Again, there were no significant differences between the three groups. Thus, treatment of animals with Injection vehicle does not affect these activities, the cells from vehicle-treated animals being equivalent to untreated control animals (Table 5.2).

#### **Induction of activities**

The activities determined in fresh cells isolated from the control and inducer-treated groups are shown in Table 5.3. PB significantly induced all four O-dealkylase activities. Both components of MCOA activity were induced to the same extent in vivo (6.8- and 6.0-fold **relative** to the **saline controls**). High affinity and total ECOA activities were induced 12.9- and 5.3-fold respectively relative to saline controls. **BNF-treatment** resulted **in** a non-significant increase in MCOA activity (3.4- and

1.8-fold Increases relative to oil-treated controls). However, there was a significant induction of both components of ECOD activity: 8.4- and 8.7-fold increases over control. It should be noted that some of the standard errors in these activities are quite large, especially amongst the PB and BNF-treated groups. This degree of variability probably reflects differences **in** the success of administration of the i.p. injections in addition to Inter-individual variation in response to the Inducers.

### 5.3.2 Induction in vitro

The activities determined in hepatocytes cultured for 72 hours **in** the presence or absence of inducer are shown in Table 5.4. After 72 hours in culture, all the activities in the control cultures are low, as expected from the data presented in Chapter Four. In the PB-treated cultures there is a slight increase in MCOD activity but this is only 1.5- to 2.5-fold relative to the control cultures. There was a significant induction of ECOD activity in culture, the Induction of total ECOD activity relative to control being 6.7, and of the high affinity form 3.6. In BNF treated cultures there was a slight Increase **in** MCOD activity (1.5- to 2.6-fold relative to control) and a significant induction of ECOD. Induction of the high affinity and total activity form was 7.2- and 20-fold respectively relative to control. The in vitro Induction data **is** summarised in Table 5.5. As was observed with the in vivo induction, there **is** a wide range of response to the Inducers. Since the culture conditions were uniform, this must reflect either inter-individual

variation in response which is retained in vitro, or differences in the cell populations obtained from the isolation process.

### 5.3.3 Comparison of induction in vivo and in vitro

The induction of activity relative to control in vivo and in vitro by PB and BNF is shown in Figures 5.1 and 5.2. It can be seen from Figure 5.1 that PB Induction is blunted in vitro, with MCOD activity being almost totally refractory to the Inducer, in contrast to the situation in vivo. Only total ECOD activity is induced in vitro to the same extent as in vivo. BNF did not Induce MCOD in vivo or in vitro (Figure 5.2). Induction of high affinity ECOD in vitro was similar to that seen in vivo whilst the induction of total ECOD in vitro was much greater than that seen in vivo. Therefore, there are not only differences between induction in culture and in vivo with respect to the magnitude of the effect, but the pattern of Increase of the four chosen activities is also altered.

### 5.3.4 Effect of selenium on PB induction in vitro

Table 5.6 shows the effects of haem, ALA and Se supplementation of WEC (i.e. WEC+H) on PB Induction of total MCOD activity. WEC+H was used as the sole control medium since MCOD activity in WEC and WEC+H has already been demonstrated to be equivalent (3.3.1). Total MCOD was chosen since it is the least well maintained, and most refractory to PB induction in **culture**. There was a numerical, but non-significant, induction (3.0-fold relative to control) of MCOD activity in PB treated cultures. The magnitude of induction was

greater than in the previous experiment (5.3.2), but whereas the induction in 5.3.2 represents the mean of 5 animals, in this experiment all the cultures used were derived from the same animal. This result confirms the observations on heterogeneity of response to Inducer in vitro. Nevertheless, the increase is only 50% of that seen in vivo, PB induction of MCOD activity in WEC+H was not significantly different to that in WEC (3,0- and 3,5-fold respectively). Therefore, the presence of Se (haem and ALA) in the medium did not Improve PB induction of MCOD in vitro,

#### 5.4 DISCUSSION

The pattern of MCOD and ECOD induction was as expected: PB Induced both MCOD and ECOD; BNF induced only ECOD activity. Whereas both components of MCOD activity were induced to the same extent in vivo, PB induced high affinity ECOD more than the total activity and BNF Induced the total more than the high affinity form. BNF also induced only ECOD activity in vitro. PB failed to induce MCOD in vitro although there was good induction of total ECOD activity, and a modest induction of the high affinity component. The Inclusion of haem, ALA and Se in the **culture** medium did not improve PB induction of MCOD activity in vitro. This contrasts with the work of Engelmann et al. (1985) in which induction of P450 content by PB was only observed in medium containing exogenous haem and Se. However, these workers used PB at a concentration of **1mM**, which did not Induce O-dealkylase activity in initial experiments performed in this study. The Se may possibly be potentiating an effect at this

lower concentration of inducer. It is also possible that the Se is increasing the total P450 Induced by PB, but that these P450s are not **PB-specific** Isozymes. This would explain the lack of effect of Se on PB Induction of MCO<sub>D</sub> activity, and would be consistent with other work on PB induction in vitro.

PB-inducible P450s have been reported previously to be refractory to induction in hepatocyte culture (Forster et al., 1986; Warren and Fry, 1988), but it also appears that the isozymes Induced by the compound in vivo and in vitro are different. Edwards et al. (1984) determined that the proportion of PB-inducible P450s that could be inhibited by metyrapone after in vitro induction was different to that after in vivo Induction, suggesting that the populations of P450 Induced in the two conditions were not identical. In 1985, Miyazaki et al. observed that although PB effectively arrested the rate of **decline** of total P450 in hepatocyte cultures and preserved the cell morphology, the main Isozyme induced by PB, P450IIB1, was not detectable **immunochemically** in the cultures.

Thus, the poor induction by PB in vitro is probably a function of altered regulation. It is known that the transcription rates of other PB-inducible proteins are different to that of P450IIB1 (Hardwick et al., 1983a), however there have been no reports on the induction in vitro of non-P450 PB-inducible proteins. It may be that changes in the regulation of PB induction reflect alterations in other factors necessary for PB-inducible gene expression.

Although no receptor for PB has been identified, it appears that protein synthesis is essential for Induced expression of the CYP2B1 and CYP2B2 genes (Chianale et al., 1988), and the Involvement of trans-acting regulatory factors has been suggested. Alterations in turnover/regulation of transcription factors in vitro could result in reduced gene expression.

Although PB did not induce MCOD in vitro, ECOD activity was induced, ECOD activity must involve a different population of isozymes, since the activity is also induced by BNF, The Induction of ECOD by PB may Involve PB Induction of **BNF-inducible** P450s, The anomalous expression of P450IA1 in untreated and PB-treated cultures has been reported previously and seems to be more marked in hormone-free culture medium (Fry et al., 1980; Turner and Pitot, 1989). Also, good expression of both P450IA1 and IA2 seems to require serum-free medium. It is therefore possible that these P450s are normally repressed (e.g. by a hormone) but that this repression is disrupted in vitro. Despite the unusual expression of P450IA1 in control and PB-treated cultures, the induction of BNF-inducible forms by BNF in vitro is similar to that seen in vivo.

It was suggested that the **variability** in response to Inducer was a result of inter-individual variation and/or variation in administration of inducer, these variations being retained on placing hepatocytes into culture. However, it is also known that hepatocyte heterogeneity exists with respect to distribution of P450

isozymes, as well as carbohydrate metabolism (Gumucio, 1989). The perivenous hepatocytes (in the distal part of the liver acinus) contain more **PB-and 3-MC-inducible** isozymes in the **uninduced** state, and whereas PB Induction predominates in perivenous hepatocytes (Baron et al., 1981), 3-MC Induction seems to predominate in the periportal regions (Tazawa et al., 1988). It has been shown that the direction of liver perfusion during hepatocyte Isolation influences the relative proportions of proximal and distal acinar hepatocytes obtained in the final preparation (Gumucio et al., 1986). It is possible then, that selective isolation and/or selective survival in culture of hepatocytes with different P450 isozyme profiles and different metabolic activities may also be a factor in altered **inducibility** of P450s in vitro.

In summary, the induction of **alkoxycoumarin** O-dealkylase activities in vitro by PB and BNF was not representative of the induction observed in vivo. It is likely that P450 induction in vivo will only be successfully reproduced in culture when the mechanisms of induction are fully understood. However, in the meantime, an alternative approach for studying induced P450s in hepatocyte cultures would be to induce the isozymes in vivo, and then culture hepatocytes from the treated animals. The feasibility of this is investigated in the following chapter.

## **TABLES AND FIGURES**

**TABLE 5.1. YIELD AND VIABILITY OF CELL PREPARATIONS FROM UNTREATED AND INDUCER-TREATED ADULT MALE RATS.**

<b>GROUP</b>	<b>YIELD (million cells)</b>	<b>PERCENTAGE VIABILITY</b>
UNTREATED	44± 3	92± 1
SALINE	40± 1	91 ± 1
PB	46± 4	91± 2
OIL OF ARACHIS	45±16	91±1
BNF	18±2	92± 2

Values are mean ± SEM (n=4).

ANOVA : no significant differences between the five groups.

**TABLE 5.2. ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES IN FRESHLY ISOLATED HEPATOCYTES FROM CONTROL GROUPS OF ADULT MALE RATS.**

SUBSTRATE CONCENTRATION ( $\mu$ M)	ACTIVITY ( pmol min <sup>-1</sup> mg <sup>-1</sup> )		
	UNTREATED	SALINE	OIL OF ARACHIS
7- MC 20	11 $\pm$ 2	8 $\pm$ 2	13 $\pm$ 1
7-MC 500	157 $\pm$ 16	138 $\pm$ 16	125 $\pm$ 6
7-EC 10	13 $\pm$ 1	9 $\pm$ 2	17 $\pm$ 1
7-EC 500	228 $\pm$ 17	294 $\pm$ 37	314 $\pm$ 19

Values are mean  $\pm$  SEM (n=4).

**ANOVA** : no significant differences between the three groups.

Untreated group: data taken from Table 4.3.

**TABLE 5.3. ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES IN HEPATOCYTES ISOLATED FROM CONTROL AND INDUCER-TREATED ADULT MALE RATS: INDUCTION *IN VIVO*.**

SUBSTRATE CONCENTRATION ( $\mu\text{M}$ )	ACTIVITY ( $\text{pmol min}^{-1} \text{mg}^{-1}$ )			
	SALINE	PB	OIL OF ARACHIS	BNF
7-MC 20	8 $\pm$ 3	54 $\pm$ 11*	13 $\pm$ 1	44 $\pm$ 7
7-MC 500	138 $\pm$ 16	834 $\pm$ 169*	125 $\pm$ 6	219 $\pm$ 34
7-EC 10	9 $\pm$ 2	116 $\pm$ 26*	17 $\pm$ 1	143 $\pm$ 21**
7-EC500	294 $\pm$ 37	1554 $\pm$ 296*	314 $\pm$ 19	2740 $\pm$ 208* *

Values are mean  $\pm$  SEM (n=4).

\* PB significantly different to saline control  $p < 0.05$ ;

\* \* BNF significantly different to oil of arachis control  $p < 0.05$ ;  
unpaired t-tests.

**TABLE 5.4. ALKOXYCOUMARIN O-DEALKYLASE ACTIVITIES IN HEPATOCYTES CULTURED IN THE PRESENCE OF INDUCER: INDUCTION *IN VITRO*.**

SUBSTRATE CONCENTRATION ( $\mu\text{M}$ )	ACTIVITY ( $\text{pmol min}^{-1}\text{mg}^{-1}$ )		
	PB	CONTROL	BNF
7-MC 20	1.710.3	0.710.2	1.810.6
7-MC 500	11.012.0	7.311.0	12.013.0
7-EC 10	7.512.0	2.110.5*	14.013.0*
7-EC 500	110138	21.0 $\pm$ 3.0*	3641112*

Values are mean  $\pm$ SEM (n=5, 7-MC; n=4, 7-EC).

\* control significantly different to PB and BNF significantly different to control  $p < 0.05$ ; paired t-test.

**TABLE 5.5. ACTIVITY AFTER INDUCTION *IN VITRO* RELATIVE TO CONTROL.**

SUBSTRATE CONCENTRATION ( $\mu\text{M}$ )	RELATIVE INDUCTION	
	PB	BNF
7-MC 20	2.5(1.9-3.3)	2.6 (1.0-5.2)
7-MC 500	1.5(1.1-1.9)	1.5 (0.8-2.3)
7-EC 10	3.6(2.8-5.2)	7.2 (3.9-11.0)
7-EC 500	6.7(1.8-13.0)	20.0 (5.6-37.0)


Induced activity relative to control was determined for each animal and the values above are the mean induced activities relative to control, with ranges (n=4 or 5).

**TABLE 5.6. EFFECT OF MEDIUM SUPPLEMENTATION ON PB INDUCTION OF TOTAL MCOB ACTIVITY,**


	MEDIUM		
	WEC+H	WEC PB	WEC+H PB
$\text{pmol min}^{-1}\text{mg}^{-1}$	12 $\pm$ 1	36 $\pm$ 7	421 3
relative induction	1.0	3.0	3.5

Values are mean  $\pm$  SEM (n=4 plates).

WEC PB not significantly different to WEC+H; WEC+H PB not significantly different to WEC PB; paired t-test.



**FIGURE 5.1. INDUCTION OF MCOD AND ECOD ACTIVITIES BY PB *IN VIVO* AND *IN VITRO*.** Activities were determined in freshly isolated cells from inducer-treated animals, or in hepatocytes cultured for 72 hours in the presence of inducer. Activities are expressed relative to the control activity, i.e. from the untreated cells or animals.



**FIGURE 5.2. INDUCTION OF MCOD AND ECOD ACTIVITIES BY BNF *IN VIVO* AND *W VITRO*.** Activities were determined in freshly isolated cells from inducer-treated animals, or in hepatocytes cultured for 72 hours in the presence of inducer. Activities are expressed relative to the control activity, i.e. from the untreated cells or animals.

CHAPTER 6

INDUCTION OF P450 AND ENZYME  
ACTIVITIES IN VIVO AND MAINTENANCE  
IN RAT HEPATOCYTE CULTURES

**CHAPTER 6**

<b>CONTENTS</b>		<b>PAGE</b>
6,1	INTRODUCTION	120
6,2	METHODS	121
6.2.1	<b>Animals</b>	121
6.2.2	Procedures	121
6.2.3	Presentation of results	122
6.3	RESULTS	122
6.3.1	Induction of enzyme activities	122
6.3.2	Induction relative to control	123
6.3.3	Maintenance of activities in culture	124
6.4	DISCUSSION	126
	SUMMARY	130

TABLES AND FIGURES

## CHAPTER 6

### INDUCTION OF P450 AND ENZYME ACTIVITIES IN VIVO AND MAINTENANCE IN RAT HEPATOCYTE CULTURES

#### 6.1 INTRODUCTION

Exposure to Inducers of P450 can profoundly alter the metabolism and toxicity of xenobiotics by altering the isozyme population. Different Isozymes have different substrate **specificities**, which is reflected by the differential induction of an activity on exposure to a range of Inducers (Okuno et al., 1989). It should be possible, therefore, to measure enzyme activities selective for different isozymes, resulting in an **activity/isozyme** profile for each inducer. This has been attempted using **stereospecific hydroxylation** products of testosterone (Darby et al., 1986), and the dealkylation of a series of **alkoxyresorufins** (Burke et al., 1985), measured in microsomes from animals treated with P450 inducers.

It was therefore decided to measure several enzyme activities which it was hoped would prove to be selective for different Induced P450 Isozymes. This was done in hepatocytes Isolated from animals treated in vivo with **prototypic** inducers of the main P450 gene families. The inducers chosen were  **$\beta$ -naphthoflavone** (BNF), phenobarbitone (PB), isoniazid (ISO) and dexamethasone (DEX) which induce P450s in the **IA**, **IIB**, **IIE** and **IIIA** families respectively. Prospective selective substrates for the different induced isozymes were chosen. Microsomal 7-ethoxyresorufin **O-deethylation** (EROD) is selectively induced by 3-MC and BNF (Burke et al., 1985);

benzphetamine **demethylation** (BZDM) has been reported to be catalysed by P450IIB1 (Ryan et al., 1979); **p-nitrophenol** hydroxylase (PNPH) is induced in microsomes from **ethanol-fed** rats (Reinke and Moyer, 1985), ethanol and isoniazid both inducing the same isozyme (P450IIE1) in the rat (Ryan et al., 1986), DEX and PCN both induce the same microsomal P450 (Heuman et al., 1982), DEX being a better Inducer. The macrolide antibiotics also induce this family of isozymes, inducing their own **metabolism** at the same time (Danan et al., 1981; Watkins et al., 1986), and therefore erythromycin **N-demethylation** (EMDM) was chosen as the fourth enzyme activity. The enzyme/activity profile for each inducer was then examined and the maintenance of the activity profile in culture determined.

## 6.2 METHODS

### 6.2.1 Animals

Adult male rats (6-8 weeks old) were treated i.p. with dexamethasone sodium phosphate (100 mgkg<sup>-1</sup> in **saline**) for 4 days or BNF (80 mgkg<sup>-1</sup> in arachis oil) for 3 days. PB and ISO (0.1%) were administered in drinking water for 5 and 10 days respectively.

### 6.2.2 Procedures

Hepatocytes were isolated by lobe perfusion, and half of the final cell suspension was sonicated to give an homogenate of fresh cells as described **in** Chapter 2.8. The other half of the suspension was plated out on "Primaria" dishes in WEC. After 24 hours in culture

the monolayers were washed with **saline** and homogenates prepared. P450, protein content and enzyme activities were determined in the cell homogenates as described in Chapter 2.11 - 2.13.

### 6.2.3 Presentation of results

Enzyme activities were calculated as **nmol** or **pmol** product  $\text{min}^{-1}$  **mg** protein<sup>1</sup> (the "activity") and as **nmol** or **pmol** product  $\text{min}^{-1}$  **nmol** P450<sup>1</sup> (the "specific activity"). Induction of activity relative to control indicated the actual change in activity, whereas changes in specific activity relative to control indicated the involvement of induced P450 Isozymes in the activity. Statistical analysis was by ANOVA and Dunnett's tests for the induction of fresh activity relative to control, and by use of paired t-tests for the maintenance data.

## 6.3 RESULTS

### 6.3.1 Induction of enzyme activities

Table 6.1 shows the P450 content and enzyme activities measured in homogenates from hepatocytes isolated from untreated and treated adult male rats. P450 content and BZDM activity were both significantly Induced by PB, DEX and BNF but not by ISO. EMDM was Increased by PB and DEX; PNPB was induced by PB, DEX and ISO. EROD was significantly Induced only by BNF. The 5,6-fold induction by PB was not significant; **this** was probably because the 320-fold induction of EROD by BNF, being so much greater than that by PB (and

the other Inducers), weighted the Dunnett's test (by yielding a very high estimate of the residual mean square value in the ANOVA).

Table 5.2 shows the specific enzyme activities. PB did not significantly increase any of the specific activities, whereas DEX significantly induced EMDM, ISO significantly induced PNPB and BNF significantly Induced EROD.

### 6.3.2 Induction **relative** to control

Figures 6.1 - 6.4 show the changes in P450 content, activity and specific activity relative to those measured in untreated rats (controls = 1.0).

PB (Figure 6.1a) induced BZDM, EMDM and EROD activities to the same extent as the P450 content (7.4-, 5.9-, 5.6- and 6.6-fold respectively), and accordingly the relative specific activities (RSA; Figure 6.1b) of these enzymes approximated to 1.0 (1.3, 0.8 and 0.8), In contrast, PNPB activity was Induced 2.4-fold byPB although the RSA was only 0.3. The demethylase results agree with microsomal data for the PB-inducible aminopyrine demethylase, in that the activity was Induced to the same extent as the P450 content (Fry, 1981). **Also**, the induction of PNPB and EROD determined here from whole cell homogenates were similar to the Inductions of the same activities determined **in** microsomes (1.7-fold induction of PNPB, Reinke and Moyer, 1985; 6-fold induction of EROD, Burke et al., 1985).

DEX (Figure 6.2) induced P450 and BZDM activity 5.6-fold, the RSA of BZDM being 1.1, as seen with PB Induction. EMDM activity was induced 11.8-fold, whereas the RSA was 2.0. Thus, only half of the observed induction of activity could be attributed to the increase in total P450. However, this was the only activity measured that was selectively induced by DEX; the RSA of PNPB and EROD were less than 0.6.

Only PNPB activity was increased by ISO as seen in Figure 6.3 (7.4-fold increase, similar to the 6.1-fold increase observed in microsomes from **ethanol-fed** rats, Reinke and Moyer, 1985). The RSA was 3.9, indicating selective induction of this activity, although the total P450 content did not increase significantly after ISO treatment.

EROD was selectively Induced by BNF (Figure 6.4; RA 320, RSA 32), and again, this was much greater than the observed induction of P450 (9-fold). The RSAs of the other enzymes were less than 0.6.

It would appear that BNF selectively Induced EROD, ISO selectively induced PNPB and DEX selectively induced EMDM, **whereas** PB induced all three demethylase activities to more or less the same level.

### **6.3.3 Maintenance of activities in culture**

The maintenance of the activities after 24 hours in culture, in hepatocytes from untreated and treated animals is shown in Figures

6.5-6.9. Activity at 24 hours relative to that of the fresh cells (RA24) and relative specific activity at 24 hours (RSA24) are both shown. An RA24 of 1.0 and an RSA24 greater than or equal to 1.0 for a particular enzyme indicates maintenance of that particular activity and loss of total P450; an **RA24** and an RSA24 less than 1.0 indicates a specific loss of activity whilst the bulk of the P450 is maintained.

In cultures from untreated rats (Figure 6.5) P450 content fell by 31%; there was a selective loss of BZDM (RSA24 0.46) and a loss of EROD activity. The loss of EROD in culture has been reported previously (Grant et al., 1985), as has the loss of P450 and of certain PB-inducible activities (Warren et al., 1985).

In cultures from PB-induced rats (Figure 6.6) there was a significant loss of P450; there was a selective loss of EMDM and maintenance of BZDM, in contrast to the control cultures.

In cultures from DEX-induced rats (Figure 6.7) the P450 content fell by 43% and unlike the control cultures BZDM was maintained, with total loss of PNPB and some loss of EMDM activity, although the RSA was maintained.

In cultures from ISO-treated animals (Figure 6.8) both P450 and EROD were maintained, as well as EMDM and PNPB activities; there was a loss of BZDM, similar to that seen in control cultures.

In cultures from BNF-treated animals (Figure 6.9) the P450 content fell by 47% and EROD activity was selectively lost. (However, EROD activity in these cultures was still 7-fold greater than that measured in control cultures). The other activities were maintained.

In general, P450 **declined** by 30-50% in hepatocytes after 24 hours in culture and EROD activity was the least stable. The activities selectively induced (as determined **in** the fresh cell homogenates) were maintained in culture over 24 hours, although some of the other forms were lost.

#### **6.4 DISCUSSION**

The selective induction of enzyme activities was demonstrated in this study, using four of the prototypic P450 inducers. ISO only induced PNPB activity and specific activity; BNF selectively induced EROD (i.e. increase in RA and RSA) and DEX selectively induced EMDM. The **latter** two inducers also increased at least one other enzyme activity, but not the relevant specific activity. PB, **in** contrast, induced all the activities but was completely non-selective (for the activities measured in this study).

The fold-induction of specific activities by BNF, ISO and DEX was greater than the fold-induction of total P450 in each case, and there are several explanations for these apparent discrepancies. Firstly, a small increase in an isozyme with a high affinity for the

substrate would increase the observed activity (especially at low substrate concentrations), but if the total P450 was induced or remained unchanged a *very* low RSA value would be **obtained**. This could explain PB induction of PNPB, where the RA was 2,4 and the RSA only 0,3, Secondly, a constitutive isozyme present at low levels **could** be dramatically Increased on induction, but still account for a small proportion of the total P450: this could result in an RSA value much higher than the increase in total P450, This probably accounts for the induction of PNPB by ISO, The RA and RSA of this Induced activity were 7,4 and 3,9 respectively, but, in contrast to the other Inducers, there was no increase in the total P450 **content**. Other workers have reported 6-fold inductions of P450IIE1 and PNPB in the absence of any increase in the total microsomal P450 (Ryan et al., 1985).

With respect to substrate specificity/affinity there were problems associated with choice of substrate in this study. There was a problem of specificity: PB did not significantly induce any RSA value. However, this may reflect the limited number of enzyme activities studied and/or the choice of activities e.g. the induction of pentoxyresorufin O-dealkylase (PROD), as opposed to BZDM, may be more specifically induced by PB (Burke et al., 1985).

In addition to the choice of substrate, it has been shown recently that DEX but not PCN (**pregnenolone-16 $\alpha$ -** carbonitrile) induces the **main** PB-inducible forms in addition to the P450III proteins (Namkung

et al., 1988), and also that PB can induce the CYP3A1 gene (Nebert and Gonzalez, 1987). Also, PCN does not induce the PB-inducible PROD activity (Burke et al., 1985). This probably explains the similar inductions of EMDM and BZDM by PB and DEX. In this study DEX was chosen over PCN because of its greater magnitude of induction. However, in the light of the work by Namkung et al. (1988) PCN would appear to be a more selective inducer of the P450III family. It is also difficult to find selective substrates for this gene family that are relatively easy to assay. The macrolide antibiotics such as **triacetyl**oleandomycin and erythromycin can present problems, since they are capable of binding to the cytochrome forming an inactive complex (Danan et al., 1981). For this reason Namkung et al. (1988) attempted to find alternative substrates; separation of different testosterone metabolites by HPLC was the most successful assay that they tried, with respect to selectivity.

In general, the selectively induced enzyme activities were maintained for 24 hours in hepatocytes cultured from the treated rats, although the total P450 content declined by 30-50% over this time period. This again demonstrated selective stability of isozymic forms, in addition to selective induction.

In hepatocytes cultured from ISO-treated animals, there was a general maintenance of both P450 and enzyme activities, although there was selective loss of BZDM (RA24 and RSA24 of less than 0.5),

similar to that seen in cultures from untreated rats. In these control cultures BZDM activity declined by more than 70%, whereas the total P450 fell by only 31%. The other activities were maintained in control cultures although there was some loss of EROD activity. This activity declined to some extent in all the cultures studied (except those from ISO-treated animals), however, constitutive BZDM appeared to be particularly labile in hepatocyte culture, unlike the induced activity.

It therefore appears that the induced form of BZDM, and also induced EMDM, are not identical to the constitutive forms present in control cultures. The induced EMDM was lost more rapidly than the constitutive form. This is consistent with the rapid degradation of P450s Induced by DEX (Watkins et al., 1986), In contrast, the BZDM Induced by PB and DEX was maintained in culture for 24 hours, whereas the constitutive activity was lost. It has been reported that the main PB-inducible P450 in the liver, P450IIB1 has a high specificity for BZDM and the 16 $\alpha$ -hydroxylation of testosterone (Ryan et al., 1979). This latter activity is catalysed by P450IIC11 in untreated rat liver (Waxman et al., 1985). It is also possible that the poor maintenance of constitutive BZDM reflects the poor maintenance of liver-specific Isozymes, especially in medium containing serum (Enat, 1984). This has been discussed in detail in previous chapters. It would appear then, that induced P450IIB1/2 Isozymes can be maintained in culture for 24 hours, and this also suggests that the inability to detect PB-induction of P450IIB1/2 in

vitro is an induction- mechanism defect, not a maintenance problem.

This study has shown that it is possible to use selective marker activities to monitor changes in Isozyme profile on induction. Induced activities can be maintained in cultured hepatocytes for 24 hours. It should be possible to extend this approach to other inducing agents, and **also** to compare profiles from compounds that induce the same P450 Isozymes. These diagnostic profiles could then be used to investigate new compounds for their ability to induce P450s.

#### SUMMARY

In the previous four chapters an hepatocyte culture system has been defined and characterised with respect to maintenance of P450 and its associated enzyme activities and the induction of these activities. The conditions resulting in the best maintenance of a range of activities seem to involve hepatocytes from young adult male rats, cultured for 24 hours in WEC medium. At this time point, the P450 content is 50-70% that of the freshly isolated cells, with a range of enzyme activities being maintained at 70% or more of the fresh activity. The liver specific forms appear to be less well maintained, so there are further modifications that could be made to this system, including re-appraisal of the use of serum-containing medium. It is also possible to induce activities in vivo and maintain them for 24 hours in the cultured hepatocytes;

this approach was more successful than Induction in vitro. The next chapter reports on investigations into P450-mediated toxicity using this culture system.

## **TABLES AND FIGURES**

**TABLE 6.1. EFFECTS OF P450 COOPERATION ON ENZYME ACTIVITIES IN SUBSTRATE METABOLISM OF TREATED RATS**

VARIABLE	TREATMENT				ISO	θNF
	CON	PB	DEX	ISO		
P450 content <sup>1</sup>	0.16±0.02	1.25±0.11*	0.09±0.18*	0.09±0.04	1.50±0.09*	
BZDM <sup>2</sup>	0.8±0.04	2.50±0.80*	1.90±0.90*	0.09±0.05	1.80±0.80*	
EMDM <sup>2</sup>	0.17±0.01	1.00±0.08*	0.00±0.08*	0.00±0.08	0.00±0.09	
PNPFR	0.04±0.04	0.08±0.05*	0.01±0.07*	1.17±0.10*	0.00±0.09	
EPD <sup>3</sup>	5.0 ± 0.8	0.8±5	7.0 ± 0.5	5.6 ± 0.6	15.00±4.00*	

Values are mean ± S.E.M. of 8-10 animals.

\* treated groups significantly different from control groups,  $p < 0.05$ .

<sup>1</sup> nmol/g protein<sup>-1</sup>

<sup>2</sup> nmol product min<sup>-1</sup>g protein<sup>-1</sup>

<sup>3</sup> pmol protein<sup>-1</sup>h<sup>-1</sup>

**TABLE 6.2.8. CCFE N ZYME C TIVITIES MEASURED IN  
XOMGENATED SHESSHLY ISOLATED XERATOCYTES FROM  
UNTREATED AND TREATED ^MULT MAE R ^B.**

**EXPERIMENT OF ANIMALS**



ACTIVITY <sup>1</sup>	CON	PS	DEX	SO	BNF
BZDM	8.0 ± 0.8	8.8 ± 0.3	8.8 ± 0.8	8.6 ± 0.4	1.1 ± 0.8
BMDM	1.8 ± 0.1	1.2 ± 0.1	8.4 ± 0.3 *	0.88 ± 0.18	8.8 ± 0.7
P1NPH	17 ± 0.4	8.5 ± 0.04	1.0 ± 0.1	8.6 ± 1.1 *	8.8 ± 0.08
EROD	84 ± 4	8.5	8 ± 1	8.0 ± 2	1.10011 00 *

Values are mean ± S.E.M for 8-8 animals.

\* treated groups significantly different to control groups, p < 0.05



<sup>1</sup>NOVA and Dunnett's tests.

18 activities are nmol (µmol) EROD per µg protein per 450 min<sup>-1</sup>.




**FIGURE 6.1. INDUCTION *IN VIVO* OF P450 AND ENZYME ACTIVITIES BY PB.** Each value is the mean activity (A), or mean specific activity (B) measured in freshly isolated hepatocytes from treated animals relative to that of the untreated animals.

A; P450 content B: BZDM C: EMDM D:PNPH E:EROD





**FIGURE 6.2. INDUCTION *IN VIVO* OF P450 AND ENZYME ACTIVITIES BY DEX.** Each value is the mean activity (A), or mean specific activity (B) measured in freshly isolated hepatocytes from treated animals relative to that of the untreated animals.

A: P450 content B: BZDM C: EMDM D:PNPH E:EROD





**FIGURE 6.3. INDUCTION *IN VIVO* OF P450 AND ENZYME ACTIVITIES BY ISO.** Each value is the meanactivity (A), or mean specific activity (B) measured in freshly isolated hepatocytes from treated animals relative to that of the untreated animals.  
 A: P450 content B: BZDM C: EMDM D:PNPH E:EROD





**FIGURE 6.4. INDUCTION *IN VIVO* OF P450 AND ENZYME ACTIVITIES BY BNF.** Each value is the mean activity (A), or mean specific activity (B) measured in freshly isolated hepatocytes from treated animals relative to that of the untreated animals.



A: P450 content B: BZDM C: EMDM D:PNPH E:EROD





**FIGURE 6.5. MAINTENANCE OF P450 AND ENZYME ACTIVITIES AT 24 HOURS IN HEPATOCYTES CULTURED FROM UNTREATED RATS.** Each value is the mean activity (A), or mean specific activity (B), with range, relative to the fresh cell value. \*  $p < 0.05$ , {paired t-test). A; P450 content B: BZDM C: EMDM D:PNPH E:EROD





**FIGURE 6.6. MAINTENANCE OF P450 AND ENZYME ACTIVITIES AT 24 HOURS IN HEPATOCYTES CULTURED FROM PB-TREATED RATS.** Each value is the mean activity (A), or mean specific activity (B), with range, relative to the fresh cell value. \*  $p < 0.05$ , (paired t-test).  
 A: P450 content B: BZDM C: EMDM D:PNPH E:EROD



**FIGURE 6.7. MAINTENANCE OF P450 AND ENZYME ACTIVITIES AT 24 HOURS IN HEPATOCYTES CULTURED FROM DEX-TREATED RATS.** Each value is the mean activity (A), or mean specific activity (B), with range, relative to the fresh cell value. \*  $p < 0.05$ , (paired t-test).  
 A: P450 content B: BZDM C: EMDM D:PNPH E:EROD



**FIGURE 6.8. MAINTENANCE OF P450 AND ENZYME ACTIVITIES AT 24 HOURS IN HEPATOCYTES CULTURED FROM ISO-TREATED RATS.** Each value is the mean activity (A), or mean specific activity (B), with range, relative to the fresh cell value. \*  $p < 0.05$ , (paired t-test). A: P450 content B: BZDM C: EMDM D:PNPH E:EROD



**FIGURE 6.9. MAINTENANCE OF P450 AND ENZYME ACTIVITIES AT 24 HOURS IN HEPATOCYTES CULTURED FROM BNF-TREATED RATS.** Each value is the mean activity (A), or mean specific activity (B), with range, relative to the fresh cell value. \*  $p < 0.05$ , (paired t-test).  
 A: P450 content B: BZDM C: EMDM D:PNPH E:EROD

CHAPTER 7

TOXICITY STUDIES IN  
CULTURED HEPATOCYTES

**CHAPTER 7**

<b>CONTENTS</b>	<b>PAGE</b>
7.1 INTRODUCTION	134
7.2 METHODS	138
7.2.1 <u>In vivo</u> induction and toxicity	138
7.2.2 <u>In vitro</u> induction and toxicity	138
7.2.3 Addition of compounds and Inhibitors	138
7.2.4 Cellular glutathione and toxicity	139
7.2.5 Analysis of results	139
7.3 RESULTS	140
7.3.1 Toxicity to hepatocytes from control rats	140
7.3.2 Toxicity to cultures from inducer-treated rats	140
7.3.3 Variability in observed toxicity	142
7.3.4 Induction <u>in vitro</u> and toxicity	143
7.3.5 Further studies with the precocenes	144
7.4 DISCUSSION	144

TABLES AND FIGURES

## CHAPTER 7

### TOXICITY STUDIES IN CULTURED HEPATOCYTES

#### 7.1 INTRODUCTION

The use of in vitro systems for toxicity testing has been reviewed in Chapter One. In recent years, increasing use has been made of hepatocyte cultures in the investigation of mechanisms of toxicity. As outlined in Chapter One, cultured hepatocytes offer several advantages over other cellular and subcellular preparations for this kind of study: they are intact cells containing both Phase I and II biotransformation enzymes that can be maintained in a defined environment free from hormonal and other physiological influences; they survive longer than hepatocyte suspensions and comprise a **metabolically** stable cell population, also unlike suspensions. There is evidence that freshly isolated cells and hepatocytes that are initially placed into culture are in a state of metabolic flux, with increased catabolism, but that by 24 hours in culture the cells have recovered from alterations in metabolism sustained during isolation and have reached a more stable state (Tanaka et al., 1978; López et al., 1988). It has also been reported that the toxicity observed when hepatocytes are exposed to a toxic compound during the first 18 hours of culture is greater than when exposure is after 24 hours in **culture**; there is **also** greater **variability** in the observed toxic response (Tolman et al., 1989). This is probably a reflection of a heterogeneous cell population with respect to metabolic **stability** in addition to changing P450 levels. Therefore, although the P450

content has declined to 50-70% of the fresh level at 24 hours (Chapter Six), in the studies described in this chapter the hepatocytes were cultured for 24 hours prior to exposure to the xenobiotic.

Cultured hepatocytes have been used in several different **toxicological** investigations. They have been used to assess the role of metabolic activation in the toxicity of xenobiotics (e.g. Acosta et al., 1987); to elucidate the temporal **relationships** of biochemical alterations (e.g. Long and Moore, 1988; Berger et al., 1989); to compare the pattern of metabolites produced in vivo and in vitro (e.g. McManus et al., 1987), and to investigate carcinogen activation (e.g. Butterworth et al., 1989).

There are also a number of methods available for assessing the toxic effects of xenobiotics. Determination of plasma membrane permeability is often used as an indicator of cell **viability**, since damaged membranes will allow access/egress of bulky, charged particles. These assays include trypan blue exclusion, fluorescein diacetate inclusion, ion leakage and enzyme leakage (Tyson and Green, 1987; Cook and Mitchell, 1989). However, membrane damage is not always the initial lesion and early toxicity can thus be underestimated. Also, loss of membrane integrity is disastrous for the cell and therefore not particularly sensitive. Enzyme leakage assays are particularly vulnerable in this respect due to problems of **compartmentalisation**, high leakage in control samples and

inactivation of the enzyme by the toxin (Tyson and Green, 1987). Also, leakage does not account for **cells** that detach from the monolayer (Chao et al., 1988), unless there is some assessment of **latency**.

Other indicators of toxicity are based on determination of cellular function e.g. DNA or protein synthesis; urea synthesis; ATP content or mitochondrial function (Tyson and Green, 1987; Cook and Mitchell, 1989). However, not all of these are suitable for routine use with large numbers of samples, and although the assay may involve measurement of an intrinsic cellular activity, there may still be wide inter-individual variations in activity. In addition, there are cell **proliferation** assays that assess colony formation and plating efficiency (Cook and Mitchell, 1989) but these cannot be used in static monolayer cultures.

There *are* also non-specific Indicators of cell injury which can demonstrate a potential for toxicity. These include cellular glutathione content and covalent binding (Tyson and Green, 1987). The depletion of reduced glutathione is not cytotoxic in itself and is usually reversible. However, a sustained depletion suggests that normal cellular regeneration/synthesis mechanisms have been inhibited/overwhelmed. Cell proteins can bind activated molecules, and this covalent binding is used as a measure of toxicity although the exact relationship of cell death to covalent binding remains to be established. It may be that the reactive metabolites bind to

critical cell proteins i.e. enzymes, inhibiting their function.

The above are all used as indicators or measures of cytotoxicity, but do not distinguish per se between directly-acting toxins and those that require metabolic activation by P450. The latter can be demonstrated using P450 inducers and inhibitors (Mitchell et al., 1973) and by showing a dependence on the presence of cofactors in microsomal incubations (Garle and Fry, 1989).

In this study, the effect of seven hepatotoxins (thought to be activated to toxic species by cytochrome P450) on hepatocyte viability was determined, using mitochondrial function (MTT reduction) as the parameter of viability (2.5.2). The effect of induction of P450-mediated activity on the toxicity of the compounds was also determined, by culturing hepatocytes from inducer-treated animals, as for the study reported in the previous chapter. A report on acetaminophen toxicity in cultured hepatocytes (Kyle et al., 1989) utilised a similar induction approach. The seven compounds used, with summaries of the available information on their **hepatotoxicity** are presented in Table 7.1. In Chapter Five it was shown that treatment of hepatocyte cultures with P450 inducers **resulted** in reduced and **altered** Induction of enzyme activities, relative to in vivo treatment with inducers. This suggested that in vitro induction would alter the observed toxicity of xenobiotics to **cultured** hepatocytes, and so **toxicity/viability** assessments were made after induction in vitro and compared to the results obtained after induction in vivo.

## 7.2 METHODS

### 7.2.1 In vivo Induction, and toxicity

Hepatocytes were isolated from untreated, and PB or BNF-treated young adult male rats and placed into culture. Hepatocytes were cultured on 24-well plates coated with collagen (as described in Chapter 2.7.2) for 24 hours. Cultures were then exposed to WEC containing the test chemical, at various concentrations, for a further 24 hours. The number of viable cells remaining was then determined using the MTT assay (2.5.2). In some experiments an inhibitor of P450-mediated activity, SKF525-A, was added at the same time as the test chemical.

### 7.2.2 In vitro induction, and toxicity

Hepatocytes were isolated from untreated male rats and cultured on collagen-coated 24-well plates for 72 hours in the presence or absence of inducer (3mM PB or 50 $\mu$ M BNF, as described in Chapter 5.2.2). Exposure to the test chemical was for a further 24 hours followed by assay of viability by MTT.

### 7.2.3 Addition of compounds and inhibitors

Test chemicals were diluted into WEC from 1M stock solutions in methanol (DMSO for 6-thiopurine and SKF525-A). Solvent concentration did not exceed 0.1%. Initial dose response experiments were performed with 0.1-10mM concentrations. However, with the exception of 4-ipomeanol (4-IP) and 2-methylfuran (2-MF),

1mM was found to be the maximum working concentration due to increased acidity of the medium (VPA, 5-TP) or precipitation out of the medium (precocenes, BHT). Plate sealers were used with 2-MF to prevent possible loss due to volatility. However, similar results were obtained with plates incubated with or without the plate sealers, so volatility was probably not an important consideration. In some experiments SKF525-A was added to the cultures; the maximum, non-toxic concentration was found to be 10 $\mu$ M.

#### 7.2.4 Cellular glutathione and toxicity

Cellular glutathione (GSH) was determined (as described in 2.16) in hepatocytes cultured on "Primaria" dishes. GSH content at different time-points after exposure of 24 hour hepatocytes to precocene II (PII) was determined, together with the viability, measured by MTT reduction.

#### 7.2.5 Analysis of results

Dose-response curves for each compound were derived from the viability data. The percentage survival at each dose (or time point) was plotted, and the concentration at which 50% of the cells survived, the ID50, was determined from the curve. The ID50 was determined for each compound in cultures from at least four animals, and the mean  $\pm$  range quoted in the results. The range of ID50 values gives an indication of inter-individual variability in response, which is an important consideration in assessing toxicity of xenobiotics.

### **7.3 RESULTS**

Figures 7.1-7.7 show representative dose-response curves for each compound, as determined in cultured hepatocytes from control, PB- and BNF-treated rats. Table 7.2 presents the mean ID50 value with the range for each compound, in each condition.

#### **7.3.1 Toxicity to hepatocytes from control rats**

VPA, BHT, PII and PI were all moderately toxic to hepatocytes from untreated rats (Figures 7.1-7.4 respectively) with mean ID50 values between 516-643 $\mu$ M. The ID50 range determined for BHT was very narrow (less than 100 $\mu$ M), with respect to the other three compounds (ID50 ranges around 300 $\mu$ M). Also, it can be seen from the dose response curves that there was a sharp decrease in viability from 80 to 20%, a difference of around 450 $\mu$ M with BHT, whereas with VPA and the precocenes the same loss occurred over a difference of 600-800 $\mu$ M.

6-TP and 2-MF were less toxic to control hepatocytes (Figures 7.5 and 7.6), the viability at 1mM being around 40%, the mean ID50 values being 720 and 800 $\mu$ M. 4-IP was toxic to control hepatocytes only at high concentrations (ID50 3.4mM).

#### **7.3.2 Toxicity to cultures from inducer-treated rats**

The seven compounds fall into three groups with respect to the effects of induction on toxicity.

#### **BHT and VPA**

PB treatment enhanced the toxicity of VPA and BHT to cultured hepatocytes (Figures 7.1 and 7.2), the mean ID50 values being 232 and 106 $\mu$ M respectively, with similar ID50 ranges of around 200 $\mu$ M (Table 7.2). However, the loss of viability from 80 to 20% is much steeper with BHT, a difference of only 150 $\mu$ M, as opposed to around 900 $\mu$ M with VPA. BNF did not significantly alter the toxicity of either compound (as judged by ID50) relative to the control cultures, the dose-response curves being *very* similar in the hepatocytes from control and BNF-treated rats.

#### **Precocenes I and II**

Both PB and BNF treatment induced the toxicity of the precocenes to cultured hepatocytes, PB having the most marked effect (Figures 7.3 and 7.4, Table 7.2). BNF produced a five-fold and PB a 14-fold increase in toxicity of precocene II and a 29-fold Increase of precocene I toxicity, with similar ID50 ranges.

#### **6-TP, 2-MF and 4-IP**

These three compounds, that had minimal toxicity in control cultures, were all toxic to cultures from PB- and BNF-treated animals. 6-TP and 2-MF were the most toxic to cultures from PB-treated rats (Figures 7.5 and 7.6) with 10- and 25-fold Increases in response respectively. BNF and PB had similar effects on 4-IP toxicity: 13 to 14-fold Increases with ID50 values around 250 $\mu$ M.

Table 7.3 summarises these results. Induction of P450 had the least effect on VPA toxicity; BHT toxicity was potentiated by PB, which markedly increased the toxicities of the precocenes, 2-MF, 4-IP and 6-TP. BNF had the greatest effect on 4-IP toxicity with moderate effects on 2-MF, 6-TP and the precocenes.

### **7.3.3 Variability in observed toxicity**

In addition to the wide range of ID50 values obtained for VPA, 6-TP and 2-MF, there was also variability in response of the cells to these compounds, in that concentrations up to 1mM did not always elicit a sufficient loss of viability for an ID50 to be determined. In the control cultures this may be simply because the compounds are only moderately toxic, the upper range of the ID50 being around 1mM. However, this variability (i.e. toxic or not toxic) was also observed in hepatocytes from inducer-treated animals. The practical considerations that could be responsible include instability of the compound/stock solution, volatility of 2-MF and intrinsic inter-animal differences. Use of fresh dilutions of fresh stock solutions had no effect on the observed variability, and the plate sealers used with 2-MF were judged to function adequately since the gradation of any effect was uniform across the plate. In any case, volatility was probably not crucial here, since incubation without plate sealers gave similar results to sealed plates. It has already been observed that there are inter-individual differences in response to Inducers (Chapter Five), and this can affect the extent of any toxicity that is due to metabolism. For

this reason it is Important to use hepatocytes from different animals, and not replicate dishes from single animals, in assessing the extent of a compound's effects. However, VPA, 6-TP and 2-MF are all more markedly toxic to Induced animals, and a complete lack of effect in some cultures is somewhat unexpected, and is **unlikely** to be due to poor induction, in which case a reduced effect would be more probable. Therefore the possible roles of other intrinsic factors have to be considered.

#### 7.3.4 Induction in vitro and toxicity

Table 7.4 compares ID50 data from the in vivo induction experiments with those observed after induction in vitro, for PII and 4-IP. These compounds were chosen since there were marked (and easily reproducible) changes in toxicity on induction in vivo. However, after treatment of hepatocytes in vitro with PB and BNF there was no toxicity of 4-IP following PB, and only a slight increase due to BNF. PB and BNF in vitro had **similar** effects on PII toxicity (mean ID50 values of 463 and 459 $\mu$ M respectively), but this response was much reduced compared to that obtained with induction in vivo. Also, no toxicity of PII to control hepatocytes was observed. This is probably due to the **decline** in P450 over the 72 hour **culture** period, and suggests that the toxicity to 24 hour hepatocytes is (in part) P-450 mediated. This failure to Induce toxicity in vitro is at least consistent with the failure to Induce P450 enzyme activities in vitro (Chapter Five) and the observed decline in some P450 activities in 72 hour cultures (Chapter Four).

### 7.3.5 Further studies with the precocenes

Figures 7.8 and 7.9 show the effects of SKF 525-A in vitro upon precocene-induced toxicity in hepatocytes from control and PB-treated rats. SKF 525-A did not inhibit precocene II toxicity in control cultures, although there was a slight shift in the precocene I ID50 range: Table 7.5. However, in hepatocytes from PB-treated rats there was a marked inhibition of PII toxicity (a 4-fold Increase in ID50 - Table 7.5), but not of PI toxicity. This was rather unusual, in that the reported effects of these two compounds are *very* similar. A further **preliminary** experiment showed that exposure of hepatocytes cultured from PB-treated animals to PII resulted in a depletion of cellular glutathione that was sustained over 24 hours, and which preceded the loss of cellular viability, as judged by MTT reduction (Figure 7.10).

## 7.4 DISCUSSION

The results presented in this chapter demonstrate that induction of P450 in vivo can potentiate the toxicity of compounds in cultured hepatocytes. A certain amount of Information on the extent and degree of toxicity can be determined from the data.

BHT was moderately toxic to hepatocytes from control and BNF-treated rats and PB significantly increased the toxicity. In all cases, the dose-response curves fell steeply between 80 and 20% viability. This suggests that BHT may have one or a few *very* specific sites of toxic assault within the cell, and that once a critical

concentration is achieved cell death occurs rapidly. It has been reported that the cytotoxicity of BHT in control hepatocytes at concentrations up to  $750\mu\text{M}$  is not P450-mediated, but a direct effect upon the mitochondria. There is a rapid loss of ATP, followed by dissipation of the membrane potential (Thompson and Moldéus, 1988). This would account for the narrow ID50 range in controls and the steep dose-response curve (since mitochondrial function is vital for cell survival). It would also indicate that BHT toxicity has a direct effect in hepatocytes on induction with BNF. PB increased BHT toxicity in hepatocytes. This agrees with reported data on BHT: that PB, but not 3-MC, increased the formation of a microsomal BHT-GSH conjugate (Tajima et al., 1985) and that PB increased serum transaminase levels in vivo, in BHT-fed rats (Nakagawa, 1987).

VPA, like BHT, was also toxic to hepatocytes from PB-treated rats, the toxicity in hepatocytes from control and BNF-treated rats being very similar. However, in contrast to BHT, the VPA dose-response curves were much flatter, the toxic effects being manifest over a much wider range of concentrations. This probably reflects more variability in inter-cellular response, and/or more than one site of action of VPA. It is thought that there are two major, competing pathways of VPA metabolism in the hepatocyte. VPA is metabolised by P450 to an unsaturated metabolite,  $\Delta^4$ -VPA, and this reaction is increased by PB in vitro (Rettie et al., 1988). A  $\Delta^4$ -VPA can exist as 2 enantiomers: the (R) form is metabolised further by P450 to 4,5-dihydroxy-VPA- $\gamma$ -lactone, and the (S) form is metabolised by

mitochondrial  $\beta$ -oxidation to a 3-oxo derivative which can then inhibit  $\beta$ -oxidation, production of the (R) enantiomer being favoured (Porubek et al., 1989a). The Inhibition of  $\beta$ -oxidation would eventually be toxic to the hepatocyte, and would explain the observed steatosis in VPA-treated rats (Kesterson et al., 1984). VPA and  $\Delta^4$ -VPA have both been reported to be hepatotoxic, but the data are confusing. PB-treatment increases the overall rate of metabolism but not the ratio of enantiomer production (Porubek et al., 1989a); PB does not increase VPA or  $\Delta^4$ -VPA covalent binding in hepatocytes, although clofibrate, an inducer of fatty acid oxidation, does (Porubek et al., 1989b); the reported toxicity of VPA and  $\Delta^4$ -VPA to hepatocyte cultures is unconvincing on critical evaluation of the presented data (Kingsley et al., 1983). Thus, it appears that the P450 system is not solely responsible for VPA toxicity (and may also be involved in detoxification reactions) and overall, it is probably the balance of the effects of VPA metabolites produced by  $\beta$ -oxidation and P450 that determine the toxicity, and that this dual effect accounts for the broad concentration range of the toxic effects and the resistance of some animals/cell cultures to VPA. In any case, the mixed in vitro data obtained with VPA mirrors the in vitro situation with respect to incidence of VPA toxicity and severity of effect, which would also be consistent with the idea that some individuals may be **physiologically** more prone to VPA toxicity, especially in conjunction with other drugs.

6-TP also gave some conflicting results. Both PB and BNF increased 6-TP toxicity, although toxicity was not always observed. PB (but not 3-MC) has been reported to increase the covalent binding of 6-TP to microsomal protein, although PB treatment decreases 6-TP covalent binding in vivo (Hyslop and Jardine, 1981a; 1981b). The authors suggest that this discrepancy is due to PB induction of conjugation enzymes, which results in increased detoxification in vivo, which are absent in microsomal preparations. If this **is** correct, then it implies that the Phase II reactions are inhibited/less active in hepatocyte cultures. It has been reported that **UDP-glucuronyl** transferases and some of the glutathione transferases are reasonably stable over 24-72 hours of hepatocyte culture, although there was a rapid depletion of UDP-glucuronic acid (UDPGA) during isolation (Crocchi and Williams, 1985; Grant and Hawksworth, 1986). This may account for the in vivo/in vitro discrepancy in PB induction of 6-TP hepatotoxicity with regard to the variability in the 6-TP results. It is also possible that P450 is not the only enzyme system involved in 6-TP metabolism. A major route of 6-TP transformation is via xanthine oxidase to **thiouric** acid; however, a xanthine oxidase inhibitor, **allopurinol**, did not inhibit the covalent binding of 6-TP (Hyslop and Jardine, 1981a). Also, 6-TP contains several nitrogen atoms and a sulphur group, which would make it a good substrate for the flavin monooxygenase system (FMO), which predominantly forms N,S and P-oxides (Gibson and Skett, 1986). The FMO appears to be fairly stable in hepatocyte cultures (Sherratt and **Damani**, 1989), but compared to the MMO, **little** work has been performed on the role

of the FMO in drug metabolism and this makes it difficult to assess the relative contributions of the two systems.

4-IP and 2-MF both contain a furan group, which has been implicated in 4-IP toxicity (Boyd et al., 1983). Both PB and BNF increased the toxicity of these furans to cultured hepatocytes. 4-IP is analogous to 6-TP in that PB increases the covalent binding of 4-IP in microsomes, but in vivo it is reduced (Boyd and Burka, 1978; Boyd et al., 1978). Statham and Boyd (1982) reported the increased urinary excretion of a **4-IP-glucuronide** on PB induction in vivo, and therefore, as suggested above, it may be a depletion of UDPGA in cultured hepatocytes that accounts for the discrepancies in the in vivo and in vitro data. The increased toxicity in vitro of 4-IP on induction with BNF is consistent with the in vivo data. PB has been shown to increase the covalent binding of 2-MF in microsomes, whereas 3-MC did not (Ravindranath et al., 1985). This does not agree with the results presented here although 2-MF has been shown to deplete GSH in microsomes from BNF-treated rats (Garle and Fry, 1989).

Both of the precocenes were toxic in control hepatocytes, induction markedly increasing their toxicity. The bigger increase in toxicity was with PB. Precocene I has been shown to deplete GSH in vivo and lead to an increase in serum transaminase levels (Halpin et al., 1984; Ravindranath et al., 1987). Both precocenes can deplete GSH, 80-90% of the dose being rapidly conjugated with GSH

(Foureman et al., 1989). PB has been shown to Increase, and SKF525-A to decrease, covalent binding of PII (Hsia et al., 1981). This agrees with the data presented here, that SKF525-A can inhibit PII toxicity, and that a sustained depletion of GSH precedes loss of cellular **viability**. That GSH depletion and loss of **viability** do not occur concurrently, suggests that GSH depletion is one of the first steps in the pathology of PII toxicity. Depletion of GSH is not in itself toxic; the inability of the cell to synthesize/regenerate GSH however would be more serious. Maintenance of GSH levels is linked to GSSG, NADPH, NADH and ATP levels. It would appear that whilst a toxic dose produces a sustained GSH depletion, a non-toxic dose results in a transient depletion, which suggests that GSH depletion is an early reversible event, not the cause of toxicity, and that some other biochemical change can precipitate a sustained loss of GSH e.g. NADPH depletion, inhibition of glutathione reductase.

Overall, the approach of in vivo Induction followed by hepatocyte culture was successful **in** this study in detection of hepatotoxicity, the results agreeing or complementing the in vivo and the microsomal data. P450 Induction has been shown to increase toxicity in culture, and inhibition of P450 was also demonstrated. This method of investigating the role of P450-mediated toxicity of xenobiotics is probably more **applicable** to interaction and mechanism studies rather than to screening of compounds of unknown toxicity, since at present the system needs constant evaluation with respect to the **toxicity invivo**.

## **TABLES AND FIGURES**

**TABLE 7.1. REPORTED TOXIC EFFECTS OF THE COMPOUNDS USED IN THIS STUDY<sup>1</sup>.**

**VALPROATE (VPA)** anticonvulsant

*in vivo* steatosis ± necrosis; inhibition of mitochondrial  $\beta$ -oxidation<sup>2</sup>;  
increased covalent binding<sup>3</sup>.  
*in vitro* PB increases rate of metabolism; covalent binding of VPA  
and A<sup>4</sup>-VPA to protein in cultured hepatocytes<sup>4</sup>.

**BUTYLATED HYDROXYTOLUENE (BHT)** antioxidant

*in vivo* necrosis; PB increases serum transaminase levels<sup>5</sup>.  
*in vitro* PB increases formation of BHT-GSH conjugate; conjugate  
formation inhibited by CO, metyrapone and SKF 525-A<sup>6</sup>.

**PRECOCENE II (PII)** insecticide, from *Ageratum houstonianum*

*in vivo* centrilobular necrosis;  
*in vitro* PB increases covalent binding; SKF 525-A inhibits covalent binding<sup>7</sup>.

**PRECOCENE I (PI)** insecticide, from *A. houstonianum*

*in vivo* necrosis; GSH depletion; increases in serum transaminase levels<sup>8</sup>.  
*in vitro* PB increases rate of metabolism<sup>9</sup>.

**6-THIOPURINE (6-TP)** antineoplastic and immunosuppressive

*in vivo* PB increases the covalent binding<sup>10</sup>.  
*in vitro* PB increases, GSH and SKF 525-A inhibit, covalent binding<sup>11</sup>.

**2-METHYLFURAN (2-MF)** constituent of coffee and cigarette smoke

*in vitro* PB increases, piperonyl butoxide inhibits, covalent binding;  
metabolism to acetylacrolein<sup>12</sup>.

**4-IPOMEANOL (4-IP)** from *Ipomea batatas* infected with *Fusarium solanae*

*in vivo* PB decreases covalent binding and lethality<sup>13</sup>;  
*in vitro* PB increases the covalent binding<sup>14</sup>.

1 *in vivo*: rat liver; *in vitro*: rat hepatic microsomes, unless stated.

2 Kesterson *et al.*, 1984

3 Porubek *et al.*, 1989a

4 Porubek *et al.*, 1989b

5 Nakagawa, 1987

6 Tajima *et al.*, 1985

7 Hsia *et al.*, 1981

8 Ravindranath *et al.*, 1987

9 Halpin *et al.*, 1984

10 Hyslop and Jardine, 1981b

11 Hyslop and Jardine, 1981a

12 Ravindranath and Boyd, 1985

13 Boyd and Burka, 1978

14 Boyd *et al.*, 1978

**TABLE 7.2. EFFECT OF INDUCTION *IN VIVO* ON TOXICITY *IN VITRO*.**

compound	mean ID <sub>50</sub> value with range (μM)		
	CON	PB	BNF
VPA	643 447-708	232 100-281*	704 501-1000
BHT	516 468-537	106 33-224*	447 422-473
Pll	550 437-794	40 16-60*	124 56-300*
PI	546 447-708	19 7.5-38*	114 56-168*
6-TP	720 501-794	76 10-251*	134 30-141*
2-MF	800 668-944	32 10-45*	84 10-211*
4-IP	3400 1400-6300	243 178-316*	259 96-335*

Values are mean ID<sub>50</sub>s, with ranges, determined from dose-response curves for 4-7 animals.

\* significantly different to control, Mann-Whitney U-test, p < 0.05.

**TABLE 7.3. SUMMARY TABLE OF THE EFFECTS OF INDUCTION  
IN VIVO ON TOXICITY IN VITRO.**

compound	CONTROL <sup>1</sup>	PB <sup>2</sup>	BNF <sup>2</sup>
VPA	+	3	0.9
BHT	+	5	1.2
PII	+	14	5.0
PI	+	29	5.0
6-TP	-	10	5.0
2-MF	-	25	9.0
4-IP	-	13	14

<sup>1</sup> indicates toxic (+) or non-toxic (-) to control cells.

<sup>2</sup> fold-induction of toxicity over control (control value = 1.0).  
Values greater than 1.0 represent an induction of toxicity,  
which is a decrease in ID<sub>50</sub>.

**TABLE 7.4. THE EFFECTS OF *IN VIVO* AND *IN VITRO* INDUCTION ON THE TOXICITY OF PRECOCENE II AND 4-IPOMEANOL TO CULTURED RAT HEPATOCYTES.**

condition	mean <b>ID<sub>50</sub></b> and range ( $\mu\text{M}$ )	
	<i>in vivo</i>	<i>in vitro</i>
4-IPOMEANOL		
CON	3400 1400-6300	>1000
PB	243 178-316	>1000
BNF	259 96-335	848 708-944
PRECOCENE II		
CON	550 237-794	>1000
PB	40 16-60	463 355-562
BNF	124 56-300	459 300-562


Each value is the mean ID<sub>50</sub> and range of 3-5 animals.

**TABLE 7.5. EFFECT OF SKF 525-A ON THE TOXICITY OF PRECOCENE I AND II IN HEPATOCYTES FROM CONTROL AND PB-TREATED RATS.**


condition		mean ID <sub>50</sub> and range (μM)	
		-SKF 525-A	+SKF 525-A
PI	CCN	546 447-708	767 708-841
	PB	39 4-71	69 56-89
PII	CON	550 237-794	701 525-708
	PB	57 33-75	234 178-300 *

\* range is significantly different to control, p<0.05 Mann-Whitney U-test. The values are the mean ID<sub>50</sub> values determined for 4 animals, the toxicity in the presence and absence of inhibitor being determined in cells from each animal.


FIGURES 7.1-7.7. Hepatocytes were isolated from control and inducer-treated animals and maintained in culture for 24 hours prior to exposure to the test compound. In the following figures the data presented are from individual, but representative rats. The mean ID<sub>50</sub> values are shown in Table 7.2.




**FIGURE 7.1. REPRESENTATIVE DOSE-RESPONSE CURVES FOR VALPROIC ACID.**




**FIGURE 7.2.** REPRESENTATIVE DOSE-RESPONSE CURVES FOR BUTYLATED HYDROXYTOLUENE.



**FIGURE 7.3.** REPRESENTATIVE DOSE-RESPONSE CURVES FOR PRECOCENE II.



**FIGURE 7.4.** REPRESENTATIVE DOSE-RESPONSE CURVES FOR PRECOCENE I.



**FIGURE 7.5.** REPRESENTATIVE DOSE-RESPONSE CURVES FOR 6-THIOPURINE.




FIGURE 7.6. REPRESENTATIVE DOSE-RESPONSE CURVES FOR 2-METHYLFURAN.






FIGURE 7.7. REPRESENTATIVE DOSE-RESPONSE CURVES FOR 4-IPOMEANOL.


**FIGURES 7.8 AND 7.9.** Hepatocytes were cultured from control and PB-treated rats. After 24 hours the cells were exposed to PII  $\pm$  SKF-525A ( $10\mu\text{M}$ ). The curves shown are from individual, but representative rats. Mean  $\text{ID}_{50}$  values are presented in Table 7.5.



**FIGURE 7.8.** EFFECT OF SKF-525A ON THE TOXICITY OF PRECOCENE II TO CULTURED HEPATOCYTES.



**FIGURE 7.9.** EFFECT OF SKF-525A ON THE TOXICITY OF PRECOCENE I TO CULTURED HEPATOCYTES.



**FIGURE 7.10. TIME COURSE OF GLUTATHIONE DEPLETION AND LOSS OF VIABILITY ON EXPOSURE TO PRECOCENE II.** Hepatocytes were cultured from PB-treated rats and exposed to 100 $\mu$ M precocene II. Values are mean  $\pm$ range of 4 animals.

**CHAPTER 8**

**DISCUSSION**

**CHAPTER 8**

<b>CONTENTS</b>		<b>PAGE</b>
GENERAL DISCUSSION		152
8.1	AGE AND SEX OF HEPATOCYTE DONOR: P450-DEPENDENT ACTIVITIES AND MAINTENANCE	153
8.2	DIFFERENTIAL MAINTENANCE OF P450 ACTIVITIES IN CULTURE	155
8.3	EFFECT OF EXOGENOUS HAEM ON MAINTENANCE OF P450	156
8.4	INDUCTION OF P450: METABOLISM AND TOXICITY	158
8.5	TOXICITY STUDIES <u>IN VITRO</u>	162
8.6	GENERAL CONCLUSIONS	163

## CHAPTER 8

### GENERAL DISCUSSION

The aims of this Investigation were to develop and characterise a system for the use of rat cultured hepatocytes in metabolism-mediated toxicity studies. This necessitates conditions in which constitutive P450 levels/activities can be maintained, and in which the in vivo induction of P450 isozymes can be reproduced. Initial studies were performed on the kinetics of alkoxy coumarin O-dealkylase activities to confirm the biphasic nature of these activities and to determine their maintenance in cultured hepatocytes. These enzymes were chosen as indicators of P450 activity because they are biphasic, the separate components representing different populations of P450 isozymes (Chapter 2.10). The results of these preliminary experiments indicated that although both MCO and ECO activities were biphasic in freshly isolated hepatocytes, MCO activity became monophasic in hepatocytes cultured for 24 hours, with complete loss of the high affinity form; the maintenance of the other activities was poor: 55% or less of the fresh cell activities. The medium used was Williams' Medium E, developed specially for hepatocyte culture (Williams and Gunn, 1974), supplemented further with insulin, dexamethasone and nicotinamide. This medium (WEC) has been shown to attenuate the loss of P450 activities in primary culture (Warren and Fry, 1985).

The studies comprising this investigation were concerned initially with improving the maintenance of P450 activities: the effects of

further supplementation of culture medium and the influence of the age and sex of the hepatocyte donor animal were determined. Subsequent experiments compared induction in vitro to that seen in vivo, and the maintenance of induced enzyme activities was also ascertained. Finally, the metabolic activation of seven known hepatotoxins was investigated in the rat hepatocyte cultures, under the previously defined conditions.

#### **8.1 AGE AND SEX OF HEPATOCYTE DONOR: P450-DEPENDENT ACTIVITIES AND MAINTENANCE**

It was suggested in Chapter Three that the maintenance of three of the four **alkoxycoumarin** O-dealkylase activities at **70%** or more of their fresh activities (in contrast to the results of the initial kinetic experiments, in which none of the activities were maintained) was due to the increased age of the donor animals. The results presented in Chapter Four confirmed this suggestion.

There were differences in fresh cell activities between immature and adult male rats and between male and female rats, with respect to MCOD and PCOD activities, indicating that there are **developmental/gender** differences in the **P450-isozyme** complement and/or the regulation of these activities. The low affinity form of PCOD activity, which is absent in adult female rats, appears to correspond to the male-specific, steroid **6 $\beta$ -hydroxylase** activity, with total MCOD activity **displaying** an adult **male-specific** component (Chapter Four). It is thought that these age and sex differences in P450 **metabolism** are due to the effects of hormones, **especially**

growth hormone (and possibly the thyroid hormones), on the hepatocyte. These differential hormonal effects may also be linked with the lower P450-reductase levels in female rats, which influences the rate of metabolism (Skett, 1988; Waxman et al., 1989).

The differences in **metabolism** extend to maintenance in primary **culture**. All the activities measured were maintained at higher **levels** in hepatocytes cultured for 24 hours from **adult** male rats with all 3 **alkoxycoumarin** O-dealkylase activities remaining biphasic in culture. Overall, this selectivity for adult male rats was lost by 72 hours in culture; only the high affinity forms of ECOD and PCOD were maintained at this time point. This is consistent with the proposal that P450 activities are maintained in hepatocytes from adult males because of the reported predominance of slow turnover P450s, compared to females and Immature males (Levin et al., 1975). It was also observed that the least well maintained activities were those for which developmental regulation, and therefore hormonal regulation, was indicated, which implies that these P450s are the rapid turnover forms described previously (Chapter 4.4).

Thus, although a range of P450-dependent activities were maintained better in hepatocytes from adult male rats, the differences in hepatic P450 metabolism and maintenance due to age and gender demonstrated here are important per se, not only in making **inter-laboratory** data comparisons but also in assessing inter-individual **susceptibility** to iatrogenic hepatic injury. It

is often assumed that the observed sex differences in drug metabolism in the laboratory rat have little relevance to Man, where sex differences are less marked. It is possible though that it is just more difficult to demonstrate any differences in Man, due to the Influences of many varied exogenous factors. However, it is well-known that neonates and young children (as well as the elderly) are more susceptible to drug-induced toxicity than adults (Hurwitz, 1969; Mirkin, 1970).

## 8.2 DIFFERENTIAL MAINTENANCE OF P450 ACTIVITIES IN CULTURE

As described above, there was a selective loss of P450-dependent O-dealkylase activities in hepatocytes cultured for 24 hours. In Chapter Six it was shown that this selectivity in maintenance extends to other enzyme activities. In control cultures the total P450 fell by 31% but EMDM and PNPB activities were well maintained over 24 hours, and EROD activity declined slightly. However, there was a 54% loss of BZDM activity. In this respect BZDM is similar to total MCO and PCOD activities in that it is poorly maintained in culture. Induced enzyme activities, however, were well maintained for 24 hours.

It was suggested in the preceding section, and in Chapter Four, that it is the **developmentally/hormonally** regulated P450s that are the most susceptible to **decline in culture**, possibly because they are fast turnover forms of P450. It was also suggested that the loss of these forms in culture could be a result of suppression of

synthesis due to the presence of hormones in the serum that is added to the medium (Chapter 4.4). Foetal calf serum contains significant, but also variable amounts, of growth hormone and thyroid hormones (and also androgens and oestrogens) which are known to have important regulatory effects on hepatic P450, e.g. growth hormone and tri-iodothyronine have both been shown to suppress the male-specific  $6\beta$ -hydroxylase (Yamazoe et al., 1989). Other workers have reported the expression of **liver-specific** P450s in vitro, only in medium lacking serum e.g. P450IA2 (Silver and Krauter, 1988). The presence of serum could effectively 'feminise' the P450 **metabolism** of the hepatocytes, in a manner similar to that seen with growth hormone **supplementation** (Guzelian et al., 1988). Serum is routinely incorporated into cell culture medium since most cell types, **including** hepatocytes do not attach and/or grow **well** without it. However, it now appears that 'blanket' addition of hormones to culture medium, in the form of serum, may be responsible for at least some of the alterations in phenotype observed on placing cells into culture. In order to maintain constitutive expression in vitro it may be necessary to replace serum-containing media with **hormonally-defined** media. The development of appropriate media will be **facilitated** by further research into the hormonal regulation of the different P450 isozymes.

### **8.3 EFFECT OF EXOGENOUS HAEM ON MAINTENANCE OF P450**

Addition of exogenous haem, ALA and Se did not affect the maintenance of **alkoxycoumarin** O-dealkylase activities in primary

culture (Chapter Three). Engelmann et al. (1985) reported a maintenance of total P450 in medium supplemented with haem, ALA and Se, but they did not measure any P450-dependent activities. In their unsupplemented cultures, the P450 content fell to 75% of the fresh cell value, equivalent to the P450 level reported in Chapter Six of this study (70% of Initial levels in control cultures at 24 hours). However, although the effect of **haem-supplemented** medium on total P450 levels was not determined in Chapter Three, it did not prevent the selective loss of MCOD activity in culture. This suggests that exogenous haem may boost total P450 levels, but that this masks alterations in the isozyme population.

Engelmann et al. also reported that haem, ALA and particularly Se were essential for induction of P450 by PB in vitro. Again, they measured total P450 content. In an experiment reported in Chapter Five, no induction of total MCOD activity by PB was observed in vitro, in medium containing haem, ALA and Se, whereas this activity is induced 6-fold by PB in vivo. The Induction of total P450 by PB in vitro was not measured. Therefore, it seems that although haem, ALA and Se may increase PB induction of total P450 in vitro, this is not necessarily an Increase in PB-specific isozymes. This also infers that determination of total P450 levels, in the absence of any activity and/or immunochemical data, is not particularly informative. The results presented in Chapters Three and Five suggest that a reduced haem supply does not contribute to the selective loss of P450 activity and Inducibility seen in primary culture.

#### 8.4 INDUCTION OF P450: METABOLISM AND TOXICITY

##### a. Induction in vivo

In Chapters Five, Six and Seven the induction of P450 and its effects on metabolism and toxicity were investigated. Induction of the different families and **subfamilies** of P450 was demonstrated using four enzyme activities (Chapter Six). DEX, ISO and BNF each produced a **characteristically** different profile of enzyme activities in hepatocytes isolated from rats treated in vivo, with specific induction of EMDM, PNPB and EROD respectively. PB, however, induced all the chosen activities to some extent. The **non-selectivity** of PB in this study was probably **related** to the choice of substrates and/or inducers, as discussed in Chapter 6.4. This approach should be refined and extended to other inducers (and in the case of PB, other enzyme activities) to obtain diagnostic profiles for the different classes of inducer (and possibly different inhibitors) which could be a useful tool in drug development for the prediction of possible drug interactions, as well as identification of novel **inducers/inhibitors**.

The selective induction of P450 activities by different inducers indicates the involvement of specific isozymes. These induced isozymes may be responsible for changes in toxicity due to metabolism. The potential in vitro toxicity of seven compounds, reported to be hepatotoxic, after induction in vivo with PB and BNF was also investigated (Chapter Seven). Of the four compounds that were toxic to hepatocytes cultured from untreated rats, two were

more toxic to hepatocytes from PB-treated rats and two were **.more** toxic to hepatocytes from PB- and BNF-treated rats. Treatment with each inducer produced significant toxicity in vitro with the three remaining compounds, which were judged to be relatively non-toxic to cultures from untreated rats. Overall, the results of the study reported in Chapter Seven agreed **well** with **available literature** data on the seven compounds, although there were some discrepancies, particularly with respect to the in vivo data where involvement of non P450-mediated **metabolism**, including Phase II **metabolism**, has been implicated as a determining factor in the toxic response. It was observed in Chapter Seven that for some compounds there were large variations in response of the cultured hepatocytes from individual animals (e.g. VPA), and for other compounds there was very little variation (e.g. BHT, in hepatocytes from control and BNF-treated animals). This is not necessarily a problem, since inter-individual variability in response to inducers and drugs is an important consideration in metabolism and toxicity studies. If the **variability** can be reproduced in vitro, the source of the **variability** can be elucidated, whether it be due to P450 isozyme content (which varies with age, **sex**, Induction etc.) or competing P450 and intermediary **metabolic** pathways (VPA). Induction can also affect Phase II metabolism, which can influence the fate of products of P450 metabolism (e.g. the effect of **glucuronidation** on 4-IP toxicity). This study has shown that toxicity observed in vivo can be reproduced in an in vivo **induction-hepatocyte** culture system, and indicates that, despite the problems that remain to be **resolved**,

hepatocyte cultures do have an important role in toxicological studies, particularly in mechanistic studies which are *very* difficult to perform in vivo.

**b. Induction in vitro**

Unfortunately, attempts to induce both P450-dependent activities and P450-mediated toxicity in culture, were unsuccessful. There were qualitative and quantitative differences on administration of PB and BNF in vitro. BNF did induce ECOD activity in vitro, but the induction of total ECOD activity was greater than that observed in vivo (Chapter Five). In contrast, with the exception of total ECOD activity, induction of activities by PB in vitro was *very poor*. This suggests that whereas the high affinity component comprises PB- and BNF-inducible forms the isozymes involved in total ECOD activity may be BNF-inducible forms that can also be induced by PB in vitro. This would explain why total ECOD activity was the only activity induced by PB in vitro. In Chapter Six it was shown that BZDM and EROD activities were induced by PB in vivo to the same extent (around 7- and 6-fold) but BNF only induced EROD activity. This is also consistent with the existence of PB- and BNF-specific isozymes, in addition to BNF-inducible isozymes that also respond to PB in vitro. It has been reported that P450IA1, the major BNF-inducible isozyme, increased *in* untreated hepatocyte primary cultures and that PB induced this form further (Turner et al., 1988; Chapter 5.4). Therefore, an increase in P450IA1 basal levels coupled with P450IA1 responsiveness to PB in culture, could account for PB induction

of total ECOD activity in vitro in the absence of MCOD induction by PB, and also for the increase in BNF induction of total ECOD activity in vitro over that seen in vivo. Also, constitutive EROD activity may be inducible by PB whereas P450IA1 induced in vivo is not.

In addition to the anomalous induction of P450IA1 in culture, it is now known that, although total P450 can be induced in culture by PB, there is no specific induction of P450IIB1/2. Thus, the regulation of PB induction in vitro appears to fail. New evidence is being accumulated on regulation of PB induction: the hepatic levels of P450IIB1 and 2 can be suppressed by growth hormone and by tri-iodothyronine (Yamazoe et al., 1989); phosphorylation of PB-inducible P450s inhibits their activity, and phosphorylation via cAMP is under hormonal control (Bartlomowicz et al., 1989; Koch and Waxman, 1989). It may be that, like the reduced expression of constitutive, **liver-specific** P450s in serum-containing medium, the induction of P450s IIB1 and 2 is suppressed by serum. Another factor could be altered regulation of transcription in vitro. The initial decrease of protein synthesis in vitro (Tanaka et al., 1978) may affect synthesis of transcription factors necessary for PB induction. Also, as discussed in Chapter Five, there appear to be intrinsic differences within the hepatocyte population with respect to induction, and these differences are retained in culture (Gumucio, 1989; Bars etal., 1989).

Another problem with induction in vitro is that cultures must be exposed to inducer for several days, over which time period the total P450 is declining. This leads to reduced metabolic, toxic and Induction responses. In Chapter Seven, Induction in vitro was Investigated for precocene II and 4-1pomeanol. However, in contrast to 24 hour control hepatocytes, PII was not toxic to the 72 hour control cells.

#### 8.5 TOXICITY STUDIES IN VITRO

Some of the problems associated with the use of cultured hepatocytes for metabolism studies have been discussed in the preceding sections. It is clear, then, that careful thought must be given to the development of protocols for the investigation of toxicity in vitro.

The choice of time in culture prior to exposure to xenobiotic is a crucial decision, since the metabolic stability of the cells must be balanced against the decline in P450. In this study, hepatocytes were cultured for 24 hours prior to exposure to allow for recovery from the isolation procedure and the **establishment** of a homogeneous cell population. By 24 hours, all the viable cells have flattened onto the dish, and other workers have suggested that the cells are in a **metabolically** stable state (Tanawa et al., 1978; López et al., 1988).

It was also clear from the results presented in Chapters Five, Six and Seven that inter-individual differences in toxicity and response to inducers persist in primary culture. This implies that cells from a number of animals should be used, rather than many cultures from the same animal, to assess the toxic effects of xenobiotics and particularly the effects of Induction on toxicity. This is less important, however, in more mechanistic studies. It is also more informative to present the results as a range of ID50 values or ID30-50-70 values rather than a single numerical value.

The toxicity results presented in Chapter Seven agree well with other literature data on the seven compounds used in this study, which suggests that an in vivo Induction-hepatocyte culture approach is potentially very useful for the investigation of the role of P450 in hepatotoxicity, particularly since many aspects of cell function can be assessed concurrently e.g. viability and cellular glutathione.

#### **8.6 GENERAL CONCLUSIONS**

This study has shown that it is possible to use cultured hepatocytes in metabolism and toxicity studies. It has been shown that:

- a range of P450 activities, both constitutive and induced, can be maintained at high **levels** in hepatocytes cultured for 24 hours.
- differences in P450 activity and in maintenance of these activities with age and sex of hepatocyte donor exist.

- P450 activities are maintained better in hepatocytes **cultured** from adult male rats.
- P450 activities can be used to profile the different classes of Inducer.
- induction in vivo coupled with hepatocyte culture is a useful approach for investigating **metabolism-mediated** toxicity.
- toxicity in vivo can be reproduced in an hepatocyte culture system.

The main problems that were identified involve the behaviour of hepatocytes in culture, and the alterations in phenotype that occur. One of the most important issues that must be addressed is the effect of the variable (and often unphysiological) levels of hormones that are added to culture medium **in** the form of serum. A more rational use of **hormonally-defined** media may enhance maintenance of **developmentally** regulated forms, in addition to improving both the overall maintenance of the constitutive P450 population in vitro and induction of P450s in vivo. Also, P450 **metabolism** in vitro cannot be investigated in isolation, particularly with respect to its role in toxicity. This became clear from the results presented in Chapter Seven, in which some of the discrepancies with the in vivo data may be due to alterations in Phase II **metabolism** in vitro. Less is known about the behaviour of non-MFO enzyme systems in hepatocyte culture e.g. Phase II metabolism, FMO. The balance of the activities of all these systems is crucial in determining whether a compound is detoxified or activated.

Overall, cultured hepatocytes would seem to have a useful role to play in the investigation of **metabolism-mediated** toxicity, in the evaluation of potential and actual toxicity, and, **particularly**, in elucidation of mechanisms of hepatotoxicity. Further research into the regulation of P450 Induction and of hepatic metabolism in general should greatly enhance the development of a culture system which mirrors the situation in vivo. Meanwhile, much information can be obtained by the use of carefully planned studies with due consideration of the present limitations governing the use of primary hepatocyte **cultures**.

## REFERENCES

- Acosta D., Mitchell D.B., Sorensen E.M. and Bruckner J.V. (1987).  
The metabolism and toxicity of xenobiotics in a primary culture system of post-natal rat hepatocytes.  
In: *The Isolated Hepatocyte: Use in Toxicology and Xenobiotic Transformations*.  
Eds. Rauckman E.J. and Padilla G.M. (Academic Press), pp189-214.
- Adesnik M. and Atchison M. (1986).  
Genes for cytochrome P450 and their regulation.  
CRC Critical Reviews in Biochemistry 19: 247-305.
- Adesnik M., Bar-Nun S., Maschio F., Zunich M., Lippman A. and Bard E. (1981).  
Mechanism of induction of cytochrome P450 by phenobarbital.  
J. Biol. Chem. 256:10 340-10 345.
- Anderson K.E., Alvares A.P., Sassa S. and Kappas A. (1976).  
Studies in porphyria. V. Drug oxidation rates in hereditary hepatic porphyria.  
Clin. Pharmacol. Ther. 19: 47-54.
- Anderson K.E., Drummond G.S., Freddara U., Sardana M.K. and Sassa S. (1981).  
Porphyrinogenic effects and induction of heme oxygenase *in vivo* by  $\delta$ -aminolevulinic acid.  
Biochem. Biophys. Acta 676: 289-299.
- Animal Clinical Chemistry Association (1988).  
Assessment of hepatic function and damage in animal species.  
J. Appl. Toxicol. 8: 249-254.
- Arlotto M.P. and Parkinson A. (1989).  
Identification of cytochrome P450a (P450IIA1) as the principal testosterone 7 $\alpha$ -hydroxylase in rat liver microsomes and its regulation by thyroid hormones.  
Arch. Biochem. Biophys. 270: 458-471.
- Bailey N.T.J. (1959).  
Statistical Methods in Biology. Hodder and Stoughton.
- Baron J., Redick J.A. and Guengerich F.P. (1981).  
An immunochemical study on the localisations and distributions of phenobarbital- and 3-methylcholanthrene-inducible cytochromes P450 within the livers of untreated rats.  
J. Biol. Chem. 256: 5 931-5 937.
- Bars R.G., Mitchell A.M., Wolf C.R. and Elcombe C.R. (1989).  
Induction of cytochrome P450 in cultured rat hepatocytes.  
Biochem. J. 262: 151-158.
- Bartlomowicz B., Friedberg T., Utesch D., Molitor E., Platt K. and Oesch F. (1989).  
Regio- and stereoselective regulation of monooxygenase activities by isozyme-selective phosphorylation of cytochrome P450.  
Biochem. Biophys. Res. Commun. 160: 46-52.

Begue J-M., Guguen-Guillouzo C, Padeloup N. and Guillouzo A. (1984).  
Prolonged maintenance of active cytochrome **P450** in adult rat hepatocytes  
co-cultured with another liver cell type.  
Hepatology 4: 839-842.

Begue J.M., Le Bigot J.F., Guguen-Guillouzo C, Kiechel J.R. and  
Guillouzo A. (1983).  
Cultured human adult hepatocytes: a new model for drug metabolism studies.  
Biochem. Pharmacol. 32: 1 643-1 646.

Bellward G.D., Chang T., Rodrigues B., McNeill J.H., Maines S., Ryan D.E.,  
Levin W. and Thomas P.E. (1988).  
Hepatic cytochrome **P450j** induction in the spontaneously diabetic BB rat.  
Mol. Pharmacol. 33: 140-143.

Belman S. (1963).  
The fluorimetric determination of formaldehyde.  
Anal. Chim. Acta 29: 120-126.

Berger M.L., Reynolds R.C., Hagler H.K., Bellotto D., Parson D., Mulligan K.J.  
and Buja L.M. (1989).  
Anoxic hepatocyte injury: role of reversible changes in elemental content and  
distribution.  
Hepatology 9: 219-228.

Bhat G.J. and Padmanaban G. (1988).  
Heme is a positive regulator of cytochrome P450 transcription.  
Arch. Biochem. Biophys. 264: 584-590.

Billings R.E. (1983).  
Sex differences in rats in the metabolism of phenytoin to  
5-(3,4-dihydroxyphenyl)-5-phenylhydantoin.  
J.Pharmacol. Exp. Ther. 225: 630-636.

Bissell D.M. and Guzelian P.S. (1979).  
Ascorbic acid deficiency and cytochrome P450 in adult rat hepatocytes  
in primary monolayer culture.  
Arch. Biochem. Biophys. 192: 569-576.

Boobis A.R., Kahn G.C., Whyte C, Brodie M.J. and Davies D.S. (1981).  
Biphasic **O-deethylation** of phenacetin and 7-ethoxycoumarin by human and  
rat liver microsomes.  
Biochem. Pharmacol. 30: 2 451-2 456.

Boobis A.R., Whyte C. and Davies D.S. (1986).  
Selective induction and inhibition of the components of 7-ethoxycoumarin  
**O-deethylase** activity in the rat.  
Xenobiotica **16**: 233-238.

- Bornheim L.M., Correia M.A. and Smith K.M. (1984).  
Functional reconstitution of rat liver cytochrome P450 with mesohemin.  
Biochem. Biophys. Res. Commun. 121: 95-101.
- Boyd M.R. and Burka L.T. (1978).  
*In vivo* studies on the relationship between target organ alkylation and the **pulmonarytoxicity** of a chemically reactive metabolite of 4-ipomeanol.  
J. Pharmacol. Exp. Ther. 207: 687-697.
- Boyd M.R., Burka L.T., Wilson B.J. and Sasame H.A. (1978).  
*In vitro* studies on the metabolic activation of the pulmonary toxin, 4-ipomeanol, by rat lung and liver microsomes.  
J. Pharmacol. Exp. Ther. 207: 677-686.
- Boyd M.R., Grygiel J.J. and Minchin R.F. (1973).  
Metabolic activation as a basis for organ selective toxicity.  
Clin. Exp. Pharmacol. Physiol. 10: 87-99.
- Bradford M.M. (1976).  
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding.  
Anal. Biochem. 72: 248-254
- Burchell B. and Coughtrie M.W.H. (1989).  
**UDP-glucuronosyltransferases.**  
Pharmacol. Ther. 43: 261-289.
- Burk R.F. and Masters B.S.S. (1975).  
Some effects of selenium deficiency on the hepatic microsomal cytochrome P450 system in the rat.  
Arch. Biochem. Biophys. 170: 124-131.
- Burke M.D., Thompson S., Elcombe C.R., Halpert J., Haaparanta T. and Mayer R.T. (1985).  
Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes **P450**.  
Biochem. Pharmacol. 34: 337-345.
- Butterworth B.E., Smith-Oliver T., Earle L., Lounsbury D.J., White R.D., Doolittle D.J., Working P.K., Cattley R.C., Jirtle R., Michalopoulos G. and Strom S. (1989).  
Use of primary cultures of human hepatocytes in toxicology studies.  
Cancer Res. 49: 1075-1084.
- Campbell R.C. (1967).  
Statistics for Biologists. Cambridge University Press.
- Chao E.S., Dunbar D. and Kaminsky L.S. (1988).  
Intracellular lactate dehydrogenase concentration as an index of cytotoxicity in rat hepatocyte primary culture.  
Cell Biol. Toxicol. 4; 1-11.

Chenery R.J., Ayrton A., Oldham H.G., Standing P., Norman S.J., Seddon T. and Kirby R. (1987).

Diazepam metabolism in cultured hepatocytes from rat, rabbit, dog, guinea pig and Man.

Drug Metab. Disp. 15: 312-317.

Chianale J., Mulholland L., Traber P.G. and Gumucio J.J. (1988).

Phenobarbital induction of cytochrome P450b,e genes is dependent on protein synthesis.

Hepatology 8: 327-331.

Clarke L. and Waxman D.J. (1989).

Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation.

Cancer Res. 49: 2 344-2 350.

Cohen A.J. (1979).

Critical review of the toxicology of coumarin with special reference to interspecies differences in metabolism and hepatotoxic response and their significance to Man.

Fd. Cosmet. Toxicol. 17: 277-289.

Conney A.H. (1967).

Pharmacological implications of microsomal enzyme induction.

Pharmacol. Rev. 19: 317-366.

Conney A.H., Miller E.C. and Miller J.A. (1956).

The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by **3-methylcholanthrene**.

Cancer Res. **16**: 450-459.

Cook J.A. and Mitchell J.B. (1989).

Viability measurements in mammalian cell systems.

Anal. Biochem. **179**: 1-7.

Cooper D.Y., Levin S., Narashihkulu S., Rosenthal O. and Estabrook R.W. (1965).

Photochemical action spectrum of the terminal oxidase of mixed function oxidase systems.

Science **147**: 400-402.

Corcos L. and Weiss M.C. (1988).

Phenobarbital, dexamethasone and benzanthracene induce several cytochrome P450 mRNAs in rat hepatoma cells.

FEBS Letts. **233**: 37-40.

Croci T. and Williams G.M. (1985).

Activities of several phase I and phase II xenobiotic biotransformation enzymes in cultured hepatocytes from male and female rats.

Biochem. Pharmacol. **34**: 3 029-3 035.

- Danan G., Descatoire V. and Pessayre D. (1981).  
Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome **P450**.  
*J. Pharmacol. Exp. Ther.* **218**: 209-214.
- Darby N.J., Lodola A. and Burnet F. (1986).  
Testosterone metabolite profiles reveal differences in the spectrum of cytochrome P450 isozymes induced by phenobarbitone, 2-acetylaminofluorene and 3-methylcholanthrene in the chick embryo liver.  
*Biochem. Pharmacol.* **35**: 4 073-4 076.
- Davies D.C., Potter W.Z., Jollow D.J. and Mitchell J.R. (1974).  
Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen.  
*Life Sci.* **14**: 2 099-2 109.
- Decad G., Hsieh D.P.H. and Byard J.L (1977).  
Maintenance of cytochrome **P450** and metabolism of aflatoxin **B1** in primary hepatocyte cultures.  
*Biochem. Biophys. Res. Commun.* **78**: 279-287.
- Delaforge M., Ioannides C. and Parke D.V. (1985).  
Ligand-complex formation between cytochromes **P450** and **P448** and methylenedioxyphenyl compounds.  
*Xenobiotica* **15**: 333-342.
- De Matteis F., Gibbs A.H. and Hollands C. (1983).  
**N-Alkylation** of the haem moiety of cytochrome **P450** caused by substituted dihydropyridines.  
*Biochem. J.* **211**: 455-461.
- Denizot F. and Lang R. (1986).  
Rapid colorimetric assay for cell growth and survival.  
*J. Immunol. Methods* **89**: 271-277.
- Dich J., Vind C. and Grunnet N. (1988).  
Long-term culture of hepatocytes: effect of hormones on enzyme activities and metabolic capacity.  
*Hepatology* **8**: 39-45.
- Dickins M. and Peterson R.E. (1980).  
Effects of a hormone-supplemented medium on cytochrome **P450** content and monooxygenase activities of rat hepatocytes in primary culture.  
*Biochem. Pharmacol.* **29**: 1 231-1 238.
- Doostdar H., Duthie S.J., Burke M.D., Melvin W.T. and **Grant** M.H. (1988).  
The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line.  
*FEBS Letts.* **241**: 15-18.

- Dowd J.E. and Riggs D.S. (1965).  
A comparison of estimates of Michaelis-Menten kinetic constants from various linear transformations.  
J. Biol. Chem. **240**: 863-869.
- Edén S. (1979).  
Age- and sex-related differences in episodic growth hormone secretion in the rat.  
Endocrinology **105**: 555-560.
- Edwards A.M. (1982).  
Regulation of  $\gamma$ -glutamyltranspeptidase in rat hepatocyte monolayer cultures.  
Cancer Res. **42**: 1 107-1 115.
- Edwards A.M., Glistak M.L., Lucas C.M. and Wilson P.A. (1984).  
7-Ethoxycoumarin deethylase activity as a convenient measure of liver drug metabolising enzymes: regulation in cultured rat hepatocytes.  
Biochem. Pharmacol. **33**: 1 537-1 546.
- Eliasson E., Johansson I. and Ingelman-Sundberg M. (1988).  
Ligand-dependent maintenance of ethanol-inducible cytochrome **P450** in primary rat hepatocyte cell cultures.  
Biochem. Biophys. Res. Commun. **150**: 436-443.
- Enat R., Jefferson D.M., Ruiz-Opazo N., Gatmaitan Z., Leinwand L.A. and Reid L.M. (1984).  
Hepatocyte proliferation *in vitro*: its dependence on the use of serum-free hormonally-defined medium and substrata of extracellular matrix.  
Proc. Natl. Acad. Sci., USA **81**:1 411-1 415.
- Engelmann G.L., Richardson A.G. and Fierer J.A. (1985).  
Maintenance and induction of cytochrome **P450** in cultured rat hepatocytes.  
Arch. Biochem. Biophys. **238**: 359-367.
- Epstein P.M., Curti M., Jansson I., Huang C-K. and Schenkman J.B. (1989).  
Phosphorylation of cytochrome P450: regulation by cytochrome **b<sub>5</sub>**.  
Arch. Biochem. Biophys. **271**: 424-432.
- Evarts R.P., Marsden E. and Thorgeirsson S.S. (1984).  
Regulation of heme metabolism and cytochrome **P450** levels in primary culture of rat hepatocytes in a defined medium.  
Biochem. Pharmacol. **33**: 565-569.
- Fevold H.R. (1983).  
Regulation of the adrenal and gonadal microsomal mixed function oxygenases of steroid hormone biosynthesis.  
Ann. Rev. Physiol. **45**: 19-36.
- Forster U., Luippold G. and Schwarz L.R. (1986).  
Induction of monooxygenase and glucuronosyltransferase activities in primary cultures of rat hepatocytes.  
Drug Metab. Disp. **14**: 353-360.

- Foureman G.L. and Eling T.E. (1989).  
Peroxidase-mediated formation of glutathione conjugates from polycyclic aromatic dihydrodiols and insecticides.  
Arch. Biochem. Biophys. 269: 55-68.
- Fry J.R. (1981).  
A comparison of biphenyl 4-hydroxylation and 4-methoxybiphenyl O-demethylation in rat liver microsomes.  
Biochem. Pharmacol. 30: 1 915-1 919.
- Fry J.R. (1982).  
Activation systems in tissue culture toxicity studies.  
Toxicology 25: 1-12.
- Fry J.R. and Bridges J.W. (1977).  
A novel mixed hepatocyte-fibroblast culture system and its use as a test for metabolism-mediated cytotoxicity.  
Biochem. Pharmacol. 26: 969-973.
- Fry J.R. and Bridges J.W. (1980).  
The metabolism of 7-ethoxycoumarin in primary maintenance cultures of adult rat hepatocytes.  
Naunyn-Schmiedeberg's Arch. Pharmacol. 311: 85-90.
- Fry J.R., Garle M.J. and Hammond A.H. (1988).  
Choice of acute toxicity measures for comparison of *in vivo/in vitro* toxicity.  
ATLA 16: 175-179.
- Fry J.R., Wiebkin P. and Bridges J.W. (1980).  
7-Ethoxycoumarin O-deethylase induction by phenobarbitone and 1,2-benzanthracene in primary maintenance cultures of adult rat hepatocytes.  
Biochem. Pharmacol. 29: 577-581.
- Galbraith R.A. and Jellinck P.H. (1989).  
Cobalt-protoporphyrin, a synthetic heme analogue, feminises hepatic androgen metabolism in the rat.  
J. Steroid Biochem. 32: 421-426.
- Garfinkel D. (1958).  
Studies on pig liver microsomes. I. Enzymic and pigment composition of different microsomal fractions.  
Arch. Biochem. Biophys. 77: 493-509.
- Garle M.J. and Fry J.R. (1989).  
Detection of reactive metabolites *in vitro*.  
Toxicology 54: 101-110.
- Gibson G.G. and Skett P. (1986).  
Introduction to Drug Metabolism. Chapman and Hall.

- Gonzalez F.J. (1989).  
The molecular biology of cytochrome P450s.  
Pharmacol. Rev. 40: 243-288.
- Gonzalez F.J., Skoda R.C, Kimura S., Umeno M., Zanger U.M., Nebert D.W., Gelboin H.V., Hardwick J.P. and Meyer U.A. (1988).  
Characterisation of the common genetic defect in humans deficient in debrisoquine metabolism.  
Nature 331: 442-446.
- Gorsky L.D., Koop D.R. and Coon M.J. (1984).  
On the stoichiometry of the oxidase and monooxygenase reactions catalysed by liver cytochrome P450.  
J. Biol. Chem. 259: 6 812-6 817.
- Gram T.E., Guarino A.M., Schroeder D.H. and Gillette J.R. (1969).  
Changes in certain kinetic properties of hepatic microsomal aniline hydroxylase and ethylmorphine demethylase associated with postnatal development and maturation in male rats.  
Biochem. J. 113: 681-685.
- Gram T.E., Okine L.K. and Gram R.A. (1986).  
The metabolism of xenobiotics by certain extra-hepatic organs and its relation to toxicity.  
Ann. Rev. Pharmacol. Toxicol. 26: 259-291.
- Granick S. (1966).  
The induction *in vitro* of the synthesis of 3-aminolevulinic acid synthetase in chemical porphyria: a response to certain drugs, sex hormones and foreign chemicals.  
J. Biol. Chem. 241: 1 359-1 375.
- Grant M.H. and Hawksworth G.M. (1986).  
The activity of **UDP-glucuronyltransferase**, sulphotransferase and **glutathione-S-transferase** in primary cultures of rat hepatocytes.  
Biochem. Pharmacol. 35: 2 979-2 982.
- Grant M.H., Burke M.D., Hawksworth G.M., Duthie S.J., Engeset J. and Petrie J.C (1987).  
Human adult hepatocytes in primary monolayer culture.  
Biochem. Pharmacol. 36: 2 311-2 316.
- Grant M.H., Duthie S.J., Gray A.G. and Burke M.D. (1988).  
Mixed function oxidase and UDP-glucuronyltransferase activities in the human Hep G2 hepatoma cell line.  
Biochem. Pharmacol. 37: 4 111-4 116.
- Grant M.H., Melvin M.A.L, Shaw P., Melvin W.T. and Burke M.D. (1985).  
Studies on the maintenance of cytochromes P450 and **b<sub>5</sub>**, monooxygenases and cytochrome reductases in primary cultures of rat hepatocytes.  
FEBS Letts. 190: 99-103.

- Gregory A.R. (1988).  
Species comparisons in evaluating carcinogenicity in humans.  
*Regul. Toxicol. Pharmacol.* 8: 160-190.
- Grisham J.W. and Smith G.J. (1984).  
Predictive and mechanistic evaluation of toxic responses in mammalian cell culture systems.  
*Pharmacol. Rev.* 36: 151S-171S.
- Guguen C, Gregori C and Schapira F. (1975).  
Modification of pyruvate kinase isozymes in prolonged primary cultures of adult rat hepatocytes.  
*Biochimie* 57: 1 065-1 071.
- Gumucio J.J. (1989).  
Hepatocyte heterogeneity: the coming of age from the description of a biological curiosity to a partial understanding of its physiological meaning and regulation.  
*Hepatology* 9: 154-160.
- Gumucio J.J. and Chianale J. (1988).  
Liver cell heterogeneity and liver function.  
In: *The Liver. Biology and Pathobiology.* Eds. Arias I.M., Jakoby W.B., Popper H., Schachter D. and Shafritz D.A. (Raven Press), pp931-948.
- Gumucio J.J., May M., Dvorak C, Chianale J. and Massey V. (1986).  
The isolation of functionally heterogeneous hepatocytes of the proximal and distal half of the liver acinus in the rat.  
*Hepatology* 6: 932-944.
- Guzelian P.S., Bissell D.M. and Meyer U.A. (1977).  
Drug metabolism in adult rat hepatocytes in primary monolayer culture.  
*Gastroenterology* 72:1 232-1 239.
- Guzelian P.S., Li D., Schuetz E.G., Thomas P., Levin W., Mode A. and Gustafsson J-A. (1988).  
Sex change in cytochrome P450 phenotype by growth hormone treatment of adult rat hepatocytes maintained in a culture system on matrigel.  
*Proc. Natl. Acad. Sci., USA* 85: 9 783-9 787.
- Halpert J.R. (1988).  
Multiplicity of steroid-inducible cytochrome P450 in rat liver microsomes.  
*Arch. Biochem. Biophys.* 263: 59-68.
- Halpin R.A., Vyas K.P., El-Naggar S.F. and Jerina D.M. (1984).  
Metabolism and hepatotoxicity of the naturally occurring benzo(b)pyran precocene I.  
*Chem. Biol. Interact.* 48: 297-315.
- Hanes C.S. (1932).  
**CLXVII.** Clinical studies on plant amylases. **I.** The effect of starch concentration upon the velocity of hydrolysis by the amylase of germinated barley.  
*Biochem. J.* 26: 1 406-1 421.

Hankinson O., Anderson R.D., Birren B.W., Sander F., Negishi M. and Nebert D.W. (1985).

Mutations affecting the regulation of transcription of the cytochrome P1-450 gene in mouse Hepa-1 cell line.

J. Biol. Chem. **260**: 1 790-1 795.

Hardwick J.P., Gonzalez F.J. and Kasper C.B. (1983a).

Transcriptional regulation of rat liver epoxide hydratase, NADPH-cytochrome P450 oxidoreductase and cytochrome P450b genes by phenobarbital.

J. Biol. Chem. **258**: 8 081-8 085.

Hardwick J.P., Gonzalez F.J. and Kasper C.B. (1983b).

Cloning of DNA complementary to cytochrome P450 induced by pregnenolone-16 $\alpha$  - carbonitrile.

J. Biol. Chem. **258**: 10 182-10 186.

Hardwick J.P., Song B.-J., Huberman E. and Gonzalez F.J. (1987).

Isolation, complementary DNA sequence, and regulation of rat hepatic lauric acid  $\omega$ -hydroxylase (cytochrome P450<sub>LA</sub> )•

J. Biol. Chem. **262**: 801-810.

Haugen D.A., Coon M.J. and Nebert D.W. (1976).

Induction of multiple forms of mouse liver cytochrome P450.

J. Biol. Chem. **251**: 1 817-1 827.

Heuman D.M., Gallagher E.J., Barwick J.L., Elshourbagy N.A. and Guzelian P.S. (1982).

Immunochemical evidence for induction of a common form of hepatic cytochrome P450 in rats treated with pregnenolone-16 $\alpha$ -carbonitrile or other steroidal or non-steroidal agents.

Mol. Pharmacol **21**: 753-760.

Hissin P.J. and Hilf R. (1976).

A fluorometric method for determination of oxidised and reduced glutathione in tissues.

Anal. Biochem. **74**: 214-227.

Hjelle J.J. (1986).

Hepatic UDP-glucuronic acid regulation during acetaminophen biotransformation in rats.

J. Pharmacol. Exp. Ther. **237**: 750-756.

Hong J., Pan J., Gonzalez F.J., Gelboin H.V. and Yang C.S. (1987).

The induction of a specific form of cytochrome P450 (P450j) by fasting.

Biochem. Biophys. Res. Commun. **142**: 1 077-1 083.

Honn K.V., Singley J.A. and Chavin W. (1975).

Fetal bovine serum: a multivariate standard (38804).

Proc. Soc. Exp. Biol. Med. **149**: 344-347.

- Horner S.A., Fry J.R., Clothier R.H. and Balls M. (1987).  
The detection of cytotoxicity produced by short-lived reactive intermediates:  
a study with bromobenzene.  
*Xenobiotica* 17: 777-782.
- Howell S.R., Hazelton G.A. and Kaassen CD. (1986).  
Depletion of hepatic UDP-glucuronic acid by drugs that are glucuronidated.  
*J. Pharmacol. Exp. Ther.* 236: 610-614.
- Hsia M.T.S., Grossman S. and Schrankel K.R. (1981).  
Hepatotoxicity of the anti-juvenile hormone precocene II and the generation  
of dihydrodiol metabolites.  
*Chem. Biol. Interact.* 37: 265-277.
- Hurwitz N. (1969).  
Predisposing factors in adverse reactions to drugs.  
*Br. Med. J.*(i) 536-539.
- Hyslop R.M. and Jardine I. (1981a).  
Metabolism of 6-thiopurines. I. Irreversible binding of a metabolite of  
6-thiopurine to mammalian hepatic protein *in vitro*.  
*J. Pharmacol. Exp. Ther.* 218: 621-628.
- Hyslop R.M. and Jardine I. (1981b).  
Metabolism of 6-thiopurines. II. Covalent binding of a 6-thiopurine  
metabolite to mammalian tissue protein *in vivo*.  
*J. Pharmacol. Exp. Ther.* 218: 629-635.
- Ingelman-Sundberg M. and Johansson I. (1984).  
Mechanisms of hydroxyl radical formation and ethanol oxidation by  
ethanol-inducible forms of rabbit liver microsomal cytochromes P450.  
*J. Biol. Chem.* 259: 6 447-6 458.
- Ingelman-Sundberg M., Johansson I., Penttilä K.E., Glaumann H. and  
Lindros K.O. (1988).  
Centrilobular expression of ethanol-inducible cytochrome P450 (IIE1) in rat liver.  
*Biochem. Biophys. Res. Commun.* 157: 55-60.
- Iype P.T. (1971).  
Cultures from adult rat liver cells. I. Establishment of monolayer cell-cultures  
from normal liver.  
*J. Cell. Physiol.* 78: 281-288.
- Jacobs J.M., Sinclair P.R., Bement W.J., Lambrecht R.W., Sinclair J.F. and  
Goldstein J.A. (1989).  
Oxidation of uroporphyrinogen by methylcholanthrene-induced cytochrome P450.  
*Biochem. J.* 258: 247-253.
- Jakoby W.B. (1988).  
Detoxication: conjugation and hydrolysis.  
In: *The Liver. Biology and Pathobiology.* Eds. Arias I.M., Jakoby W.B., Popper H.,  
Schachter D., Shafritz D.A. (Raven Press), pp 375-388.

- Jansson I., Tamburini P.P., Favreau L. and Schenkman J.B. (1985).  
The interaction of cytochrome b<sub>5</sub> with four cytochrome P450 enzymes from the untreated rat.  
Drug Metab. Disp. 13: 453-458.
- Jansson J-O., Ekberg S., Isaksson O., Mode A. and Gustafsson J-A. (1985).  
Imprinting of growth hormone secretion, body growth and hepatic steroid metabolism by neonatal testosterone.  
Endocrinology 117: 1 881-1 889.
- Jauregui H.O., Hayner N.T., Driscoll J.L., Williams-Holland R., Lipsky M.H. and Galletti P.M. (1981).  
Trypan blue dye uptake and lactate dehydrogenase in adult rat hepatocytes-freshly isolated cells, cell suspensions and primary monolayer cultures.  
In Vitro 17: 1 100-1 110.
- Jeffery E.H. (1983).  
The effect of zinc on NADPH oxidation and monooxygenase activity in rat hepatic microsomes.  
Mol. Pharmacol. 23: 467-473.
- Johansson I., Ekstrom G., Scholte B., Puzycki D., Jörnvall H. and Ingelman-Sundberg M. (1988).  
Ethanol-, fasting- and acetone-inducible cytochromes P<sub>450</sub> in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies.  
Biochemistry 27: 1 925-1 934.
- Kamataki T., Ando M., Yamazoe Y., Ishii K. and Kato R. (1980).  
Sex difference in the O-dealkylation activity of 7-hydroxycoumarin O-alkyl derivatives in liver microsomes of rats.  
Biochem. Pharmacol. 29: 1 015-1 022.
- Kamataki T., Maeda K., Shimada M., Kitani K., Nagai T. and Kato R. (1985).  
Age-related alteration in the activities of drug-metabolizing enzymes and contents of sex-specific forms of cytochrome P450 in liver microsomes from male and female rats.  
J. Pharmacol. Exp. Ther. 233: 222-228.
- Kamataki T., Maeda K., Yamazoe Y., Nagai T. and Kato R. (1982).  
Evidence for the involvement of multiple forms of cytochrome P<sub>450</sub> in the occurrence of sex-related differences of drug metabolism in the rat.  
Life Sci. 31: 2 603-2 610.
- Kamataki T., Maeda K., Yamazoe Y., Nagai T. and Kato R. (1983).  
Sex-difference of cytochrome P450 in the rat: purification, characterization and quantitation of constitutive forms of cytochrome P<sub>450</sub> from liver microsomes of male and female rats.  
Arch. Biochem. Biophys. 225: 758-770.

Kato R. (1979).

Characteristics and differences in the hepatic mixed function oxidases of different species.

Pharmacol. Ther. 6: 41-98.

Kato R. (1977).

Drug metabolism under pathological and abnormal physiological states in animals and Man.

Xenobiotica 7: 25-92.

Kato R. and Gillette J.R. (1965a).

Sex differences in the effects of abnormal physiological states on the metabolism of drugs by liver microsomes.

J. Pharmacol. Exp. Ther. **150**: 285-291.

Kato R. and Gillette J.R. (1965b).

Effect of starvation on NADPH-dependent enzymes in liver microsomes of male and female rats.

J. Pharmacol. Exp. Ther. **150**: 279-284.

Kesterson J.W., Granneman G.R. and Machinist J.M. (1984).

The hepatotoxicity of valproic acid and its metabolites in rats.

I. Toxicologic, biochemical and histopathologic studies.

Hepatology (Baltimore) 4: 1 143-1 152.

Kingsley E., Gray P., Tolman K.G. and Tweedale R. (1983).

The toxicity of metabolites of sodium valproate in cultured hepatocytes.

J. Clin. Pharmacol. 23: 178-185.

Klingenberg M. (1958).

Pigments of rat liver microsomes.

Arch. Biochem. Biophys. 75: 376-386.

Knowles B.B., Howe CC. and Aden D.P. (1980).

Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

Science 209: 497-499.

Koch J.A. and Waxman D.J. (1989).

Posttranslational modification of hepatic cytochrome P<sub>450</sub>.

Phosphorylation of phenobarbital-inducible P<sub>450</sub> forms PB-4 (11B1) and PB-5 (11B2) in isolated hepatocytes and *in vivo*.

Biochemistry 28: 3 145-3 152.

Kreamer B.L., Staeker J.L., Sawada N., Sattler G.L., Hsia M.T. and

Pitot H.C (1986).

Use of a low-speed, iso-density percoll centrifugation method to increase the viability of isolated rat hepatocyte preparations.

In Vitro Cell. Develop. Biol. 22: 201-211.

Kutty R.K., Daniel R.F., Ryan D.E., Levin W. and Maines M.D. (1988).  
Rat liver cytochrome P450b, P420b and P420C are degraded to biliverdin  
by haem oxygenase.  
Arch. Biochem. Biophys. 260: 638-644.

Kyle M.E., Nakae D., Serroni A. and Farber J.L. (1988).  
**1,3-(2-Chloroethyl)-1-nitrosourea** potentiates the toxicity of acetaminophen  
both in phenobarbital-induced rat and in hepatocytes cultured from such animals.  
Mol. Pharmacol. 34: 584-589.

Laishes B.A. and Williams G.M. (1976a).  
Conditions affecting primary cell cultures of functional adult rat hepatocytes.  
I. The effect of insulin.  
In Vitro **12**: 521-532.

Laishes B.A. and Williams G.M. (1976b).  
Conditions affecting primary cell cultures of functional adult rat hepatocytes.  
II. **Dexamethasone** enhanced longevity and maintenance of morphology.  
In Vitro 12: 821-832.

Lake B.G. and Paine A.J. (1982).  
The effect of hepatocyte culture conditions on cytochrome P450-linked  
drug metabolizing enzymes.  
Biochem. Pharmacol. 31: 2 141-2 144.

Lave L.B. and Omenn G.S. (1988).  
Screening toxic chemicals: how accurate must tests be?  
J. Am. Coll. Toxicol. 7: 565-574.

LeBlanc G.A. and Waxman D.J. (1988).  
Feminisation of rat hepatic P450 expression by cisplatin.  
J. Biol. Chem. 263: 15 732-15 739.

Lehninger A.L. (1975).  
Biochemistry: the molecular basis of cell structure and function. 2nd Ed. Worth.

Levi A.J., Sherlock S. and Walker D. (1968).  
Phenylbutazone and isoniazid metabolism in patients with liver disease in  
relation to previous drug therapy.  
Lancet (i) 1 275-1 279.

Levin W., Ryan D., Kuntzman R. and Conney A.H. (1975).  
Neonatal imprinting and the turnover of microsomal cytochrome **P450**  
in rat liver.  
Mol. Pharmacol. 11: 190-200.

Liem H.H., Johnson E.F. and Muller-Eberhard U. (1983).  
The effect *in vivo* and *in vitro* of allylisopropylacetamide on the content  
of hepatic microsomal cytochrome P450 of phenobarbital treated rabbits.  
Biochem. Biophys. Res. Commun. 111: 926-932.

- Long R.M. and Moore L. (1988).  
Biochemical evaluation of rat hepatocyte primary cultures as a model for carbon tetrachloride hepatotoxicity: comparative studies *in vivo* and *in vitro*.  
Toxicol. Appl. Pharmacol. 92: 295-306.
- López M.P., Gómez-Lechón M.J. and Castell J.V.  
Active glycolysis and glycogenolysis in early stages of primary cultured hepatocytes. Role of AMP and fructose 2,6-bisphosphate.  
In Vitro Cell. Develop. Biol. 24: 511-517.
- Lu A.H.Y. and Coon M.J. (1968).  
Role of hemoprotein P450 in fatty acid  $\omega$ -hydroxylation in a soluble enzyme system from liver microsomes.  
J. Biol. Chem. 243: 1 331-1 332.
- Lu A.Y.H. and West S.B. (1980).  
Multiplicity of mammalian microsomal cytochromes P450.  
Pharmacol. Rev. 31: 277-295.
- Lu A.H.Y., Junk K.W. and Coon M.J. (1969).  
Resolution of the cytochrome P450 containing  $\omega$ -hydroxylation system of liver microsomes into three components.  
J. Biol. Chem. 244: 3 714-3 721.
- Lubet R.A., Nims R.W., Mayer R.T., Cameron J.W. and Schechtman L.M. (1985).  
Measurement of cytochrome P450-dependent dealkylation of alkoxyphenoxazones in hepatic S9s and hepatocyte homogenates: effects of dicoumarol.  
Mutation Res. 142: 127-131.
- Ma Q., Dannan G.A., Guengerich F.P. and Yang C.S. (1989).  
Similarities and differences in the regulation of hepatic cytochrome P450 enzymes by diabetes and fasting in male rats.  
Biochem. Pharmacol. 38: 3 179-3 184.
- Maeda K., Kamataki T., Nagai T. and Kato R. (1984).  
Postnatal development of constitutive forms of cytochrome P450 in liver microsomes of male and female rats.  
Biochem. Pharmacol. 33: 509-512.
- Mahgoub A., Dring L.G., Idle J.R., Lancaster R. and Smith R.L. (1977).  
Polymorphic hydroxylation of debrisoquine in Man.  
Lancet (ii) 584-586.
- Maines M.D. and Kappas A. (1976).  
Selenium regulation of hepatic heme metabolism: induction of  $\delta$ -aminolevulinatase synthase and heme oxygenase.  
Proc. Natl. Acad. Sci., USA 73: 4 428-4 431.
- Maines M.D. and Kappas A. (1977).  
Metals as regulators of heme metabolism.  
Science 198: 1 215-1 221.

- Maron D.M. and Ames B.N. (1983).  
Revised methods for the *Salmonella* mutagenicity test.  
Mutation Res. 113: 173-215.
- Maslansky C.J. and Williams G.M. (1982).  
Primary cultures and the levels of cytochrome P450 in the hepatocytes  
from mouse, rat, hamster and rabbit liver.  
In Vitro 18: 683-693.
- Matsubara T., Otsubo S., Yoshiha E. and Touchi A. (1983).  
Biotransformation of coumarin derivatives. (2) Oxidative metabolism of  
7-alkoxycoumarin by microsomal enzymes and a simple assay procedure  
for 7-alkoxycoumarin O-dealkylase.  
Japan. J. Pharmacol. 33: 41-56.
- Matsunaga T., Nagata K., Holsztyńska E.J., Lapenson D.P., Smith A., Kato R.,  
Gelboin H.V., Waxman D.J. and Gonzalez F.J. (1988).  
Gene conversion and differential regulation in the rat P450IIA gene subfamily.  
J. Biol. Chem. 263: 17 995-18 002.
- Matsuura Y., Fukuda T., Yoshida T. and Kuroiwa Y. (1988).  
Inhibitory effect of zinc-protoporphyrin on the induction of haem oxygenase  
and the associated decrease in cytochrome P450 content in rats.  
Toxicology 50: 169-180.
- McManus M.E., Edwards A.M., Stupans I., Burgess W., Lucas C and  
Birkett D.J. (1987).  
Effect of dexamethasone on cytochrome P450-mediated metabolism of  
2-acetylaminofluorene in cultured rat hepatocytes.  
Biochem. Pharmacol. 36: 237-243.
- Michalopoulos G. and Pitot H.C. (1975).  
Primary culture of parenchymal liver cells on collagen membranes.  
Exp. Cell Res. 94: 70-78.
- Michalopoulos G., Sattler G.L. and Pitot H.C. (1976)  
Maintenance of microsomal cytochromes b<sub>5</sub> and P450 in primary cultures of  
parenchymal cells on collagen membranes.  
Life Sci. 18: 1 139-1 144.
- Miller J.A., Cramer J.W. and Miller E.C. (1960).  
The N- and ring-hydroxylation of 2-acetylaminofluorene during carcinogenesis  
in the rat.  
Cancer Res. 20: 950-962.
- Mirkin B.L. (1970).  
Developmental pharmacology.  
Ann. Rev. Pharmacol. 10: 255-272.

Mitchell J.R., Jollow D.J., Potter W.Z., Davis D.C, Gillette J.R. and Brodie B.B. (1973).

Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism.  
J. Pharmacol. Exp. Ther. **187**: 185-195.

Miyazaki M., Handa Y., Oda M., Yabe T., Miyano K. and Sato J. (1985).

Long-term survival of functional hepatocytes from adult rat in the presence of phenobarbital in primary culture.  
Exp. Cell Res. **159**: 176-190.

Muller-Eberhard U. and Vincent S.H. (1985).

Concepts of heme distribution within hepatocytes.  
Biochem. Pharmacol. **34**: 719-725.

Nakagawa Y. (1987).

Effects of buthionine sulfoximine and cysteine on the hepatotoxicity of butylated hydroxytoluene in rats.  
Toxicol. Letts. **37**: 251-256.

Namkung M.J., Yang H.L, Hulla J.E. and Juchau M.R. (1988).

On the substrate specificity of cytochrome P450III<sub>A1</sub>.  
Mol. Pharmacol. **34**: 628-637.

Nash T. (1953).

The colourimetric estimation of formaldehyde by means of the Hantzsch reaction.  
Biochem. J. **55**: 416-421.

Nebert D.W. and Gonzalez F.J. (1987).

P450 genes: **structure, evolution** and regulation.  
Ann. Rev. Biochem. **56**: 945-993.

Nebert D.W., Nelson D.R., Adesnik M., Coon M.J., Estabrook R.W., Gonzalez F.J., Guengerich F.P., Gunsalus I.C., Johnson E.F., Kemper B., Levin W., Phillips I.R., Sato R. and Waterman M.R. (1989).

The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci.

DNA **8**: 1-13.

Nebert D., Adesnik M., Coon M., Estabrook R., Gonzalez F., Guengerich P., Gunsalus I., Johnson E., Kemper B., Levin W., Phillips I., Sato R. and Waterman M. (1987).

The P450 gene superfamily: recommended nomenclature.  
DNA **6**: 1-11.

Nef P., Heldman J., Lazard D., Margalti T., Jaye M., Hanukoglu I. and Lancet D. (1989).

Olfactory-specific cytochrome P450.  
J. Biol. Chem. **264**: 6 780-6 785.

Nelson D.R. and Strobel H.W. (1988).

On the membrane topology of vertebrate cytochrome P450 proteins.  
J. Biol. Chem. **263**: 6 038-6 050.

Netter K.J. (1980).

Inhibition of oxidative drug metabolism in microsomes.  
Pharmacol. Ther. 10: 515-535.

Oglesby L.A., Brock K.H. and Moore M.M. (1989).

Induced hepatocytes as a metabolic activation system for the mouse-lymphoma assay.  
Mutation Res. 223: 295-302.

Okuno H., Nakanishi S., Kitao Y., Takasu M., Murase T., Shiozaki Y. and Sameshima Y. (1989).

Comparison of the effects of various inducers on 7-alkoxycoumarin O-dealkylase activities in liver microsomes.  
Japan. J. Pharmacol. 50: 1-9.

Omura T. and Sato R. (1962).

A new cytochrome in liver microsomes.  
J. Biol. Chem. 237: 1 375-1 376.

Omura T. and Sato R. (1964).

The carbon monoxide binding pigment of liver microsomes.I. Evidence for its haemoprotein nature.  
J. Biol. Chem. 239: 2 370-2 378.

Ortiz de Montellano P.R. and Correia M.A. (1983).

Suicidal destruction of cytochrome **P<sub>450</sub>** during oxidative drug metabolism.  
Ann. Rev. Pharmacol. Toxicol. 23: 481-503.

Paine A.J. and Legg R.F. (1978).

Apparent lack of correlation between the loss of cytochrome **P<sub>450</sub>** in hepatic parenchymal cell culture and the stimulation of haem oxygenase activity.  
Biochem. Biophys. Res. Commun. 81: 672-679.

Paine A.J., Hockin L.J. and Allen C.M. (1982).

Long term maintenance and induction of cytochrome **P<sub>450</sub>** in rat liver cell culture.  
Biochem. Pharmacol. 31: 1 175-1 178.

Paine A.J., Hockin L.J. and Legg R.F. (1979).

Relationship between the ability of nicotinamide to maintain nicotinamide-adenine dinucleotide in rat liver cell culture and its effect on cytochrome **P<sub>450</sub>**.  
Biochem. J. **184**: 461-463.

Parkinson A., Robertson L.W. and Safe S. (1982).

Binding of metyrapone to dithionite-reduced cytochrome **P<sub>450</sub>** from rats treated with xenobiotics.  
Biochem. Pharmacol. 31: 3 489-3 494.

Parkinson A., Thomas **P.E.**, Ryan D.E. and Levin W. (1983).

The *in vivo* turnover of rat liver microsomal epoxide hydrolase and both the apoprotein and heme moieties of specific **P<sub>450</sub>** isozymes.  
Arch. Biochem. Biophys. 225: 216-236.

Pasco D.S., Boyum K.W., Merchant S.N., Chalberg S.C and Fagan J.B. (1988).  
Transcriptional and post-transcriptional regulation of the genes encoding  
cytochromes P450c and P450d *in vivo* and in primary hepatocyte cultures.  
J. Biol. Chem. 263: 8 671-8 676.

Paterson P. and Fry J.R. (1983).  
The effect of ascorbic acid on the conjugation of 4-hydroxybiphenyl in  
rat isolated hepatocytes.  
Xenobiotica 13: 607-610.

Paterson P., Fry J.R. and Horner S.A. (1984).  
Influence of cytochrome P450-type on the pattern of conjugation of  
7-hydroxycoumarin generated from alkoxy coumarins.  
Xenobiotica 14: 849-859.

Paul J. (1970).  
Cell and Tissue Culture. E.S.Livingstone, Edinburgh and London.

Pohl R.J. and Fouts J.R. (1980).  
A rapid method for assaying the metabolism of 7-ethoxyresorufin by  
microsomal subcellular fractions.  
Anal. Biochem. 107: 150-155.

Poland A., Glover E. and Kende A.S. (1976).  
Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-  
dioxin by hepatic cytosol.  
J. Biol. Chem. 251: 4 936-4 946.

Porter T.D., Khani S.C. and Coon M.J. (1989).  
Induction and tissue-specific expression of rabbit cytochrome P450IIE1  
and IIE2 genes.  
Mol. Pharmacol. 36: 61-65.

Porubek D.J., Barnes H., Meier P., Theodore L.J. and Baillie T.A. (1989a).  
Enantiotropic differentiation during the biotransformation of valproic acid  
to the hepatotoxic olefin 2-n-propyl-4-pentenoic acid.  
Chem. Res. Toxicol. 2: 35-40.

Porubek D.J., Grillo M.P. and Baillie T.A. (1989b).  
The covalent binding to protein of valproic acid and its hepatotoxic metabolite,  
2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes.  
Drug Metab. Disp. 17: 123-130.

Poulsen H.E. and Loft S. (1988).  
Antipyrine as a model drug to study hepatic drug-metabolizing capacity.  
J. Hepatology 6: 374-382.

Prescott L.F., Critchley J.A.J.H., Balali-Mood M. and Pentland B. (1981).  
Effects of microsomal enzyme induction on paracetamol metabolism in Man.  
Br. J. Clin. Pharmacol. 12: 149-153.

Prough R.A., Burke M.D. and Mayer R.T. (1978).  
Direct fluorometric methods for measuring mixed function oxidase activity.  
In: Methods in Enzymology 52 part C. Eds. Fleischer S. and Packer L.  
(Academic Press), pp 372-377.

Pyerin W., Taniguchi H., Stier A., Oesch F. and Wolf C.R. (1984).  
Phosphorylation of rabbit liver cytochrome P420 LM2 and its effect on  
monooxygenase activity.  
Biochem. Biophys. Res. Commun. 122: 620-626.

Quinn G.P., Axelrod J. and Brodie B.B. (1958).  
Species, strain and sex differences in metabolism of hexobarbitone,  
amidopyrine, antipyrine and aniline.  
Biochem. Pharmacol. 1: 152-159.

Rappaport A.M., Borowy Z.J., Loughheed W.M. and Lotto W.N. (1954).  
Subdivision of hexagonal liver lobules into a structural and function unit.  
Anat. Record **119**: 11-33.

Ravindranath V. and Boyd M.R. (1985).  
Metabolic activation of 2-methylfuran by rat microsomal systems.  
Toxicol. Appl. Pharmacol. 78: 370-376.

Ravindranath V., Boyd M.R. and Jerina D.M. (1987).  
Hepatotoxicity of precocene I in rats. Role of metabolic activation *in vivo*.  
Biochem. Pharmacol. 36: 441-446.

Reese J.A. and Byard J.L. (1981).  
Isolation and culture of adult hepatocytes from liver biopsies.  
In Vitro **17**: 935-940.

Reinke L.A. and Moyer M.J. (1985).  
**p-Nitrophenol** hydroxylation. A microsomal oxidation which is highly  
inducible by ethanol.  
Drug Metab. Disp. 13: 548-552.

Rettenmeier A.W., Prickett K.S., Gordon W.P., Bjorge S.M., Chang S-L.,  
Levy R.H. and Baillie T.A. (1985).  
Studies on the biotransformation in the perfused rat liver of **2-n-propyl-**  
**4-pentenoic acid**, a metabolite of the antiepileptic drug valproic acid.  
Drug Metab. Disp. 13: 81-96.

Rettie A.E., Boberg M., Rettenmeier A.W. and Baillie T.A. (1988).  
Cytochrome **P450-catalysed** desaturation of valproic acid *in vitro*.  
J. Biol. Chem. 263: 13 733-13 738 .

Reyes E.F. and Virgo B.B. (1988).  
Neonatal programming of ethylmorphine demethylase and corticosteroid  
**5 $\alpha$** -reductase by testosterone, dihydrotestosterone and estradiol.  
Drug Metab. Disp. **16**: 93-97.

- Rietjens I.M.C.M., Ancher L.J. and Veeger C (1989).  
On the role of phospholipids in the reconstituted cytochrome P<sub>450</sub> system.  
Eur. J. Biochem. 181: 309-316 .
- Rizzardini M. and Smith A.G. (1982).  
Sex differences in the metabolism of hexachlorobenzene by rats and the development of porphyria in females.  
Biochem. Pharmacol. 31: 3 543-3 548.
- Roberts D.V. (1977).  
Enzyme kinetics. Cambridge University Press.
- Rush G.F. and Alberts D. (1986).  
tert-Butyl hydroperoxide metabolism and stimulation of the pentose phosphate pathway in isolated hepatocytes.  
Toxicol. Appl. Pharmacol. 85: 324-331.
- Ryan D.E. and Levin W. (1990).  
Purification and characterization of hepatic microsomal cytochrome P<sub>450</sub>.  
Pharmacol. Ther. 45: 153-239.
- Ryan D.E., Koop D.R., Thomas P.E., Coon M.J. and Levin W. (1986).  
Evidence that isoniazid and ethanol induce the same microsomal cytochrome P<sub>450</sub> in rat liver, an isozyme homologous to rat liver cytochrome P<sub>450</sub> isozyme 3a.  
Arch. Biochem. Biophys. 246: 633-644.
- Ryan D.E., Ramanathan L., Iida S., Thomas P.E., Haniu M., Shively J.E., Lieber C.S. and Levin W. (1985).  
Characterization of a major form of rat hepatic microsomal cytochrome P<sub>450</sub> induced by isoniazid.  
J. Biol. Chem. 260: 6 385-6 393).
- Ryan D.E., Thomas P.E., Korzeniowski D. and Levin W. (1979).  
Separation and characterization of highly purified forms of liver microsomal cytochrome P<sub>450</sub> from rats treated with polychlorinated biphenyls, phenobarbital and 3-methylcholanthrene.  
J. Biol. Chem. 254: 1 365-1 374.
- Sadano H. and Omura T. (1983).  
Turnover of two drug-inducible forms of microsomal cytochrome P<sub>450</sub> in rat liver.  
J. Biochem. 93: 1 375-1 383.
- Salazar D.E., Sorge CL and Corcoran G.B. (1988).  
Obesity as a risk factor for drug-induced organ injury. VI. Increased hepatic P<sub>450</sub> concentration and microsomal ethanol oxidising activity in the obese overfed rat.  
Biochem. Biophys. Res. Commun. 157: 315-320 .

Sawada N., Tomomura A., Sattler C.A., Sattler G.L., Kleinman H.K. and Pitot H.C. (1987).  
Effects of extracellular matrix components on the growth and differentiation of cultured rat hepatocytes.  
*In Vitro Cell. Develop. Biol.* 23: 267-273.

Schenkman J.B., Jansson I. and Robie-Suh K.M. (1976).  
The many roles of cytochrome **b<sub>5</sub>** in hepatic microsomes.  
*Life Sci.* 19: 611-624.

Schenkman J.B., Remmer H. and Estabrook R.W. (1967).  
Spectral studies of drug interaction with hepatic microsomal cytochrome.  
*Mol. Pharmacol.* 3: 113-123.

Schuetz E.G. and Guzelian P.S. (1984).  
Induction of cytochrome P450 by glucocorticoids in rat liver. II. Evidence that glucocorticoids regulate induction of cytochrome P450 by a nonclassical receptor mechanism.  
*J. Biol. Chem.* 259: 2007-2012.

Schuetz E.G., Li D., Omiecinski C.J., Muller-Eberhard U., Kleinman H.K., Elswick B. and Guzelian P.S. (1988).  
Regulation of gene expression in adult rat hepatocytes cultured on a basement membrane matrix.  
*J. Cell. Physiol.* 134: 309-323.

Schuetz E.G., Wrighton S.A., Barwick J.L. and Guzelian P.S. (1984).  
Induction of cytochrome P450 by glucocorticoids 1. Evidence that glucocorticoids and pregnenolone 16 $\alpha$ -carbonitrile regulate *de novo* synthesis of a common form of cytochrome P450 in cultures of adult rat hepatocytes and in the liver *in vivo*.  
*J. Biol. Chem.* 259: 1999-2006.

Schuetz E.G., Wrighton S.A., Safe S.H. and Guzelian P.S. (1986).  
Regulation of cytochrome P450P by phenobarbital and **phenobarbital-like** inducers in adult rat hepatocytes in primary monolayer culture and *in vivo*.  
*Biochemistry* 25:1124-1133.

Shaddock J.G., Heflich R.H., McMillan D.C., Hinson J.A. and Casciano D.A. (1989).  
Pretreatment with mixed-function oxidase inducers increases the sensitivity of the hepatocyte/DNA repair assay.  
*Environ. Mol. Mutagen.* 13: 281-288.

Sherratt A.J. and Damani L.A. (1989).  
Activities of cytosolic and microsomal drug oxidases of rat hepatocytes in primary culture.  
*Drug Metab. Disp.* 17: 20-25.

- Shiraki H. and Guengerich F.P. (1984).  
Turnover of membrane proteins: kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P450, NADPH-cytochrome P450 reductase and epoxide hydrolase.  
Arch. Biochem. Biophys. 235: 86-96.
- Sies H. and Brauser B. (1970).  
Interaction of mixed function oxidase with its substrates and associated redox transitions of cytochrome P450 and pyridine nucleotides in perfused rat liver.  
Eur. J. Biochem. 15: 531-540.
- Silver G. and Krauter K.S. (1988).  
Expression of cytochrome P450C and P450d mRNAs in cultured rat hepatocytes.  
J. Biol. Chem. 263: 11 802-11 807.
- Simmons L., McQuiddy P. and Kasper CB. (1987).  
Induction of the hepatic mixed-function oxidase system by synthetic glucocorticoids. Transcriptional and post-transcriptional regulation.  
J. Biol. Chem. 262: 326-332.
- Sirica A.E., Richards W., Tsukada Y., Sattler CA. and Pitot H.C. (1979).  
Fetal phenotypic expression by adult rat hepatocytes on collagen gel/nylon meshes.  
Proc. Natl. Acad. Sci., USA 76: 283-287.
- Skett P. (1987).  
Hormonal regulation and sex differences of xenobiotic metabolism.  
In: Progress in Drug Metabolism Vol. 10. Eds. Bridges J.W., Chasseaud L.F. and Gibson G.G. (Taylor and Francis), pp85-140 .
- Skett P. (1988).  
Biochemical basis of sex differences in drug metabolism.  
Pharmacol. Ther. 38: 269-304.
- Sorensen E.M.B. and Acosta D. (1985).  
Relative toxicities of several nonsteroidal antiinflammatory compounds in primary cultures of rat hepatocytes.  
J. Toxicol. Environ. Health 16: 425-440.
- Statham C.N. and Boyd M.R. (1982).  
Effects of phenobarbital and 3-methylcholanthrene on the *in vivo* distribution, metabolism, and covalent binding of 4-ipomeanol in the rat; implications for target organ toxicity.  
Biochem. Pharmacol. 31: 3 973-3 977.
- Steward A.R., Dannan G.A., Guzelian P.S. and Guengerich F.P. (1985).  
Changes in the concentration of seven forms of cytochrome P450 in primary cultures of adult rat hepatocytes.  
Mol. Pharmacol. 27: 125-132.

Strom S.C, Monteith D.K., Manoharan K. and Novotny A. (1987).  
Genotoxicity studies with human hepatocytes.  
In: The Isolated Hepatocyte: Use in Toxicology and Xenobiotic Transformations.  
Eds. Rauckman E.J. and Padilla G.M. (Academic Press), pp 265-280.

Swinney D.C, Ryan D.E., Thomas P.E. and Levin W. (1988).  
Evidence for concerted oxidation of progesterone by purified rat hepatic  
cytochrome P450g.  
Biochemistry 27: 5 461-5 470.

Symons A.M., Turcan R.G. and Parke D.V. (1982).  
Hepatic microsomal drug metabolism in the pregnant rat.  
Xenobiotica 12: 365-374.

Tajima K., Yamamoto K. and Mizutani T. (1985).  
Formation of a glutathione conjugate from butylated hydroxytoluene by  
rat liver microsomes.  
Biochem. Pharmacol. 34: 2 109-2 114.

Tamburini P.P., Masson H.A., Bains S.K., Makowski R.J., Morris B. and  
Gibson G.G. (1984).  
Multiple forms of hepatic P450.  
Eur. J. Biochem. 139: 235-246.

Tanaka K., Sato M., Tomita Y. and Ichihara A. (1978).  
Biochemical studies on liver functions in primary cultured hepatocytes  
of adult rats.  
Biochem. J. 84: 937-946.

Taniguchi H., Pyerin W. and Stier A. (1988).  
Conversion of hepatic microsomal P450 to P420 upon phosphorylation by  
cyclic AMP dependent protein kinase.  
Biochem. Int. 16: 1 127-1 135.

Tazawa J., Endou H., Sato A., Hasumura Y. and Takeuchi J. (1985).  
Functional heterogeneity of rat hepatocytes: predominance of aryl  
hydrocarbon hydroxylase activity in perivenular zone.  
Biochem. Pharmacol. 34: 1 835-1 837.

Tee L.B.G., Davies D.S., Seddon CE. and Boobis A.R. (1987).  
Species differences in the hepatotoxicity of paracetamol are due to  
differences in the rate of conversion to its cytotoxic metabolite.  
Biochem. Pharmacol. 36: 1 041-1 052.

Thomas P.E., Reik L.M., Ryan D.E. and Levin W. (1983).  
Induction of two immunochemically related rat liver cytochrome P450  
isozymes, cytochromes P450C and P450d, by structurally diverse xenobiotics.  
J. Biol. Chem. 258: 4 590-4 598.

- Thompson D. and Moldéus P. (1988).  
Cytotoxicity of butylated hydroxyanisole and butylated hydroxytoluene in isolated rat hepatocytes.  
Biochem. Pharmacol. 37: 2 201-2 207.
- Thompson T.N., Watkins J.B., Gregus Z. and Klaassen CD. (1982).  
Effect of microsomal enzyme inducers on the soluble enzymes of hepatic phase II biotransformation.  
Toxicol. Appl. Pharmacol. 66: 400-408.
- Thor H., Smith M.T., Harzell P., Bellomo G., Jewell S.A. and Orrenius S. (1982).  
The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells.  
J. Biol. Chem. 257: 12 419-12 425.
- Thurman R.G. and Kauffman F.C (1980).  
Factors regulating drug metabolism in intact hepatocytes.  
Pharmacol. Rev. 31: 229-251.
- Timbrell J.A. (1983).  
Drug hepatotoxicity.  
Br. J. Clin. Pharmacol. 15: 3-14.
- Tolman K.G., Gray P.D., El Masry S., Luther R.R. and Janicki R.S. (1989).  
Toxicity of uricosuric diuretics in rat hepatocyte culture.  
Biochem. Pharmacol. 38: 1 181-1 184.
- Törrönen R., Pelkonen K. and Kärenlampi S. (1989).  
Enzyme-inducing and cytotoxic effects of wood-based materials used as bedding for laboratory animals. Comparison by a cell culture study.  
Life Sci. 45: 559-565.
- Turcan R.G., Tamburini P.P., Gibson G.G., Parke D.V. and Symons A.M. (1981).  
Drug metabolism, cytochrome P450 spin state and phospholipid changes during pregnancy in the rat.  
Biochem. Pharmacol. 30:1 223-1 225.
- Turner N.A. and Pitot H.C. (1989).  
Dependence of the induction of cytochrome P<sub>450</sub> by phenobarbital in primary cultures of adult rat hepatocytes on the composition of the culture medium.  
Biochem. Pharmacol. 38: 2 247-2 251.
- Turner N.A., Wilson N.M., Jefcoate C.R. and Pitot H.C. (1988).  
The expression and metabolic activity of cytochrome P450 isozymes in control and phenobarbital-induced primary cultures of rat hepatocytes.  
Arch. Biochem. Biophys. 263: 204-215.

Tyson CA. and Green CE. (1987).  
Cytotoxicity measures: choices and methods.  
In: The Isolated Hepatocyte: Use in Toxicology and Xenobiotic Transformations.  
Eds. Rauckman E.J. and Padilla G.M. (Academic Press), pp119-158.

Vergères G., Winterhalter K.H. and Richter C (1989).  
Identification of the membrane anchor of microsomal rat liver cytochrome P450.  
Biochemistry 28: 3 650-3 655.

Vesell E.S. (1982).  
Genetic and environmental factors affecting drug disposition in Man.  
Clin. Pharmacol. Ther. 22: 659-678.

Vesell E.S. (1988).  
Pharmacogenetics.  
In: The Liver. Biology and Pathobiology. Eds. Arias I.M., Jakoby W.B., Popper H.,  
Schachter D., Shafritz D.A. (Raven Press), pp1 213-1 234.

Vind C, Dich J. and Grunnet N. (1988).  
The content and activity of cytochrome P450 in long-term culture of  
hepatocytes from male and female rats.  
Biochem. Pharmacol. 37: 1 371-1 375.

Warren B.L., Pak R., Finlayson M., Gontovnick L., Sunhara G.  
and Bellward G.D. (1983).  
Differential effects of diabetes on microsomal metabolism of various substrates.  
Biochem. Pharmacol. 32: 327-335.

Warren M. and Fry J.R. (1988).  
Influence of medium composition on 7-alkoxycoumarin O-dealkylase  
activities of rat hepatocytes in primary maintenance culture.  
Xenobiotica 18: 973-981.

Warren M., Fry J.R. and Balls M. (1985).  
The effect of glucose, insulin and dexamethasone upon 7-ethoxycoumarin  
O-deethylase activity of adult rat hepatocytes in primary culture.  
Xenobiotica 15: 775-779.

Watkins P.B., Wrighton S.A., Schuetz E.G., Maurel P. and Guzelian P.S. (1986).  
Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive  
cytochrome P450p in rat hepatocytes *in vivo* and in primary culture.  
J. Biol. Chem. 261: 6 264-6 271.

Waxman D.J. (1988).  
Interactions of hepatic cytochromes P450 with steroid hormones.  
Biochem. Pharmacol. 37: 71-84.

- Waxman D.J., Dannan G.A. and Guengerich F.P. (1985).  
Regulation of rat hepatic cytochrome **P450**: age-dependent expression, hormonal imprinting and xenobiotic inducibility of sex-specific isozymes. *Biochemistry* 24: 4 409-4 417.
- Waxman D.J., Ko A. and Walsh C (1983).  
Regioselectivity and stereoselectivity of androgen hydroxylations catalysed by cytochrome **P450** isozymes purified from phenobarbital-induced rat liver. *J. Biol. Chem.* 258:11 937-11 947.
- Waxman D.J., LeBlanc G.A., Morrissey J.J., Staunton J. and Lapenson D.P. (1988).  
Adult male-specific and neonatally programmed rat hepatic **P450** forms RLM2 and RLM2a are not dependent on pulsatile plasma growth hormone for expression. *J. Biol. Chem.* 263: 11 396-11 406.
- Waxman D.J., Morrissey J.J. and LeBlanc G.A. (1989).  
Hypophysectomy differentially alters P450 protein levels and enzyme activities in rat liver: pituitary control of hepatic NADPH-cytochrome **P450** reductase. *Mol. Pharmacol.* 35: 519-525.
- Wiebel F.J., Park S.S., Kiefer F. and Gelboin H.V. (1984).  
Expression of cytochromes P450 in rat hepatoma cells. *Eur. J. Biochem.* 145: 455-462.
- Wilkinson G.N. (1961).  
Statistical estimations in enzyme kinetics. *Biochem. J.* 80: 324-332.
- Williams G.M. and Gunn J.M. (1974).  
Long-term cell culture of adult rat liver epithelial cells. *Exp. Cell Res.* 89: 139-142.
- Williams G.M., Bermudez E., San R.H.C, Goldblatt P.J. and Laspia M. F. (1978).  
Rat hepatocyte primary cultures. IV. Maintenance in defined medium and the role of production of plasminogen activator and other proteases. *In Vitro* 14: 824-837.
- Winer B.J. (1971).  
Statistical Principles in Experimental Design. McGraw-Hill, pp201-204.
- Wrighton S.A., Maurel P., Schuetz E.G., Watkins P.B., Young B. and Guzelian P.S. (1978).  
Identification of the cytochrome **P450** induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P450p. *Biochemistry* 24: 2 171-2 178.

Yamazoe Y., Murayama N., Shimada M. and Kato R. (1989).  
Thyroid hormone suppression of hepatic levels of phenobarbital-inducible  
P450b and **P450 $\alpha$**  and other neonatal P450S in hypophysectomised rats.  
Biochem. Biophys. Res. Commun. **160**: 609-614.

Yamazoe Y., Murayama N., Shimada M., Yamauchi K., Nagata K., Imaoka S.,  
Funae Y. and Kato R. (1988).

A sex-specific form of cytochrome **P450** catalysing propoxycoumarin  
**O-depropylation** and its identity with testosterone **6 $\beta$ -hydroxylase** in  
untreated rat livers: reconstitution of the activity with microsomal lipids.  
J. Biochem. **104**: 785-790.

Ziegler D.M. (1988).

Detoxication: oxidation and reduction.

In: The Liver. Biology and Pathobiology. Eds. Arias I.M.,Jakoby W.B., Popper H.,  
Schachter D., Shafritz D.A. (Raven Press), pp1 087-1 104.

ADDENDA:

Estabrook R.W., Peterson J., Baron R., and Hildebrandt A. (1972).

In: Methods in Pharmacology, volume 2. Ed. Chignell C.F.(Appleton-Century-  
Crofts), pp303-350.

## PUBLICATIONS

Fry J.R. and Hammond A.H. (1988).

Influence of donor age on the maintenance of cytochrome **P<sub>450</sub>-related** enzyme activities of rat hepatocytes in culture.

Br. J. Pharmacol. 95: 833P.

Fry J.R., Garle M.J. and Hammond A.H. (1988).

The detection of reactive metabolites generated by the microsomal mixed function oxidase system.

ATLA **16**: 8-13.

Fry J.R., Garle M.J. and Hammond A.H. (1988).

Choice of acute toxicity measures for comparison of *in vivo/in vitro* toxicity.

ATLA **16**: 175-179.

Fry J.R., **Garle M.J.**, Hammond A.H. and Hatfield A. (1988).

Correlation of cytotoxicity *in vitro* of anti-tumour compounds with acute toxicity.

Br. J. Pharmacol. 95: 834P.

Garle M., Hammond A.H. and Fry J.R. (1987).

The cytotoxicity of 27 chemicals to V79 Chinese hamster cells.

ATLA 15:30-32.

Hammond A.H. and Fry J.R. (1990).

The influence of donor age and sex on the activities and maintenance in culture of 7-alkoxycoumarin **O-dealkylases** of rat isolated hepatocytes. In Vitro Toxicology (in press).

Hammond A.H. and Fry J.R. (1990).

The *in vivo* induction of rat hepatic cytochrome **P<sub>450</sub>-dependent** enzyme activities and their maintenance in culture.

Biochem. **Pharmacol.** (in press).

Hammond A.H. and Fry J.R.

The use of hepatocytes cultured from inducer-treated rats in the detection of cytochrome **P<sub>450</sub>-mediated** cytotoxicity.

Toxicology In Vitro (accepted for publication).